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Abstract 
Viral oncolytic therapy, a novel treatment for cancer using specially designed 
viruses to kill malignant cells while leaving normal cells unharmed, is currently 
under intense investigation. Several receptors are up-regulated in cancer cells, 
including decay-accelerating factor (DAF; CD55) and integrins (αvβ3, αvβ6) and 
viruses which recognise these receptors could be useful for therapy. Several 
echoviruses, including Echovirus 11 (E11), bind to DAF; coxsackievirus A9 (CVA9) 
utilizes an RGD motif to bind to integrins, particularly αvβ6. Some isolates of CVA9 
also bind to heparan sulfate proteoglycans (HSPG). This thesis describes work 
designed to improve our understanding of CVA9 and echovirus cell/receptor 
tropism. Several echoviruses and CVA9 variants were tested in a panel of 9 cell 
lines. Distinct patterns of infection were seen, but did not fully correlate with 
receptor expression, suggesting that other determinants also help to define 
tropism. To investigate this further, E11 was adapted by passaging on two cell 
lines, A549 and HeLa. Two mutations were seen in A549-adapted virus, and both 
mapped to the DAF-binding footprint, suggesting changes to E11/DAF 
interactions. A single mutation in VP4 was seen in HeLa-adapted virus, and may 
affect a later stage in cell entry. To investigate CVA9 binding to HSPG, 3 isolates 
were propagated on A549 cells and heparin-blocked mutants were isolated. 
Although the isolates are diverse, the same mutation (VP3 Q59R) was seen in two 
isolates and probably gives a positively-charged cluster with adjacent amino acids. 
Other mutations were seen close to the RGD motif, where there is already a highly 
basic sequence. The results suggest multiple potential mechanisms for HSPG-
binding. Combinations of some of the adapting mutations discovered could 
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significantly enhance the tropism of these viruses to specific cancer cells and 
optimise them as oncolytic agents. 
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1.1 Introduction to Virology 
Viruses are very small infectious agents that depend on host cells and need to 
replicate inside cells for proliferation (Cann, 2011). Viruses can infect all cellular 
life forms such as bacteria, animals and plants and can cause serious disease in 
humans and agriculturally-important animals and plants (Carter et al., 2007). 
Viruses are transmitted through many different routes and for human viruses 
these include the faecal-oral and respiratory routes, as well as transmission 
through fomites and through insect bites. A total understanding of the nature of 
viruses is needed to permit researchers to identify ways of prevention, treatment 
and diagnosis of virus infection, for instance through the development of efficient 
vaccines and anti-viral drugs (Ehrenfeld et al., 2010).   
In addition to their ability to cause disease, viruses can be useful and have 
potential applications, such as DNA delivery in gene therapy. Genetically 
modified viruses can also be used as anti-cancer agents (e.g herpes simplex 
virus and vaccinia virus) to infect and destroy specific tumor cells and leave 
normal cells totally unharmed (Carter et al., 2007). 
Picornaviruses are among the oldest known viruses. A priest shown in a temple 
record from 1400 BC appears to show the signs of paralytic poliomyelitis. 
Furthermore, poliomyelitis was first recognised as a viral disease by Karl 
Landsteiner and Erwin Popper in 1909, and so was one of the earliest diseases 
known to be caused by a virus. Foot and Mouth Disease Virus (FMDV), the first 
known animal virus to be identified, is also a picornavirus and was recognised 
even earlier, by Friedrich Loeffler and Paul Frosch in 1898 (Semler and Wimmer, 
2002). 
  
3 
1.2  Picornavirus Classification and Importance 
Picornaviruses are viruses that belong to the family Picornaviridae. The name is 
derived from the word “pico” which means “small”, and “RNA” referring to the 
ribonucleic acid (RNA) genome. Therefore "picornavirus" means small RNA virus 
(Carter et al., 2007). The family is considered one of the largest viral families 
consisting of 29 genera: Aphthovirus, Aquamavirus, Avihepatovirus, Avisivirus, 
Cardiovirus, Cosavirus, Dicipivirus, Enterovirus, Erbovirus, Gallivirus, 
Hepatovirus, Hunnivirus, Kobuvirus, Kunsagivirus, Megrivirus, Mischivirus, 
Mosavirus, Oscivirus, Parechovirus, Pasivirus, Passerivirus, Rosavirus, 
Sakobuvirus, Salivirus, Sapelovirus, Senecavirus, Sicinivirus, Teschovirus and 
Tremovirus (Knowles et al., 2012; Adams et al., 2013). Several other viruses are 
unassigned and may represent new genera or species. The genetic relationship 
between all Picornaviridae genera/species and unassigned viruses is shown in 
Figure 1.1. The family is diverse, but 4 groups of virus can be seen which include 
Enterovirus/Sapelovirus plus some unassigned viruses; Aphthovirus/Cardiovirus 
and several other genera; Kobuvirus/Salivirus and other genera; 
Hepatovirus/Parechovirus and other genera (Knowles, 2014). 
Picornaviruses are responsible for various diseases of both humans and animals 
worldwide. In human, they cause several diseases, ranging from mild infections 
such as skin rash and common cold infections through to more serious, acute 
and chronic nervous system, liver and heart problems, which may even lead to 
death (Table 1.1). There are more than 300 serotypes and due to their medical 
and economical importance they have been studied over the past years actively. 
Over the past thirty years, great progress has been made in understanding the 
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bases of their pathogenic properties and how they infect cells, as well as their 
epidemiology (Carter et al., 2007; Lin et al., 2009; Cann, 2011; Stanway, 1990 
and Ehrenfeld et al., 2010; Knowles et al., 2012). 
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 HQ595341 Bat PV-1 [unassigned]
 HQ595340 Bat PV-1 [unassigned]
 HQ595342 Bat PV-2 [unassigned]
 HQ595343 Bat PV-2 [unassigned]
 JN831356 Canine PV-1 [unassigned]
 JQ814852 Ia io PV-1 [unassigned]
 HQ595345 Bat PV-3 [unassigned]
 HQ595344 Bat PV-3 [unassigned]
 JN572116 Feline PV-1 [unassigned]
 JN572115 Feline PV-1 [unassigned]
unassigned
 AF406813 Porcine sapelovirus ["Sapelovirus A"]
 AY064708 Simian sapelovirus ["Sapelovirus B"] Sapelovirus
Sapelovirus AY563023 Avian sapelovirus
unassigned JN674502 Quail PV-1 [unassigned]
 FR727144 Pigeon PV-B [unassigned]
 KC560801 Pigeon PV-B [unassigned] unassigned
 FJ445111 Rhinovirus A
 DQ473485 Rhinovirus B
 M88483 Enterovirus B
 J02281 Enterovirus C
 EF077279 Rhinovirus C
 D00820 Enterovirus D
 AF326759 Enterovirus H
 AY421760 Enterovirus A
 AF326766 Enterovirus J
 AF363453 Enterovirus G
 D00214 Enterovirus E
 DQ092770 Enterovirus F
Enterovirus
 JQ941880 Hunnivirus A
 HM153767 Hunnivirus A Hunnivirus
Teschovirus AF231769 Porcine teschovirus ["Teschovirus A"]
 EU236594 Bovine rhinitis B virus
 JN936206 Bovine rhinitis A virus
 AY593829 Foot-and-mouth disease virus
 DQ272578 Equine rhinitis A virus
Aphthovirus
Erbovirus X96871 Equine rhinitis B virus ["Erbovirus A"]
Mosavirus JF973687 Mosavirus A
Cosavirus FJ438902 Cosavirus A
Senecavirus DQ641257 Seneca Valley virus ["Senecavirus A"]
Mischivirus JQ814851 Mischivirus A
 JQ864242 Boone cardiovirus 1 ["Cardiovirus C"]
 JX683808 Boone cardiovirus 2 ["Cardiovirus C"]
 M81861 Encephalomyocarditis virus ["Cardiovirus A"]
 M20562 Theilovirus ["Cardiovirus B"]
Cardiovirus
 KC876003 Mesivirus 1 [unassigned]
 KC811837 Mesivirus 2 [unassigned]
 HM751199 Melegrivirus A
Megrivirus
Dicipivirus JN819202 Cadicivirus A
Rosavirus JF973686 Rosavirus A
 GU182408 Oscivirus A
 GU182410 Oscivirus A Oscivirus
"Sicinivirus" KF741227 Sicinivirus 1 ["Sicinivirus A"]
Passerivirus GU182406 Passerivirus A
Gallivirus JQ691613 Gallivirus A
 GQ184145 Salivirus A
 GQ179640 Salivirus A Salivirus
"Sakobuvirus" KF387721 Feline sakobuvirus ["Sakobuvirus A"]
 AB040749 Aichivirus A (human)
 JF755427 Aichivirus A (murine)
 JN387133 Aichivirus A (canine)
 EU787450 Aichivirus C (porcine)
 KF793927 Caprine kobuvirus [unassigned]
 AB084788 Aichivirus B (bovine)
 GU245693 Aichivirus B (ovine)
 KF006985 Aichivirus B (ferret)
Kobuvirus
Hepatovirus M14707 Hepatitis A virus ["Hepatovirus A"]
Tremovirus AJ225173 Avian encephalomyelitis virus ["Tremovirus A"]
 KF306267 Carp PV-1 [unassigned]
 KC465953 Fathead minnow PV [unassigned]
 JX134222 Bluegill PV-1 [unassigned]
unassigned
"Kunsagivirus" KC935379 European roller PV ["Kunsagivirus A"]
Aquamavirus EU142040 Aquamavirus A
Avisivirus KC465954 Avisivirus A
Avihepatovirus DQ226541 Duck hepatitis A virus ["Avihepatovirus A"]
unassigned KC843627 Eel PV-1 [unassigned]
Pasivirus JQ316470 Pasivirus A
unassigned KF006989 Ferret parechovirus [unassigned]
 L02971 Human parechovirus ["Parechovirus A"]
 AF327920 Ljungan virus ["Parechovirus B"]
 HF677705 Sebokele virus [unassigned]
Parechovirus
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Fig. 1. Phylogenetic tree showing the relationships (amino acid) between picornaviruses in the P1 capsid. 
Maximum likelihood mtREV with Freqs. (+F) model, Gamma distributed with Invariant sites (G+I), with 
1000 bootstrap replicates. Proposed new genus and species names are shown in quotes (species names are 
also within square brackets []). The subject(s) of this proposal are indicated by a red diamond (♦).
Sicinivirus 
Sakobuvirus 
Kunsagivirus 
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Figure 1.1 Phylogenetic tree showing the relationships between the 29 
picornavirus genera and corresponding species in the P1 capsid region.  
All the currently-recognised species, together with a number of unassigned viruses are 
included. The maximum-likelihood mtREV with Freqs. (+F) model, Gamma distributed 
with Invariant sites (G+I) as estimated in MEGA 6.06, with 1000 bootstrap replicates. 
Proposed new or renamed genus and species are shown between square brackets and 
quotation marks. Proposed new genera are indicated to the right inside quotation marks 
(adapted from Knowles, 2014). 
(http://www.ictvonline.org/proposals/2014.018a-dV.A.v3.Sicinivirus.pdf). 
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Table 1.1 Summary of the medical and agricultural effects of some 
important picornaviruses (Carter et al., 2007; Ehrenfeld et al., 2010) 
	
Genus Examples Diseases 
Enterovirus 
Poliovirus  
Central nervous system (CNS) 
infections may result in: poliomyelitis, 
meningitis, and encephalitis.  
Enterovirus 71 (EV71) 
A range of illness from mild to serious 
complications. It is a human pathogen 
which may cause severe to fatal 
neurological disease, especially in 
children. Also, hand-foot-and-mouth 
disease (HFMD) and severe CNS 
symptoms including encephalitis, 
aseptic meningitis and acute flaccid 
paralysis (poliomyelitis-like paralysis) 
Coxsackieviruses 
A range of medical conditions in 
humans such as myocarditis (heart 
disease), pancreatitis, type 1 
diabetes, CNS infections such as 
aseptic meningitis, skin rash and 
upper respiratory tract infections. 
Rhinoviruses 
(common cold viruses) 
Upper respiratory tract infections 
(common colds) in humans. 
Hepatovirus 
Hepatitis A virus 
(HAV) 
Infants and children: infections are 
undetected, asymptomatic or mild. 
Adults: hepatitis (liver infections).  
Aphthovirus  
Foot-and-mouth 
disease virus (FMDV) 
Foot-and-mouth disease (FMD) in 
farm animals such as cattle, sheep, 
goats and pigs. 
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Parechovirus 
 
Human parechovirus 
(HPeV) 
Cause respiratory and 
gastrointestinal infections in children 
(usually mild but HPeV3 causes 
potentially fatal sepsis) 
Kobuvirus Aichi virus 
Outbreaks of gastroenteritis 
associated with eating shellfish 
Teschovirus  Porcine teschovirus 
Enteric infections in pigs- originally an 
important animal but now rare 
Avihepatovirus  Duck hepatitis virus High mortality infection of ducklings 
Cardiovirus  
Theiler’s virus  
Saffold virus 
Mainly thought to be rodent viruses 
e.g. Theiler's virus causes disease 
similar to MS and is used as an 
animal model. The recently 
discovered Saffold virus was isolated 
from humans, but its significance is 
not known. 
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1.3  Picornavirus Structure  
Picornaviruses are small (25-30 nm in diameter) particles and consist of an 
icosahedral protein capsid, which is non-enveloped, surrounding a single-
stranded, positive sense RNA genome with approximate length from 7 kb in 
Tremovirus (Avian encephalomyelitis virus) to 8.8 kb in Erbovirus (ERBV) 
(Palmenberg et al., 2010; Cann, 2011; King et al., 2012).  
 
1.3.1 Particle Structure  
The picornavirus capsid is assembled from 60 protomers; each protomer 
contains a copy of the four structural viral proteins (VPs) known as VP1, VP2, 
VP3 and VP4 that are arranged to give icosahedral symmetry. VP1- VP3 (~30 
kDa in mass) are on the external surface of the capsid and VP4 (~ 7 kDa) is a 
small protein and completely internal. VP4 and VP2 are cleaved from a 
precursor, VP0, and in some picornaviruses, including parechoviruses and 
kobuviruses, VP0 cleavage does not happen (Stanway, 1990; Ehrenfeld et al., 
2010; Yamashita et al., 1998). These viruses only have 3 capsid proteins, VP0, 
VP3 and VP1. An icosahedron has 5-fold, 3-fold and 2-fold axes of symmetry 
(imaginary lines around which the particle can be rotated to give 5, 3 and 2 
identical structures) as shown in (Figure 1.2). Each of VP1, VP2 (or VP0 in 
picornaviruses where VP0 is not cleaved) and VP3 share the common fold of an 
eight-stranded β-barrel (Rossmann et al., 1985). The amino acid chain between 
the beta strands and also the amino and carboxyl terminal portions of the protein 
contain a series of loops, and these loops comprise the antigenic sites that are 
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found on the virion surface, which are responsible for the neutralisation of viral 
infection (Stanway et al., 1990; Palmenberg et al., 2010; Chen et al., 2013; 
Williams et al., 2004; Bergelson, 2010). Diversity and evolution in picornaviruses 
is caused mainly by variability in these regions of the capsid proteins, which is 
reflected in the presence of distinct serotypes. This kind of antigenic variability 
causes problems for the development of vaccines against these viruses.    
Several picornaviruses, including rhinoviruses and polioviruses, have a deep cleft 
known as the “canyon” around each 5-fold axis of the icosahedron. These 
canyons contain the virus binding site for receptors and are lined by the C termini 
of VP1 and VP3 molecules (Rossmann et al., 1985; Rossmann et al., 2002). 
There is also a hydrophobic pocket with a close contact with the canyon floor and 
this pocket contains a small molecule called the pocket factor. This pocket is 
known to be the binding site for many antiviral drugs (such as WIN51711 and 
pleconaril). Once these bind they stabilize the capsid and inhibit the uncoating 
process (Bergelson, 2010; Smyth et al., 2003).   
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Figure 1.2 Picornavirus particle structure. A) The icosahedral capsid consists of 60 
protomers, each protomer contains a copy of the four structural viral proteins VP1-VP4, 
of which VP1, VP2 and VP3 are external, while VP4 is completely internal. B) 
Icosahedron showing locations of 2-, 3- and 5-fold axes of symmetry and VP1-3. 
(Solomon et al., 2010; Rowlands, 2010) 
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1.3.2 Genome Structure and Organization 
The picornavirus genome is made up of a single-stranded RNA molecule, which 
is covalently attached to a small (20-25 amino acids) protein, VPg, at the 5’ end. 
There is a long 5’ untranslated region [5’UTR] (about 10 % of the genome size), a 
single open-reading frame, a 3’ untranslated region [3’ UTR] and a poly A tail. 
The structure of a typical picornavirus genome is shown in Figure 1.3. The 5’UTR 
contains a complex structure, the IRES (internal ribosome entry site), which is 
needed for translation of the virus RNA, and structures needed for RNA 
replication. The 3’UTR and poly A tail may also be involved in translation and 
replication (Lin et al., 2009) 
Most picornaviruses encode all proteins in a single open reading frame (ORF) 
(more than 2300 codons). The protein encoded is proteolytically cleaved into 
precursor proteins then into the final proteins (Stanway, 1990; Ehrenfeld et al., 
2010; King et al., 2012) (Figure 1.4). Recently, a bicistronic canine 
picodicistrovirus (genus Dicipivirus) with an interrupted ORF has been identified. 
This has an additional internal ribosome entry site (IRES) at the P1/P2 junction 
that separated it into two ORFs. Therefore, it is the first naturally occurring 
bicistronic picornavirus to be discovered (Woo et al., 2012).  
The picornavirus proteins are numbered from their positions in the polyprotein as 
follows: L, 1A (VP4), 1B (VP2), 1C (VP3), 1D (VP1), 2A, 2B, 2C, 3A, 3B (VPg), 
3C, 3D, as shown in (Figure 1.3). The first precursors produced during cleavage 
of the polyprotein are known as P1, P2 and P3.  P1 includes VP1, VP2, VP3 and 
VP4, the capsid (structural) and P2 and P3 include 2A, 2B, 2C, 3A, 3B, 3C, 3D, 
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which are non-structural proteins. L is also a non-structural protein. The non-
structural proteins are involved in RNA replication and polyprotein processing.  
The picornavirus RNA genome is positive sense and can function directly as an 
mRNA (Cann, 2011; Stanway, 1990; Ehrenfeld et al., 2010). The genome has 
untranslated regions (UTR) at both 5’ end and 3’ end (5’UTR and 3’UTR, 
respectively). These have complex secondary structures. The UTR at the 5’ end 
is longer and varies in length from 600 bp in the rhinoviruses to 1250 bp in the 
aphthoviruses. It plays a role in viral translation, virulence and possibly 
encapsidation. The UTR at the 3’ end is shorter, about 42 bp in the rhinoviruses 
(HRV) to 317 bp in the avihepatovirus (DHAV), and is thought to be important for 
negative strand synthesis during replication; it is followed by a poly-A tail (Cann, 
2011; Stanway, 1990; Ehrenfeld et al., 2010). The 5’ UTR contains the internal 
ribosome entry site (IRES). IRES elements contain cis-acting regions that recruit 
the translation machinery internally in the mRNA. Thus, a successful replication 
cycle of the picornavirus and the efficiency of infection are based on the accurate 
function of the IRES (Fernández-Miragall et al., 2009; Martinez-Salas, 2008). 
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Figure 1.3 Schematic diagram of a typical picornavirus genome. The untranslated 
regions (5’UTR and 3’UTR) are shown in purple and the poly A tail in grey hatching. The 
single open-reading frame is in white and is made up of the regions L, 1A-D, 2A-C and 
3A-D which encode the final virus proteins produced by cleavage of the single 
polyprotein. The pink square shows the small protein VPg which is covalently attached to 
the 5’ end of the virus RNA. The protein-encoding regions 1A, 1B, 1C and 1D encode 
the proteins usually called VP4, VP2, VP3 and VP1. L is not present in all picornaviruses 
(Cann, 2009). 
 
 
Figure 1.4 Schematic diagram of cleavage of the picornavirus polyprotein. 
Cleavage is done by virus proteases (2A, 3C) and occurs in several steps giving a series 
of precursors before the final virus proteins are made. The diagram is typical for 
enteroviruses such as poliovirus (Cann, 2009). 
3B	(VPg)*	
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1.3.3 Picornavirus Life Cycle and Replication 
The replication cycle of picornavirus shows some variation between species. 
However, for a typical picornavirus it occurs in the host cell cytoplasm (Figure 
1.5), and starts upon attachment and receptor binding of a virus at the host cell 
surface, followed by the entry of the virus (DePalma et al., 2008; Wanger et al., 
2008). The genome is uncoated, then translated, followed by the polyprotein 
cleavage to produce individual viral proteins. Then, RNA replication occurs on 
membrane vesicles; assembly of the virus particle then happens and the 
replication cycle ends with the release of newly formed viral particles from the cell 
(DePalma et al., 2008). A number of changes to the cell are made by the virus 
during infection, including host cell translation shut-off which reduces competition 
for cell resources and prevents anti-virus responses (Lin et al., 2009).  
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Figure 1.5 Summary of the picornavirus life cycle. The main events in the replication 
process are started by attachment and receptor binding, and include virus entry, 
uncoating, IRES-driven translation, polyprotein processing, -ve (red) and +ve (purple) 
strand synthesis by the virus replication complex, which gives multiple +ve strand 
copies, assembly, maturation, packing and viral release (Whitton et al., 2005). 
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1.3.3.1 Cellular Receptors 
Viruses take advantage of receptors on the cell surface, which are internalised 
and take the virus into the cell. It is a key step in infection and possibly a drug 
target, as well as being an important determinant of host, tissue tropism and 
pathogenesis, as only cells expressing the required receptor can be infected. 
Picornaviruses bind to a range of specific cell surface receptors and studies have 
identified at least 12 receptors that are utilized by different picornaviruses for cell 
entry. These are: integrins (several types), low density lipoprotein receptor 
(LDLR), heparan sulphate proteoglycans (HSPG), Decay-accelerating factor 
(DAF; CD55), Intracellular adhesion molecule-1 (ICAM-1), Coxsackie-adenovirus 
receptor (CAR), Poliovirus receptor (PVR; CD155), HAV-cr1 (Hepatitis A virus 
cellular receptor 1), human P-selectin glycoprotein ligand-1 (PSGL-1), the human 
scavenger receptor class B number 2 (SCARB2) and sialic acid as shown in 
(Figure 1.5) (Mercer et al., 2010; Ehrenfeld et al., 2010; Semler and Wimmer, 
2002). Molecules such as β2 microglobulin and GRP78 may also be 
receptors/co-receptors or involved in events after virus binding (Ward et al., 
1998; Triantafilou et al., 2002). A summary of different receptors used by 
picornaviruses is shown in Table 1.2 and a schematic of many of them in Figure 
1.6. All these molecules that viruses bind to are related to other cellular functions, 
such as cell-cell recognition, ion transport, and binding to the extracellular matrix 
(ECM). These molecules are glycoconjugates (glycoproteins, glycolipids, 
proteoglycans), and the carbohydrate moieties can play a key role in virus 
binding (Mercer et al., 2010).  
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Figure 1.6 Schematic diagram of different proteins known to be picornavirus 
receptors. Members of the Ig superfamily: CAR, coxsackie–adenovirus receptor; PVR, 
poliovirus receptor; ICAM-1, intracellular adhesion molecule type 1 and VCAM-1, 
vascular cell adhesion molecule type 1. Integrins α2β1 and αvβ3 (like integrin αvβ3, 
integrin αvβ6 is RGD dependent and is probably the preferred receptor for several 
picornaviruses with an RGD motif); DAF (CD55), decay-accelerating factor; GPI, 
glycosylphosphatidylinositol; HAVcr-1, hepatitis A virus cellular receptor 1; LDL-like, low 
density lipoprotein; LDLR, low density lipoprotein receptor; SCR-like, short consensus 
repeat; T/S/P, threonine/serine/proline. (Taken from Flint et al., 2009)	
 
 
 
 
DAF 
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1.3.3.1.1 Integrins 
Integrins are large, heterodimeric cell surface glycoproteins composed of two 
non-covalently associated subunits called α and β (Figure 1.6, 1.7). There are a 
variety of heterodimers made from 18 α- and 8 β- subunits that can be combined 
to form at least 24 distinct αβ combinations in humans (Hynes, 2002; Takada et 
al., 2007). They bind to several different ligands including extracellular matrix 
proteins such as collagens, laminins, fibronectin and vitronectin. They are named 
for their roles in integrating the intracellular cytoskeleton with the extracellular 
matrix and involved in cell adhesion, cell-cell interactions and stimulation of 
signal transduction (Ehrenfeld et al., 2010; Semler and Wimmer, 2002; Williams 
et al., 2004; Berinstein et al., 1995).  
Integrins can be used by several picornaviruses, such as E1, FMDV, E9, CVA9 
and HPeV1 (Nelsen-Salz et al., 1999; Williams et al., 2004; Seitsonen et al., 
2010). The α2β1 integrin (VLA-2; collagen and laminin receptor) binds to E1 in a 
non-RGD-dependent way involving the α2 I domain (Xing et al., 2004). In 
contrast, the other picornaviruses contain an RGD (Arg-Gly-Asp) motif in their 
VP1 C-terminus, or in the case of FMDV in the VP1 GH loop, and this is 
recognised by one or more RGD-dependent integrins, mainly αv integrins such 
as αvβ3 and αvβ6  (Williams et al., 2004; Vuorinen et al., 1999; Ehrenfeld et al., 
2010; Merilahti et al., 2012). Moreover, studies show that FMDV (Aphthovirus) 
utilizes the integrins αvβ1, αvβ3, αvβ6 and αvβ8 as receptors to initiate infection via 
the RGD motif located on the VP1 GH loop (Berinstein et al., 1995; Jackson et 
al., 2000a, 2002, 2004). 
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Figure 1.7 The structure of integrin α and β subunits that combine to form a 
heterodimer and serve as a cell-surface receptor. The α and β subunits are linked 
together via noncovalent bonds. The α subunit contains four divalent cation-binding 
sites. The extracellular part of the β unit has a single divalent cation-binding site and a 
cysteine-rich region (Taken from Alberts et al., 2002).   
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1.3.3.1.2 Heparan Sulphate Proteoglycans 
Heparan sulphate (HS) is a family of linear polysaccharides found on the surface 
of mammalian cells and in extracellular matrix (Figure 1.8 and Figure 1.9) 
(Reijmers et al., 2013; Häcker et al., 2005). HS is a glycosaminoglycan (GAG), 
which are unbranched polysaccharides consisting mainly of a repeating 
disaccharide unit [GlcA-GlcNAc]n, where GlcA stands for glucuronic acid and 
GlcNAc is N-acetylglucosamine. Some of the disaccharides are modified by 
sulphation making HS highly negatively charged. HS is attached to core proteins 
(proteoglycans) giving heparan sulphate proteoglycans (HSPG). These 
proteoglycans are mainly syndecans and glypicans. HSPG has a potential role in 
the differentiation processes, the regulation of cell growth and transformation and 
cell adhesion (Barth et al., 2006; Häcker et al., 2005; Christianson and Belting, 
2014; Byrnes et al., 1998). HSPG is also known to serve as a cellular receptor for 
several viruses such as certain echovirus serotypes, coxsackievirus B3 (CVB3), 
foot-and-mouth disease virus (FMDV) and swine vesicular disease virus (SVDV) 
(Goodfellow et al., 2001; Zautner et al., 2006; Jackson et al., 1996; Romero et 
al., 2004). In most cases, HSPG is considered as an initial receptor which 
increases the efficiency of another receptor to facilitate the attachment to the host 
cell surface (Romero et al., 2004).  
A treatment of cells with heparinase 1, or treating virus with heparin, blocks the 
binding of viruses to the cell surface if the virus uses this molecule (Goodfellow et 
al., 2001). Heparin is a commercial derivative of heparan sulphate; both share 
identical sugar chain structure but differ in degree of sulphation. It is used as a 
cheaper and more available alternative of heparan sulphate in virus interaction 
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studies. HS interactions with cellular and virus proteins are naturally electrostatic; 
therefore, positively charged amino acid residues interact with the negatively 
charged sulphate. Bonding may be due to a linear eptitope or due to cluster of 
positively charged amino acids on the virus surface (Romero et al., 2004). FMDV 
is known to use an RGD motif to interact with integrins, yet some FMDV 
serotypes can use HSPG as a receptor, particularly after cell culture adaptation 
(Jackson et al., 2000b). Interestingly, non-RGD-dependent/non-HSPG-
dependent variants of FMDV can also be isolated, suggesting that FMDV can 
use other receptors in addition to integrins and HSPG (Berryman et al., 2013)    
 
 
 
 
 
 
 
 
 
 
 
 
 
  
24 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic representation of HS structure. (A) Unmodified disaccharide 
consisting of GlcA and GlcNAc, simplified as a blue and red symbol, respectively. (B) 
Modified disaccharide consisting of a C5-epimerized IdoA (green symbol) sulfated at the 
C2-position and GlcNAc sulfated at the N-, C3- and C6-position. (C) An HSPG core 
protein with an HS chain attached to it, via a linkage tetrasaccharide (Modified from 
Reijmers et al., 2013). 
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Figure 1.9 Structure of heparan sulphate proteoglycans. Glypicans contain an N-
terminal globular domain that is stabilized by disulphide bonds. Attachment sites for 
glycosaminoglycans (GAGs) are located near the C terminus, to which a 
glycosylphosphatidylinositol (GPI) anchor is attached that links the core protein to the 
cell membrane. The GPI anchor can be cleaved to shed the heparan sulphate (HS) 
proteoglycan from the cell surface. Syndecans are type I transmembrane proteins with 
up to five GAG attachment sites. Syndecans can also be shed by proteolytic cleavage. 
(Häcker et al., 2005) 
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1.3.3.1.3 Decay-accelerating factor  
Decay-accelerating factor (DAF; CD55) is a 70-kDa extracellular glycoprotein and 
is expressed on the surface of almost all cells (Figure 1.5, 1.10, 1.11). It serves 
as a cellular receptor for CVB, CVA21 and many echoviruses (E3, 6, 7, 11, 12, 
13, 19, 21, 24, 25, 29, 30, and 33) (Clarkson et al., 1995; He et al., 2002; 
Newcombe et al., 2004; Shafren et al., 1998). In the uninfected cell it plays a role 
in down-regulation of complement activity by accelerating the decay of C3 and 
C5 convertases enzymes. DAF comprises of five domains from the N-terminus 
including four short consensus repeats (SCRs), with approximately 60 amino acid 
residues, and a C- terminal serine/Threonine-rich region, with approximately 70 
amino acids, and is attached to the cell surface by a glycosylphosphatidyl inositol 
(GPI) anchor (Clarkson et al., 1995; Shafren et al., 1998; Plevka et al., 2010; 
Novoselova et al., 2012). DAF does not bind in the virion canyon but folds around 
the virus surface near the 2-fold axis of symmetry (Ehrenfeld et al., 2010). The 
binding of DAF to EV7, EV12 and CVB3 uses different combinations of SCRs 
and slightly different parts of the virus surfaces are involved (Plevka et al., 2010) 
(Figure 1.10). Viruses which use DAF have the ability of causing 
hemagglutination (HA) of human red blood cells, which is linked with DAF 
binding, and DAF interactions can be recognised in this way. E11 is one of the 
best-studied viruses in terms of DAF binding and several strains have been 
shown to interact with DAF, through inhibition of infection by anti-DAF 
monoclonal antibodies or by soluble DAF (Stuart et al., 2002). 
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Figure 1.10 Schematic diagram of DAF structure. The green ellipses represent the 4 
SCR domains. The yellow circles are O-linked and the orange circles are N-linked 
carbohydrate moieties. GPI, glycosylphosphatidylinositol (Taken from He et al., 2002) 
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Figure 1.11 Interaction of DAF with EV7 and CVB3. Surface-rendered view of each 
virus complexed with DAF, with all density at a radius of 160 Å shown in blue, which 
corresponds mostly to DAF density. (Middle) Outer surface of the virus, viewed from 
outside the virus and subdivided into small areas representing individual amino acids, 
with residues in VP1 shown in blue, those in VP2 shown in green, and those in VP3 
shown in pink. Residues in contact with DAF are coloured similarly, but in darker shades. 
(Right) Inner surface of DAF, viewed from inside the particle (with SCR1 residues in 
pink, SCR2 residues in green, SCR3 residues in orange, and SCR4 residues in blue), 
with DAF residues contacting the virus shown in darker shades. The asymmetric unit is 
indicated by a black triangular outline (Taken from Plevka et al., 2010). 
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1.3.3.1.4 Immunoglobulin Superfamily Receptors: ICAM 
ICAM-1 
Intracellular adhesion molecule-1 (ICAM-1) belongs to the immunoglobulin 
superfamily (IgSF) and has five extracellular Ig-like domains (Figure 1.5). It is 
present in the membrane of leukocytes and endothelial cells, thus providing 
adhesion between them (Vuorinen et al., 1999; Rossmann et al., 2002; Xiao et 
al., 2001; Semler and Wimmer, 2002). It is a cell surface molecule that is 
recognized as the receptor for the major group of human rhinoviruses (~90 
serotypes such as HRV3, HRV14 and HRV16), as well as CVA21. The 
interaction between ICAM-1 and rhinoviruses is via the N-terminal domain that 
inserts into the centre of the virus canyon (Olson et al., 1993).  
 
CAR 
Coxsackievirus and adenovirus receptor (CAR) is the common receptor for both 
Coxsackievirus B (CVB) and adenoviruses (Bergelson et al., 1997). CAR is a cell 
surface glycoprotein (46-kDa) with two extracellular immunoglobulin Ig-like 
domains (Figure 1.5). It is expressed in many human tissues and in the 
developing central nervous system. It functions as a cell adhesion molecule. CAR 
is recognized as a receptor by all six CVB serotypes for both the attachment and 
infection of cells. In many adenoviruses, it acts as a receptor to mediate the initial 
attachment of the virus to the cell surface, while the entry of virus is mediated by 
an integrin. In CVBs it is known to bind to the virus canyon and causes formation 
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of the A particle, an intermediate in uncoating of the virus (Ehrenfeld et al., 2010, 
Rossmann et al., 2002).  
 
PVR 
Poliovirus receptor (PVR; CD155) is a transmembrane glycoprotein with three 
extracellular immunoglobulin Ig-like domains (Figure 1.5). Its cellular functions 
are not yet clearly understood but it seems these are related to cell-cell 
interactions, extracellular matrix proteins interactions, cell migration and NK cell 
function. It acts as a receptor for all three serotypes of poliovirus and the first N-
terminal Ig-like domain (D1) of PVR seems to be responsible for virus binding 
and infection by binding within the canyon. Studies indicate that PVR is the only 
receptor that is associated with PV attachment and infection and so it is a critical 
determinant of PV infection. Most poliovirus isolates cannot recognise mouse 
PVR and mouse cells cannot be infected. Transgenic mice expressing human 
PVR can be infected, showing that PVR is a host tropism determinant (He et al., 
2000; Racaniello et al., 1996; Ehrenfeld et al., 2010; Semler and Wimmer, 2002). 
 
1.3.3.1.5 LDLR family 
Member of the low-density lipoprotein receptor (LDLR) family vary greatly in sizes 
(up to 600 kD). LDLR structures are very repetitive and one receptor molecule 
can make contact with many capsid proteins, which may stabilised the virion 
against pH-induced conformational changes (Figure 1.5) (Semler and Wimmer, 
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2002; Ehrenfeld et al., 2010; Tuthill et al., 2010). There are two types of receptor 
in the family: low-density lipoprotein receptor (LDLR) and very low-density 
lipoprotein receptor (VLDLR). These receptors carry cysteine-rich N-terminal 
repeats “Cys-repeats” to which the minor group of human rhinoviruses (HRV1A, -
1B, -2, -23, -24, -25, -29, -30, -31, -44, -47, -49 and -62) attach and soluble forms 
of LDLR can block virus binding to cultured cells (Uncapher et al., 1991; Marlovits 
et al., 1997). The receptor binds to a star-shaped prominence around the 5-fold 
axis symmetry of the virus and not within the canyon. LDLR functions to deliver 
virus to the endosomal compartment where the uncoating process is started as 
part of the endosomal acidification (Semler and Wimmer, 2002; Ehrenfeld et al., 
2010; Tuthill et al., 2010).  
 
1.3.3.1.6 PSGL-1 and SCARB2 
Two transmembrane proteins, human P-selectin Glycoprotein Ligand-1 (PSGL-1) 
and human Scavenger Receptor Class B-2 (SCARB2), have been both identified 
as cellular receptors for Enterovirus 71 (EV71) (Tan et al., 2013; Yamayoshi et 
al., 2013). PSGL-1 is a sialomucin membrane protein expressed in leukocytes, 
which is important in the tethering and rolling of leukocytes for their recruitment 
from blood vessels into inflamed tissues. It seems to be involved in the viremic 
phase of EV71 infection but is not thought to be a major receptor as transgenic 
mice expressing human PSGL-1 are not more susceptible to EV71 infection (Liu 
et al., 2012). SCARB2 is a type III double-transmembrane protein located 
primarily in endosomes but also expressed on the cell surface, it has been 
reported that it plays an important role in the maintenance of lysosomes. It is also 
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expressed in neurons in the central nervous system (Tan et al., 2013; Liu and 
Rossmann, 2014; Yamayoshi et al., 2013). It appears to be the essential EV71 
receptor (Yamayoshi et al., 2013).  
 
1.3.3.1.7 Sialic Acid 
Sialic acid (SA) is known as neuraminic acid and usually linked to glycoproteins 
and gangliosides. It functions as a receptor for cell attachment and entry of many 
viruses and can be a determinant of tropism and pathogenicity These viruses 
include influenza viruses, EV71, EV70, Theiler’s virus and EMCV (Matrosovich et 
al., 2013; Yang et al., 2009; Alexander et al., 2002; Tuthill et al., 2010). SAs are 
highly present and expressed and are attached at terminal ends of N- and O-
glycans as well as glycolipids. The most common sialic acid in humans is α5-N-
acetylneuraminic acid (Neu5Ac). Studies showed that EV70 binds Neu5Ac as an 
α2,3-linkage to galactose, while CVA24 variant is able to use both α2,3- and 
α2,6-linked Neu5Ac as receptors (Zocher et al., 2014; Ströh and Stehle , 2014). 
 
1.3.4 Viral Entry  
Following attachment, viruses must be internalised and uncoat. This process 
usually involves a cellular endocytosis pathway (Mercer et al., 2010). A number 
of endocytosis pathways for internalisation have been identified (Figure 1.12), for 
example, macropinocytosis, clathrin-mediated endocytosis (CME), caveolin-
mediated mechanisms, caveolar/lipid raft-dependent and others that remain 
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poorly understood (Mercer et al., 2010; Heikkilä et al., 2010; Sieczkarski and 
Whittaker, 2002; Merilahti et al., 2012).  
The most important advantage of using endocytosis for internalization is that 
endocytosis can avoid leaving any evidence of virus entry on the surface of the 
cell, which could be recognised by the immune system. In addition, the virus can 
be delivered to a cell compartment where uncoating of the genome and 
replication can start. Some viruses such as herpes simplex virus 1 (HSV-1) and 
human immunodeficiency virus 1 (HIV-1) have the ability of entering directly but 
they often prefer to use endocytic pathway for productive entry (Mercer et al., 
2010). Some mechanisms are pinocytic and promoting the uptake of fluid, 
solutes and small particles; while, some viruses are internalized by on-going 
endocytic activities. Endocytosis can also be virus-triggered. Phagocytosis is 
typically restricted to large particles and few cell types (Mercer et al., 2010).  
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Figure 1.12 Summary of different endocytic mechanisms used by viruses for 
infection. These include clathrin-mediated endocytosis (CME), macropinocytosis, 
phagocytosis, caveolar/raft-mediated mechanisms and several novel mechanisms. 
Some of these pathways are via dynamin-2 as indicated by the beads around the neck 
of the endocytic indentations. Phagocytosis is restricted to a few cell types. There are 
several possible internalization pathways such as IL-2, the GEEC pathway, and the 
flotillin- and ADP-ribosylation factor 6 (Arf6)-dependent pathways that normally carry 
specific cellular cargo. (Taken from Mercer et al., 2010) 
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1.3.4.1 Clathrin-mediated Endocytosis (CME) 
CME is one of the most common pathways for virus entry (Mercer et al., 2010). 
Clathrin is assembled on the inside face of the plasma membrane, forming 
invaginated pits which then become clathrin-coated vesicles (CCVs). Other 
essential molecules that also interact with clathrin are Eps15, ampiphysin and the 
AP2 adapter proteins and the dynamin GTP. Clathrin plays a key role in the 
internalization of several viruses, such as some adenoviruses, vesicular 
stomatitis virus (VSV), influenza virus and semliki forest virus (SFV), which were 
identified previously in clathrin-coated pits (CCPs) in the plasma membrane at 
early stages of internalization by transmission electron microscope (TEM) 
(Mercer et al., 2010; Sieczkarski and Whittaker, 2002). FMDV is internalised 
through this pathway (Berryman et al., 2005) and a recent study indicates that 
HPeV1 is endocytosed via the clathrin-mediated pathway (Merilahti et al., 2012).  
 
1.3.4.2 Caveolar/lipid rafts-dependent Endocytosis 
Caveolae seem to be used for entry by several viruses including polyomavirus 
and simian virus 40 (SV40). They are characterised by the formation of primary 
endocytic vesicles which depends on cholesterol, lipid rafts (cholesterol-rich 
microdomains) and a complex signalling pathway including tyrosine kinases and 
phosphatases. Dynamin is essential in the caveolar pathway to close off the neck 
of the vesicle (Mercer et al., 2010; Sieczkarski and Whittaker, 2002).  
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1.3.4.3 Macropinocytosis 
Macropinocytosis is considered to be a non-specific mechanism for 
internalization, not related to a specific receptor. During this process fluids and 
membrane are internalized into large vacuoles leading to plasma membrane 
ruffling. Endocytic vesicles occur as a response to cell stimulation of actin and 
microfilaments. The ruffles form as lamellipodia (planer folds), filopodia or blebs 
and are closed at the membrane ruffling sites forming a large vesicle known as a 
macropinosome. The formed closed vacuoles are no longer attached to the 
plasma membrane.  Macropinosomes have the ability to become acidified and 
interact with early endosomes, and the same is true of vesicles produced by 
several different entry pathways (Sieczkarski and Whittaker, 2002; Mercer and 
Helenius, 2009). Echovirus 1 and coxsackievirus B are picornavirus examples of 
entering the cell via the macropinocytosis pathway (Mercer and Helenius, 2009). 
 
1.3.5 Particle Uncoating and Genome Release  
In this stage, the process of uncoating happens when the virus particle is 
disrupted to some extent and naked RNA is transmitted to the cytoplasm of the 
host cell. This can be as a result of changes in the pH (due to endosomal 
acidification) or some other less understood processes (Tuthill et al., 2010; 
Smyth and Martin, 2002). 
A "pore" runs through the capsid at the 5-fold axis (Rossmann et al., 1985).  At 
the base of this pore there is myristate residue, which is covalently linked to the 
N-terminus of VP4. There is also a concentration of hydrophobic protein regions, 
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e.g. the N-terminus of VP1. Following interaction with the receptor, these 
hydrophobic residues are exposed and interact with the cell or endosomal 
membrane. Originally, this was thought to allow the RNA to pass through the 
pore and the membrane to enter the cytoplasm. However, it now seems that in 
enteroviruses the RNA is released by changes, which make an opening at the 2-
fold axis (Wang et al., 2012). VP4 is released from the capsid during uncoating 
and it has been shown recently that this protein can form multimers which have 
pore forming ability, which may be related to entry (Panjwani et al., 2014). A 
mutation in VP4 has been shown to prevent infection at a step after receptor 
binding (Moscufo et al., 1993).  
 
1.3.6 Translation  
Following the release of genomic RNA, translation in picornaviruses is initiated by 
the internal ribosome entry site (IRES) element located in the 5’UTR. The 
genomic RNA acts as mRNA and is translated to a single polyprotein which is the 
precursor of the viral protein. The IRES is formed of approximately 450 nt from 
the whole 5’UTR (~ 600 to 1300 nts) and is made up of several RNA secondary 
structures (Ehrenfeld et al., 2010; Tuthill et al., 2010; Wanger et al., 2008). 
Picornavirus IRES are divided into five types: type I e.g. enteroviruses; type II 
e.g. aphthoviruses; type III in hepatoviruses; type IV a hepatitis C (HCV)-like 
IRES element found e.g. in teschoviruses; type V e.g. kobuviruses (Lin et al., 
2009). 
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1.3.7 Polyprotein processing: 
The success of viral replication depends on the activity of proteases encoded 
within the polyprotein to process it into mature viral protein. The proteases used 
are: 2A, 3C and leader protein (L) (Figure 1.4). 
 
2A  
2A protein shows considerable differences amongst picornaviruses genera and is 
found within the P2 region. For instance, in enteroviruses 2A protein is a trypsin-
like, cysteine protease which is responsible for cis cleavage at its N terminus 
between VP1 and 2A, which is the first step in polyprotein processing (Stanway 
and Hyypia, 1999; Hughes and Stanway, 2000). 2A is also involved in shut-off of 
host-cell macromolecular synthesis, which reduces competition and enhances 
virus replication. 2A does this by cleaving the eIF4GI (eukaryotic translation 
initiation factor 4GI) component of the cap-binding complex during infection, 
which leads to reduction of host cell translation (Stanway and Hyypia, 1999; 
Hughes and Stanway, 2000; Semler and Wimmer, 2002). A number of other 
cellular proteins are cleaved by 2A such as eIF4GII, eIF-4F and dystrophin (Lin et 
al., 2009; Porter, 1993). In many picornaviruses, 2A protein is linked with an 
unusual C-terminal activity, where during translation no peptide bond is made 
between the G and P of a NPGP motif (ribosome skipping) (Hughes and 
Stanway, 2000). Other picornaviruses lack either of these types of protein and 2A 
does not seem to be involved in cleavage/ribosome skipping. 
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3C 
The 3C protein, found within the P3 region, is the main protease in all 
picornaviruses and is responsible for the majority of cleavage. In some cases this 
is as the precursor 3CD. It is active in both cis and trans cleavage (Semler and 
Wimmer, 2002; Porter, 1993). 3C is structurally and functionally related to the 
large trypsin-like serine proteases (Porter, 1993). 3C also cleaves cell proteins 
such as eIF4AI, which lead to the shut off of host translation (Lin et al., 2009).  
 
Leader (L) Protein 
The L protein is distinct structurally and functionally among picornavirus and is 
only present in some picornaviruses. L protein is encoded at the N-terminus of 
the polyprotein in several picornaviruses including aphthoviruses, cardioviruses, 
erboviruses, tescovirus, sencavirus and kobuviruses (Hughes and Stanway, 
2000). In aphthoviruses and erboviruses L is a papain-like protease. The L 
protein of aphthoviruses cleaves between its own C-terminus and the N-terminus 
of VP4; this is the only known cleavage of this enzyme on the viral polyprotein. 
However, is also cleaves eIF4GI (eukaryotic translation initiation factor 4GI), thus 
preventing the host cell from translating its own capped mRNA, in a similar 
manner to 2A in enteroviruses and rhinoviruses (Lin et al., 2009; Hughes and 
Stanway, 2000; Semler and Wimmer, 2002). 
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1.3.8 Genome Replication 
In picornaviruses there are several activities that occur during genome 
replication. In the initial step, the positive strand viral RNA is copied to produce 
multiple copies of minus strands RNA, which are then used as templates for 
positive strand RNA replication (Carter et al., 2007; Lin et al., 2009). 
Picornaviruses have a peptide called VPg, a small protein of about 23 residues, 
and the first step of viral RNA replication is synthesis of uridylylated VPg. Firstly, 
a tyrosine residue at position 3 (Tyr-3) is modified by the viral RNA-dependent 
RNA polymerase (3Dpol) to produce uridylylated VPg (VPg-pU-pU). This process 
is called uridylylation. Secondly, the VPg-pU-pU is then used as a primer to 
produce full-length genomic RNA. The mechanism that is involved in VPg-pU-pU 
formation is termed ‘slide back’, in which a single adenylated residue located in 
the loop of an RNA stem-loop structure, called the cre motif (cis-acting replication 
element) or oriI (origin of replication internal), is used as the template for VPg 
uridylylation (Pathak et al., 2007; Shen et al., 2008; Lin et al., 2009). RNA 
replication occurs on replication complexes, derived from different host cell 
membranes in different picornaviruses. These concentrate the components 
needed for replication and possibly also protects the dsRNA, which is present 
during RNA synthesis from being recognised by cell defence mechanisms (Nagy 
and Pogany, 2012). 
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1.3.9 Assembly and Maturation 
This step is mainly completed by packing the viral genome into the capsid. 
Capsid assembly first starts by cleavage of the polyprotein into three proteins P1, 
P2 and P3. P1 forms the subunit of the virus capsid VP0, VP1, and VP3. The 
VP0, VP1 and VP3 assembled into 6S promoters. Five of these promoters are 
assembled into a 14S pentamer and 12 pentamers are assembled to form a 
150S particle. The final stage involves insertion of the RNA into empty capsid. At 
this stage, the maturation happens and the precursor of VP0 is cleaved to VP2 
and VP4 and then the virion is a mature. The release of virus from the host cell is 
mostly by cell lysis (Semler and Wimmer, 2002).      
 
1.4  Tropism of Picornaviruses  
Viruses are often highly specific for particular organisms, for instance poliovirus 
will only infect humans and closely related primates and the same is true of 
human rhinoviruses. Enterovirus 71 also seems to be specific for humans (Wang 
and Yu, 2014). Sometimes viruses can alter their tropism and an example of this 
in picornaviruses is SVDV (swine vesicular disease virus), which is closely 
related to the primate virus CVB5 but has accumulated several mutations, which 
are presumably involved in this change in host (Jimenez-Clavero et al., 2005).  
The pathogenicity of enteroviruses is highly complex due to variation in the 
genetic background of populations and immunological aspects, and this is difficult 
to study due to restrictions to investigations in higher primates. This inspired 
scientists to develop animal models for studies of the important pathogens such 
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as human enterovirus 71 (HEV71), major-group human rhinoviruses (HRVs) and 
some coxsackieviruses A (CVAs) (Wang et al., 2011; Zaini et al., 2012). New 
born mice have been used as animal models as these seem to be susceptible to 
some enteroviruses, but cannot be infected after a few days. This model was 
used to define CVB and CVA isolates as these have different effects in new born 
mice (Stanway and Hyypia, 1999). EV71 adapted to grow in adult mice have also 
been used to study disease caused by this virus (Wang and Yu, 2014).  
As well as host tropism, viruses can have different tissue tropism and this can be 
important in pathogenesis, for example in poliovirus virulence. Several regions of 
the virus genome have been shown to be help to define host and tissue tropism.  
 
1.4.1  Picornavirus Receptors 
The interaction between the virus and its specific cellular receptor is a key 
determinant of cell tropism and pathogenicity. Viruses may use multiple 
attachment receptors and/or co-receptors for entry and several conformational 
changes may occur. Viral tropism, virulence and development of diseases can be 
affected by any of these changes (Schneider-Schaulies, 2000). Transgenic mice 
expressing the human form of CD155, the poliovirus receptor, are an example of 
where receptor interactions play a role in defining host tropism. Poliovirus does 
not recognize the mouse CD155 and so mice are not infected with poliovirus, but 
the transgenic mice are infected and are important in research and vaccine 
testing (Ren and Racaniello, 1992). Transgenic mice expressing SCARB2 can be 
infected with EV71 and so are useful models (Wang and Yu, 2014). 
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Studies show that in recombinants between coxsackieviruses A9 and B3 (CVA9, 
CVB3), which show different pathogenicity in new-born mice, this correlated with 
the P1 region and so probably involved receptor interactions (Harvala et al., 
2002).  
Adaptation of viruses to different cell lines or different hosts often involves 
changes in the capsid proteins, which map to known receptor binding domains. 
For instance, E11 has been adapted to several cell lines and mutations tend to 
map either to known DAF binding domains and change the DAF binding 
phenotype, or to the canyon region where it is suggested that interactions with an 
unknown receptor are affected (Stuart et al., 2002; Rezaikin et al., 2009; 
Novoselov et al., 2012). 
 
1.4.2  Other Tropism Determinants 
5’UTR 
Previous studies have identified that the 5’UTR of enteroviruses is a key factor in 
tissue tropism and viral pathogenesis. For instance, several sites in the 5’UTR of 
all 3 poliovirus serotypes are cited as neurovirulent/attenuation determinants 
(Minor, 1996). Also, the 5’UTR of CVB1 and CVB3 were shown to include 
cardiovirulent determinants (Lin and Shih, 2014). Attenuating mutations in the 
enterovirus 5’UTR influence translation efficiency in different cells, which might 
be a major factor affecting tropism (Harvala et al., 2005; Svitkin et al., 1988). 
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Non-Structural Proteins  
The aphthovirus, FMDV is one of the most important animal diseases worldwide 
and the natural hosts are mainly cattle, goats and sheep. Studies show that 
deletions in the non-structural protein 3A were related to attenuation for cattle of 
FMDV serotypes O and C and also contribute to high virulence of swine FMDV 
serotype O (Núñez et al., 2001). Another example, is that amino acid changes in 
the 2C protein of HRV-16 can increase the cytopathic effect and level of viral 
RNA production seen when this virus infects mouse cells (Harris and Racaniello, 
2005).  
 
1.5  History of Coxsackieviruses and Their Importance  
Coxsackievirus was named according to a village called Coxsackie in New York 
State, USA. In 1948, Gilbert Dalldorf discovered the coxsackieviruses while 
investigating an outbreak of poliomyelitis in the US. Isolation of unrecognized 
agents from the faeces of two suspected polio cases was done. The first 
coxsackievirus was identified when faecal specimens were injected into suckling 
mice and paralysis was induced (Dalldorf, 1950; Carter et al., 2007; James, 
1952). Coxsackieviruses are divided into 2 groups, Coxsackie A viruses and 
Coxsackie B viruses (CVA and CVB) according to their pathogenic effects in 
new-born mice. CAVs infect skeletal muscle causing flaccid paralysis, while 
CBVs, detected in several tissues including the central nervous system causing 
spastic paralysis (Harvala et al., 2005). 
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Coxsackieviruses belong to the genus Enterovirus in the family of Picornaviridae. 
The genus Enterovirus is classified into 12 species: Enterovirus A, Enterovirus B, 
Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F and Enterovirus G, 
Enterovirus H, Enterovirus J, Rhinovirus A, B and C, mainly based on genetic 
relationships (Knowles et al., 2012; Adams et al., 2013). Coxsackieviruses do not 
form one group of viruses on this basis, as some belong to Enterovirus A (some 
CVAs), Enterovirus B (CVA9 and CVBs) and Enterovirus C (poliovirus and some 
CVAs). This is one reason why enteroviruses are no longer assigned to either the 
Coxsackievirus or echovirus groups and new viruses are just given an 
enterovirus number e.g. EV70, EV71 etc.   
Coxsackieviruses are an important and large group that cause a wide range of 
illnesses in humans, including aseptic meningitis, respiratory and undifferentiated 
febrile illness, herpangina, hand-foot-and-mouth disease, and acute 
haemorrhagic conjunctivitis, myocarditis (Brooks et al., 2007). Initial replication of 
enteroviruses in the body usually occurs in the cells of the respiratory or 
gastrointestinal tracts. Thereafter, the viruses can reach the bloodstream and 
cause viraemia, which occasionally leads to infection of secondary target organs 
such as the central nervous system (CNS), heart, skin, liver and pancreas 
(Vuorinen et al., 1999).  
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1.5.1 Coxsackievirus A9  
1.5.1.1 General Properties  
Coxsackievirus A9 (CVA9); is part of the species Enterovirus B (Knowles et al., 
2012; Adams et al., 2013). CVA9 is one of the 10 most commonly-isolated 
enteroviruses and causes infections of the central nervous system, myocarditis 
and respiratory infections (Heikkilä et al., 2009; Williams et al., 2004).  
 
1.5.1.2 Cellular Receptors and Endocytosis 
CVA9 utilizes integrins as primary receptors for cell attachment. They use 
integrin αvβ3 in target cell recognition but αvβ6 is probably more important 
(Heikkilä et al., 2010; Williams et al., 2004; Vuorinen et al., 1999). The interaction 
between CVA9 and cell surface integrins αvβ3 and αvβ6 is via an arginine-glycine-
aspartic acid (RGD) motif in the C terminus of capsid protein VP1 (Heikkilä et al., 
2009; Heikkilä et al., 2010; Williams et al., 2004). Although the RGD is an 
important motif in CVA9 infection, particularly in cell lines expressing integrin 
αvβ6, there also seem to be RGD-independent receptors in some cell lines as an 
RGD deletion mutant can still infect many cell lines and in some cases the 
deletion has little effect on infection (Hughes et al., 1995; Merilahti et al., 2012).  
RGD motifs have been found in many other picornaviruses such as human 
parechoviruses (HPeVs), foot-and-mouth disease virus (FMDV) and echovirus 9 
(E9). β2-microglobulin (β2-M, a subunit of histocompatibility complex class I 
[MHC-I]) and GRP78 (glucose-regulated protein 78-kDa) are used as co-
receptors in the internalization process, and possibly play roles in post-
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attachment step in several picornaviruses including CVA9 (Triantafilou et al., 
2002; Heikkilä et al., 2009; Heikkilä et al., 2010; Huttunen et al., 2014; Shakeel et 
al., 2013). Studies indicate that the internalisation of CVA9 appears to depend on 
β2-M, dynamin and the Arf6 pathway but are independent of the clathrin and 
caveolin-1 pathways (Heikkilä et al., 2009; Heikkilä et al., 2010; Merilahti et al., 
2012).  
Several picornaviruses, including different species of the genus Enterovirus, 
interact with heparan sulphate proteoglycan (HSPG) and HSPG serves as a co-
receptor for some strains of CVA9. Analysis of the HSPG-binding domain 
suggested that an arginine (R) at position 132 in VP1 in the folded form clusters 
around the 5-fold axis of symmetry and produces a positively-charged area 
allowing interactions with HSPG (McLeish et al., 2012). 
 
1.6  Echoviruses  
Echoviruses (E) are members of the Enterovirus genus and are a group of 
pathogens can infect the human enteric tract (Brooks et al., 2007; Stuart et al., 
2002b; Novoselov et al., 2012; Sobo et al., 2011). The term ECHO is an acronym 
for Enteric Cytopathogenic Human Orphan, where orphan means that the 
disease that is caused by echoviruses was not known when the name was 
invented (Brooks et al., 2007; Stuart et al., 2002b).  There are 28 serotypes (E1-
E33, but E8 [now thought to be the same as E1], E10 [a rheovirus], E22, E23 
[both parechoviruses] and E28 [rheovirus] were reclassified as different viruses). 
Echoviruses are now known to cause a range of illness. Most infections are 
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either asymptomic or show only mild symptoms such as diarrhea, common colds 
and mild ocular disease, but more serious infections are possible, from aseptic 
meningitis, paralysis, encephalitis, myocarditis and hemorrhagic conjunctivitis 
(Brooks et al., 2007; Sobo et al., 2011).  
To date, a variety of cell surface receptors have been identified for echoviruses. 
Decay-accelerating factor (DAF; CD55) appears to be a major echovirus 
receptor, binding many echovirus serotypes, including E3, 6, 7, 11, 12, 13, 19, 
21, 24, 25, 29, 30 and 33 (Powell et al., 1998). Echovirus serotype 1 binds a 
subunit of the very late antigen (VLA-2) α2β1integrin and uses it as a receptor. 
Integrin αvβ3 has been reported to serve as a receptor for E9 (Nelsen-Salz et al., 
1999). Also, human leucocyte antigen (HLA) class I molecules may be involved 
in the attachment and entry of E11 into susceptible cells (Razaikin et al., 2009). 
HSPG seem to be involved in some cases (Goodfellow et al., 2001; McLeish et 
al., 2012). 
 
1.6.1 Echovirus 11  
Echovirus 11 (E11); belongs to the genus Enterovirus B in the family of 
Picornaviridae (Knowles et al., 2012; Adams et al., 2013). Most isolates of E11 
are hemagglutinating and utilize DAF as a primary cell surface receptor, although 
non-DAF binding variants can be isolated (Novoselov et al., 2012; Stuart et al., 
2002b). 
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1.7  Cancer 
1.7.1 Cancer- An Introduction 
Cancer is considered one of the most dangerous diseases worldwide. Cancer is 
a group of different diseases characterized by uncontrolled cell proliferation in the 
human body leading to rapid growth of abnormal tissue. Tumours are described 
as benign if they are unable to invade normal tissue while a malignant tumour 
invades tissue and has the potential to metastasize (King and Robins, 2006). 
According to the Cancer Research UK report in 2012, around 22% of all human 
deaths in the UK are due to cancer, and around 46% of all cancer deaths are 
caused by lung, bowl, breast and prostate cancers (Cancer Research UK report, 
2012). 
Cancer is usually treated with chemotherapy, radiotherapy, immunotherapy, 
surgery resection (used in combination with chemo- or radio- therapy) or other 
methods. The choice of therapy that should be used to treat the cancer depends 
on the stage and location of the tumour, also the general state of the patient 
(King and Robins, 2006). Unfortunately, many cancer patients suffer from these 
aggressive treatments as they are not specific for malignant cells and cause side 
effects; they are also expensive and not always successful. Consequently, new 
and efficient therapies are urgently needed for the prevention and treatment of 
cancer. 
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1.8  Oncolytic Virotherapy (OV) 
Oncolytic (onco=cancer; lytic=killing) Virotherapy or cancer-killing viruses, is a 
novel treatment for cancer by using viruses, either genetically engineered or 
naturally occurring. These are specially designed to infect and destroy malignant 
cells, directly by virus replication inside the cells then lysing the cells, or indirectly 
by induction of apoptosis, while leaving normal cells largely unharmed (Berry et 
al., 2008; Reddy et al., 2007; Nakhaeil et al., 2005; Meerani and Yao, 2010). A 
successful virus replication in cancer cells leads to release of newly formed 
infectious virus particles and as a result the virus will infect neighbouring tumor 
cells. In general, cancer cells often lack interferon (IFN) or tumour suppressor 
pathways, and as a result cancer cells maybe more susceptible to infections 
(Nakhaeil et al., 2005; Murphy et al., 2012). In addition, molecules that used as 
cell-surface receptors by viruses are often up-regulated in cancer cells (Berry et 
al., 2008; Allen et al., 2013; Liu et al., 2014; Koretz et al., 1992). Thus, oncolytic 
viruses can specifically infect, replicate within and destroy cancer cells (Murphy 
et al., 2012). 
 
1.8.1 History of Oncolytic Viruses 
Experiments with animals in the 1920s proved that viruses were successful in 
infecting and lysing experimental murine tumours (Mullen and Tanabe, 2002). 
Several reports followed in the 1950s demonstrating oncolysis of murine tumours 
by Newcastle disease virus (NDV) and influenza virus. In the late 1940s and 
early 1950s, studies of oncolytic viruses in human cancer cases were initiated. 
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The most famous of these studies was one reported from the National Cancer 
Institute in 1956, in which wild-type adenoviruses of different serotypes were 
injected into patients with cervical carcinomas (Mullen and Tanabe, 2002). More 
than half of the patients given live virus showed tumour regression without 
evidence of toxicity, on the other hand the control patients given inactivated virus 
exhibited no response. However, the initial tumour regression was followed by 
tumour progression in all patients. This apparent lack of long-term anti-tumour 
efficacy led investigators to abandon this type of therapy in the 1970s and 1980s 
(Mullen and Tanabe, 2002). However, in 2005 a reappearance of the oncolytic 
virus idea led to a genetically modified oncolytic adenovirus H101 (Kelly and 
Russell, 2007). Advances in cancer biology, molecular genetics and virology in 
the second half of the 20th century set the stage for the current enthusiasm for 
the therapeutic potential of oncolytic viruses. There are two main approaches to 
oncolytic viral therapy; one of them is the direct treatment of tumours with 
replicating oncolytic viral vectors alone or in combination with therapeutic 
transgene delivery, chemotherapy or radiotherapy. The other is the indirect 
enhancement of anti-tumour immunity via the modulation of the immune 
response, as manifested with viral oncolysate vaccines, and tumour-protective 
monoclonal antibodies (Mullen and Tanabe, 2002).   
 
1.8.2 Potential Oncolytic Viruses in Cancer Therapy 
A number of viruses have been identified and used as oncolytic virotherapy, such 
as: vesicular stomatitis virus (VSV), sindbis virus, adenoviruses, reovirus, 
measles virus, herpesviruses and Newcastle disease virus (Reddy et al., 2007; 
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Kelly and Russell, 2007; Au et al., 2007; Murphy et al., 2012). In addition, several 
enteroviruses from the Picornaviridae family have been investigated for this 
purpose, for example poliovirus, coxsackievirus A21 (CVA21) and Echovirus 1 
(E1) (Berry et al., 2008; Reddy et al., 2007; Kelly and Russell, 2007). These 
show effective oncolytic activity in vivo against human neuroblastoma, malignant 
melanoma and ovarian tumours, respectively (Berry et al., 2008; Au et al., 2007; 
Toyoda et al., 2007; Shafren et al., 2004). Recently, poliovirus has shown 
promise for treating several cancer cell lines, as it replicates efficiently inside 
cells. For example, an attenuated oncolytic poliovirus with a manipulated cre 
element that is needed for replication (Toyoda et al., 2007). 
 CVA21 gives common cold symptoms. It targets and destroys susceptible cells 
via a specific cellular receptor complex comprising of ICAM-1 and DAF then 
subsequent cell lysis. It has been suggested that CVA21- mediated oncolysis of 
malignant melanomas may be a promising new approach to treatment of 
metastatic melanoma. The major advantages for the selection of CVA21 as a 
potential oncolytic agent lie in its mild pathogenicity in humans. Also CVA21 
offers the ability to prepare highly purified virions directly from genetically 
characterized full-length infectious cDNA clones (Au et al., 2007; Shafren et al., 
2004). Echovirus 1 is another potential oncolytic enterovirus that shows a high 
level of tropism for human cancer cells including ovarian cancer cells. Lytic 
infection of E1 is initiated via Integrin α2β1 that is widely expressed on ovarian 
cancer and has high levels on the cell surface (Shafren et al., 2005).  
A successful virotherapy of cancer using oncolytic enteroviruses requires the 
expression of viral receptors on the cell surface that is necessary for the 
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attachment of viruses and cellular interactions (Berry et al., 2008). In fact, 
numerous virus receptors are up-regulated in cancer cells, for example decay-
accelerating factor (DAF), intercellular adhesion molecule-1 (ICAM-1) and α2β1 
are expressed in several human prostate cancer cells. DAF is over-expressed in 
melanomas, breast cancer and colorectal carcinoma. Heparan sulphate 
proteoglycans (HSPGs) are over-expressed on human breast cancers. Some 
integrins, for example αvβ6 is up-regulated on pancreatic cancers (Berry et al., 
2008; Allen et al., 2013; Liu et al., 2014; Koretz et al., 1992; Shafren et al., 2004; 
Lim et al., 2015) 
Oncolytic virotherapy offers prostate cancer patients a novel treatment, especially 
those with tumours at stages that are resistant to other cancer therapies, as 
some studies suggest that patients with advanced prostate cancer showed an 
increase in DAF expression on prostate tumour epithelial cells unlike non-
malignant prostate epithelium (Berry et al., 2008; Loberg et al., 2005).    
It has been suggested that the direct lysis of tumour cells by oncolytic viruses is 
the measurement of the technique’s efficiency (Meerani and Yao, 2010). 
Importantly, inhibition of the immune response may be useful, so the virus is not 
eliminated. However, another point of view suggests that the lysis of tumour cells 
relies on the activation of the immune response against cancer proliferation, by 
boosting the immune response even if it then neutralizes the virus (Meerani and 
Yao, 2010). Oncolytic virotherapy has been shown to be safe and has generated 
clinical responses in tumours that are resistant to chemotherapy or radiotherapy 
(Eager and Nemunaitis, 2001). 
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1.9  Aims of This Thesis 
The aims of this thesis were to identify cell tropism determinants of enteroviruses, 
to contribute to an understanding of how viruses could be targeted more 
efficiently to different cancer cells. This was approached by: 
Ø Analyzing the ability of different echoviruses and CVA9 variants to infect 
cancer cells. 
Ø Adapting E11 to cancer cell lines and finding the sequence changes 
present and to determine if other possible mechanisms can be used by 
adapting this virus onto different cancer cell line. 
Ø Identifying the mechanisms that CVA9 can use to bind to HSPG. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  Chapter 2
 
Materials and Methods 																				
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2.1 Materials 
2.1.1  Virus Strains 
Several virus isolates were used in this work as followed:  
• Coxsackievirus A9 wild-type (CVA9wt; Griggs strain), Coxsackievirus A9 
S2871R (CVA9; genetically engineered mutant), Coxsackievirus A9 P2023S 
(CVA9; genetically engineered mutant). These were derived from a 
Coxsackievirus A9 Griggs cDNA clone (Hughes et al., 1995).  
• CVA9D (A549-adapted mutant), CVA9B (A549-adapted mutant), these were 
produced by passaging the Griggs strain on A549 cells (Williams, 2002). 
• Coxsackievirus A9 clinical isolates CO62, CO79, CO85 and CO87 (Chang et 
al., 1992).  
• Several enterovirus isolates (Echovirus 11, Echovirus 15, Echovirus 20, 
Echovirus 30, Echovirus 6, EV-06, CVA9-1884, were obtained from Dr.Merja 
Roivainen, THL, Helsinki, Finland. 
 
2.1.2 Mammalian Cell Lines 
Several mammalian cell lines were used: 
• GMK- Green Monkey Kidney epithelial cell line 
• A549- Human epithelial lung adenocarcinoma cell line 
• MCF-7- Human breast adenocarcinoma cell line 
• PC-3- Human adenocarcinoma prostate cancer cell line 
• HeLa- Human epithelial cervical cancer cell line 
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• MDA-MB-435- Human melanoma cell line 
• MDA-MB-231- Human breast adenocarcinoma cell line 
• HT-29- Human epithelial colorectal adenocarcinoma cell line 
• RD- Human rhabdomyosarcoma cell line  
These were obtained originally from ATCC and provided by Dr Merja Roivainen, 
THL, Helsinki, Finland (GMK); Dr Sisko Tauriainen, University of Turku, Finland 
(A549, RD); Dr Andrea Mohr (HT-29); Professor Nelson Fernandez (MCF-7, 
HeLa) and Professor Elena Klenova (PC-3, MDA-MB-435, MDA-MB-231) 
(University of Essex). 
 
2.1.3 Tissue Culture Reagents 
Cells were cultured in:  
• DMEM- Dulbecco’s Modified Eagle’s Medium. High Glucose (4.5 g/L) with L-
Glutamine (Biosera) 
• RPMI-1640 Medium- Roswell Park Memorial Institute (Sigma)    
• McCoy's 5A (modified) medium (1x) (Gibco) 
• FBS- Fetal Bovine Serum (Research grade, Sigma) 
• NEAA- MEM Non-essential Amino Acid Solution (100x) (Sigma) 
• Gentamicin solution (50mg/mL) (Sigma) 
• Penicillin-Streptomycin solution (100x) (Sigma) 
• Trypsin-EDTA (1x liquid, 0.25% Trypsin 1mM) (Gibco) 
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• Accutase solution (1x Accutase enzymes in Dulbecoo’s PBS, 0.5 mM EDTA) 
(Sigma)  
• PBS- Phosphate Buffered Saline tablets (1x) (Fisher). 1 tablet of PBS was 
dissolved in 100 ml of water then autoclaved. 
 
2.1.4 General Chemicals / Solutions  
• DMSO- Dimethyl sulfoxide Hybri-Max, ≥99.7% (Sigma) 
• EDTA-Ethylenediaminetetraacetic Acid anhydrous (Sigma) 
• TBS- Tris Buffered Saline (made up of 20 mM Tris+150 mM NaCl) (Sigma), 
and adjusted to pH 7.5 then autoclaved.  
• Calcium chloride CaCl2 (Sigma). A 20 mM of solution was prepared and 
adjusted to pH 7.5 then autoclaved. 
• Calcium plus magnesium chloride (MgCl2) (Sigma). A 20 mM of solution was 
prepared and adjusted to pH 7.5 then autoclaved. 
	
2.1.5 Chemical inhibitors 
• Heparin sodium salt, from porcine intestinal mucosa (Sigma) - heparin was 
dissolved in water to give a 50 mg/ml solution and filter sterilised using a 20 
nm filter.     
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2.1.6 Antibodies  
• Monoclonal Anti-Integrin αvβ6 antibody, produced in mouse (MAB2077Z, 
Millipore)  
• Purified Mouse IgG2a, κ Isotype Ctrl Antibody for αvβ6 (400201, biolegend). 
• Monoclonal Anti-Integrin αvβ3 antibody, produced in mouse (MAB1976Z, 
Millipore). 
• Purified Mouse IgG1, κ Isotype Ctrl Antibody for αvβ3 (401401, biolegend). 
• Monoclonal Anti-Coxsackievirus A9 antibody, produced in mouse (MAB947, 
Millipore). 
• PE anti-human CD55 Antibody (clone JS11, biolegend). 
• PE Mouse IgG1, κ Isotype Ctrl (400113, biolegend).  
• Secondary Antibody: Goat anti-mouse IgG [Alexa fluor 555] 
(Lifetechnologies). 
 
2.1.7 Plaque Overlay Medium and Crystal Violet Stain 
• Agarose (general purpose, Fisher) 
• CarboxyMethyl Cellulose (CMC, Sigma).  
• A 2 % CMC/agarose overlay was produced by adding 2.0 g of CMC and 
2.0 g of agarose to 100 ml of distilled water then autoclaved. 
• A 2 % Liquid CMC overlay was produced by adding 2.0 g to 100 ml of 
distilled water then autoclaved 
  
60 
• A 0.1% w/v solution of Crystal Violet was produced by dissolving 0.5 g of 
Crystal Violet powder (ACROS Organics, Fisher) in 495 ml of distilled water + 
5 ml of absolute ethanol. 
 
2.1.8 Immunofluorescence Reagents 
• 4 % Formaldehyde (FA): 40 % formaldehyde (Fisher) was diluted with x1 
PBS to give a 4% solution. 
• Washing buffer: 100 mM glycine was prepared by dissolving 0.751 g of 
glycine (Fisher) in 100 ml of 1x PBS. 
• Permeabilization buffer: 250 µl of Triton X-100 (0.25 %) (Fisher) was mixed 
with 100 ml of 1x PBS. 
• Blocking Solution: 2 % FBS, 1 % Bovine Serum Albumin (BSA) (Sigma), 
0.05 % TWEEN® 20 (Sigma), 1x PBS. 
• Antibody diluents: 1 % BSA, 0.05 % TWEEN® 20, 1x PBS 
• VECTASHIELD HardSet Mounting Medium with DAPI (Vector Laboratories).  
 
2.1.9 Extraction and Purification Techniques  
A variety of extraction and purification kits were used for purifying DNA, viral RNA 
or PCR products (Qiagen). These include:   
• QIAGEN- QIAquick PCR purification kit (50), using a microcentrifuge. 
• QIAGEN- QIAquick Gel Extraction kit (50), using a microcentrifuge. 
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• QIAGEN- QIAamp Viral RNA Mini Kit (50), for purification of viral RNA (Spin 
Protocol) from tissue cultures. 
 
2.1.10 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
• SuperScript III one-Step RT-PCR System with Platinum Taq DNA 
polymerase kit (Lifetechnologies). 
 
2.1.10.1 Primers 
Oligonucleotides (Table 2.2 and Table 2.3) were used for RT-PCR and 
sequencing. They were obtained from Fisher on a 50 nmole scale and dissolved 
in sterile distilled water to give a 100 µM solution.  
 
2.1.11 Agarose Gel Electrophoresis 
• Agarose (general purpose, Fisher) 
• TopVision Low Melting Point Agarose (Thermo scientific) 
• Loading mixture for a 5 mm agarose gel lane: 1 µl GeneRuler 1 Kb DNA 
ladder (0.5 µg/µl), 1 µl 6x DNA loading dye, were mixed and the volume was 
made up to 6 µl with nuclease-free water (Thermo scientific). 
• Loading buffer (5x): 25 ml of glycerol, 100 µl of 0.5 M EDTA pH 8 and 0.2 g 
of bromophenol blue were mixed and volume made up to 50 ml with sterile 
distilled water. For some DNA isolations, loading buffer without bromophenol 
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blue was used to avoid co-purification of DNA/bromophenol blue and make 
bands migrating to the approximate bromophenol blue position more visible. 
Loading buffer was added to DNA samples at a ratio of 1:5. 
• SafeView Nucleic Acid Stain (NBS Biologicals) was used at 5 µl/ 50 ml gel. 
• ELFO buffer (50x): A mixture of 242 g Tris base and 100 ml of 0.5 M EDTA 
(pH 8.0) was adjusted to pH 7.7 with glacial acetic acid and made up to 1 L 
with water. 
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Table 2.1 Oligonucleotides that were used for RT-PCR and sequencing the 
overlapping fragments of CVA9 isolates/variants. 
Virus 
Primers 
name 
Orientation 
(5’- 3’ à , 3’ – 5’ ß) 
Primers sequence (5’ à  3’) 
Length 
(bp) 
CVA9-wt 
OL2055 Fragment 1-Fwd à AGT CCT CCG GCC CCT GAA TG 20 
OL2079 Fragment 1-Rev ß CTT CCA CCA CCA CCC CAC CGA 21 
OL2080 Fragment 2-Fwd à GTG TGC TAA CGT GGT GGT GGG GT 23 
OL2081 Fragment 2-Rev ß AGG TTC TTC ACT TCT CCT GGG ATG 24 
OL2082 Fragment 3-Fwd à CTA TGC CGA CAC CGC ATC CAC 21 
OL2083 Fragment 3-Rev ß TGG CTT CTT CCA CAT CCC CTT G 22 
OL2145 Fragment 4-Fwd à ACG TGT TGG TAT CAG ACT GGT ATG 24 
OL2146 Fragment 4-Rev ß CTT CCG TCC AGA AAA TGC TGG GGT 24 
OL2147 Fragment 5-Fwd à TCG ACA AGA CCC CGG AAC AAC CCT 24 
OL2148 Fragment 5-Rev ß TCG TGC TCA CAA GGA GGT CTC T 22 
CO87 
OL2055 Fragment 1-Fwd à AGT CCT CCG GCC CCT GAA TG 20 
OL2101 Fragment 1-Rev ß GTG AAC TCA TAT GCC TTG TCC CCA 24 
OL2102 Fragment 2-Fwd à CAG GGG TGT CTG TTG GTC GTG TG 23 
OL2103 Fragment 2-Rev ß ACG CGA TCA GGA ACT TGC CTG TTG 24 
OL2104 Fragment 3-Fwd à CAC ACC CTA CTG GGG GAG ATT CT 23 
OL2105 Fragment 3-Rev ß ACG CGC CGG CGC ATT TCC TTC TGT 24 
OL2106 Fragment 4-Fwd à GAT TAT GTA TGT ACC ACC CGG TGG A 25 
OL2107 Fragment 4-Rev ß GTT TCC CAC ATA CAC GGC CCC TG 23 
CO62 
OL2055 Fragment 1-Fwd à AGT CCT CCG GCC CCT GAA TG 20 
OL2094 Fragment 1-Rev ß CAC CGT TAG CCA TTG CAG TAG AG 23 
OL2095 Fragment 2-Fwd à AGT TCC ACC AAG GGT GGC TGC TG 23 
OL2096 Fragment 2-Rev ß TCT TCG GGG GGT TTG CTC CTG GT 23 
OL2097 Fragment 3-Fwd à CTA CGC GCA TTG GTC AGG CAG T 22 
OL2098 Fragment 3-Rev ß GTT CCC TTC CGT CCA GAA GAT ACT G 25 
OL2099 Fragment 4-Fwd à AGC ACA AGA CAT GCC AGT GTT GAC A 25 
OL2100 Fragment 4-Rev ß GTT CCC CAC GTA AGC AGC ACC TG 23 
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Table 2.2 Oligonucleotides that were used for RT-PCR and sequencing the 
overlapping fragments of echovirus 11 (E11) isolates/variants. 
Virus 
Primers 
name 
Orientation 
(5’- 3’ à , 3’ – 5’ ß) 
Primers sequence (5’ à  3’) 
Length 
(bp) 
a. 
E11 
general 
OL2053 Fragment 1-Fwd à TTA AAA CAG CCT GTG GGT TG 20 
OL2054 Fragment 1-Rev ß ACC CAA AGT AGT CGG TTC CGC  21 
OL2055 Fragment 2-Fwd à AGT CCT CCG GCC CCT GAA TG 20 
OL2056 Fragment 2-Rev ß AGG GAA TTT CCA CCA CCA NCC 21 
OL2057 Fragment 3-Fwd à CAT GTG TGC CTT GGA TTA GYC ARA C 25 
OL2058 Fragment 3-Rev ß GTC CCT GTT GTA RTC YTC CCA 21 
OL2171 Fragment 1/2-Fwd à GTT TCG CTC CAC ACA ATC CCA GTG 24 
OL2172 Fragment 1/2-Rev ß CAG ATG GTG AGT TGA GGG CAG GCA 24 
OL2173 Fragment 2/3- Rev ß GAA GAT CAG CCA ACC CAA CCA GAT G 25 
OL2174 Fragment 2/3- Fwd à TCA TTG CAA GCT GAC ACG AAG CAC A 25 
b. 
E11 V5-7A 
OL2208 Fragment 1-Fwd à TGG CTG CTT ATG GTG ACG ATC GAG 24 
OL2209 Fragment 1-Rev ß TGC CGA CTC CAA CTC CCA TTC CGG CA 26 
OL2210 Fragment 2-Fwd à TGG GGT GTA GCG ATG TTA ACG GGG T  25 
OL2211 Fragment 2-Rev ß AGG AGG ACT GCA GAC CCA CGT CCC A  25 
OL2212 Fragment 3-Fwd à CTA CGC CCA CTG GTC GGG TAG TGT CA 26 
OL2213 Fragment 3-Rev ß GAC CTA GTT GGG TTC CCT GGT CCT 24 
OL2214 Fragment 4-Fwd à AGC AGC ATG CGT GTA CAT GGG AG 23 
OL2215 Fragment 4-Rev ß CAG TTT TGC CAA TCG TTG TGT GTC GCC A 28 
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2.2 Methods 
2.2.1 Cell Biology and Virology Techniques 
2.2.1.1 Passaging Cell Lines 
GMK, A549, MDA-MB-435, MDA-MB-231, HeLa and RD cells monolayer were 
grown in 50 ml (25 cm2) tissue culture flasks in DMEM supplemented with 10% 
FCS, 1 % NEAA and 50 µg/ml Gentamicin or 5 µg/ml Penicillin-Streptomycin. 
PC3 and MCF-7 cells were maintained in RPMI-1640 containing 10% FCS and 
50 µg/ml Gentamicin or 5 µg/ml Penicillin-Streptomycin. HT-29 cells were 
maintained in McCoy's 5A medium supplemented with 10% FCS and 5 µg/ml 
Penicillin-Streptomycin. 
To propagate the cells the entire growth medium was discarded carefully from 
flasks, then the cells were washed gently twice with 1x PBS, 300-500 µl of 
Trypsin-EDTA or Accutase were added and the cells were placed on a rocking 
platform shaker at room temperature for 3 minutes until all cells were detached. 
In order to culture the cells in flasks, 4 ml of growth medium was added to the cell 
suspension and 1 ml aliquots were then placed into flasks containing 3 ml of 
fresh medium, then the flasks were incubated at 37°C in 5% CO2 and passaged 
after an ~80-100 % confluent cells monolayer was observed (3-5 days). 
 
2.2.1.2 Cryopreservation of Mammalian Cells for Storage 
Freezing: cells were washed twice with 1x PBS and detached by 300-500 µl of 
Trypsin-EDTA or Accutase. Then were re-suspended in 90 % FBS and 10 % 
DMSO before being transferred to labeled cryovials (Nunc). The cryovials were 
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then wrapped in cotton wool and frozen at -80°C for 48 hours. For long-term 
storage, the cells were transferred into liquid nitrogen. 
Thawing: frozen cells were removed from -80°C freezer or liquid nitrogen and 
immediately transferred to a 37°C water-bath for a minute, then cells were 
transferred to a flask containing 4 ml of DMEM and incubated at 37°C 5% CO2 
incubator. Next day, the growth of cells was checked and the old medium was 
replaced with 4 ml of fresh DMEM. 
 
2.2.1.3 Viral Plaque Assay 
Plaque assays were performed in 25 cm2 tissue culture flasks. Confluent cell 
monolayers was obtained 3-4 days after splitting cells, medium was discarded 
and 100 µl of each diluted virus were added to 1 ml of fresh growth medium then 
the flasks were placed on a rocking platform for 45 minutes at room temperature. 
The infected cells were covered with 4 ml of overlay made from warm DMEM 
(56 °C) and a 2 % solution of CMC and agarose (melted in a boiling water bath) 
at a ratio of 1:3 (CMC/ agarose : DMEM). The flasks were then incubated at 37°C 
in a 5% CO2 incubator for 3 days or until plaques had formed. Once the plaques 
were observed, the overlay medium was removed gently by washing twice with 
1x PBS, and 0.1 % Crystal Violet stain was added. After 5 minutes the flasks 
were washed with PBS and the plaques were counted. In order to perform the 
plaque assays in 6-well plates, cells were treated the same way as above with a 
slight difference in the CMC overlay (2 % CMC without agarose was used) with a 
ratio of (1:2 / CMC:DMEM).    
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2.2.1.4 Viral Propagation 
In order to propagate the virus, the medium was discarded from the confluent 
monolayers of cells and 1 ml of fresh growth medium was added. Then, 10 µl of 
virus sample was added and placed on a rocking platform for 1 hour to allow 
each virus particle to adsorb to a cell and initiate a spreading infection. After that, 
3 ml of media was added and the flasks incubated at 37 °C in a 5% CO2 
incubator for 3-4 days to allow cytopathic effect (CPE) to progress. Virus was 
then released by freeze-thawing three times and then 1 ml aliquots of these 
infected cells were placed in microcentrifuge tube and stored at -80 °C. 
  
2.2.1.5 Plaque purification from Virus Stock  
In order to pick plaques, a plaque assay was performed. When plaques have fully 
developed, individual and rounded plaques were marked then a sterile 
micropipette tip was pushed to the center of plaque through the CMC/agarose 
overlay. The plaque was scratched and about 10 µl of fluid in the vicinity was 
withdrawn then transferred to a microcentrifuge tube contained 200 µl of fresh 
growth medium. The mixture was briefly vortexed and 100 µl was transferred to a 
fresh monolayer of cell to propagate the picked plaques (section 2.2.1.4). 
 
2.2.1.6 Tropism of Enteroviruses to Different Cell Lines  
To study the cytopathic effects (CPE) of a panel of viruses on GMK, A549, 
MCF7, PC3, MDA-MB-231, HeLa, MDA-MB-435, HT-29 and RD, cells were 
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grown in 24-well plates for 2 days. All media were removed and 5 µl of undiluted 
samples of enteroviruses (CVA9, CVA9D, Echo11, Echo15, Echo20, Echo30, 
CVA9-1884, Echo6, EV-06, CVB) were added to 500 µl of growth medium to 
each well. Then plates were placed on a rocking platform for 45 minutes at room 
temperature. After that, 1 ml of growth medium was added to each well and 
incubated at 37 °C in a 5% CO2 incubator, then plates were monitored 
periodically. When all the cells in some wells seemed to be detached, cells were 
washed gently with 1x PBS and stained with 0.1 % Crystal Violet. 
 
2.2.1.7 Flow Cytometry Analysis of CD55 Surface Expression on Different 
Cell Lines 
Expression of DAF (Decay accelerating factor; CD55) on the cell surface was 
analyzed by flow cytometry using a specific monoclonal antibody (PE labelled 
anti human CD55 [clone JS11], Biolegend). A PE labelled isotype antibody was 
used as a control (IgG1, k, Biolegend). Sub-confluent monolayers of cells were 
washed with PBS and detached using (Trypsin-EDTA) then harvested in 10 ml of 
DMEM. Cells were visualised and counted using a hemocytometer under a 
microscope and re-suspended at 5 x 105 cells per ml in DMEM. Then cells were 
centrifuged for 5 min at 1300 rpm. Cells were re-suspended in 95 µl of DMEM 
after pelleting and then incubated with the appropriate mAb; 5 µg/ml of anti-
human CD55 antibody (primary antibody), 5 µg/ml of Isotype control (IgG1, k) 
and mock-treated (cells only). Then cells were incubated in the dark at 4 °C for 
20 min. After that, 1 ml of DMEM were added, cells were pelleted, then re-
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suspended in 200 µl of DMEM, vortexed, and then analyzed with FACS Calibur 
flow cytometry (Becton Dickinson; BD Accuri™ C6). 
 
2.2.1.8 Virus Blocking Assay Using Soluble Heparin 
Cells were grown in 25 cm2 flasks to ~ 100 % confluence. 90 µl of virus dilution 
were incubated with 10 µl of 50 mg/ml of heparin at room temperature for 20 
minutes. 90 µl of virus plus 10 µl of water was used as a control. Then, the virus 
mixtures were added to 1 ml of medium and added to the cell monolayer. 
Incubation continued for 1 hour on a rocking platform at room temperature. After 
this time, the infected cells were overlaid with a 2 % solution of CMC/agarose in 
DMEM (flasks) or a 2 % solution of liquid CMC in DMEM (plates), then incubated 
at 37°C in a 5% CO2 incubator for 3-4 days. Upon plaque formation, cells were 
stained with 0.1 % Crystal Violet. 
 
2.2.1.9 Temperature Sensitivity Assays 
The temperature sensitivity of viruses was measured by adding diluted viruses 
(CVA9, CVA9D and P2023S) to cell monolayers (A549 and GMK cells) and 
carrying out a plaque assay but incubating at different temperatures i.e. 34°C, 
37°C and 40°C, for 3 days. Upon obtaining the plaques the cells were stained 
with 0.1% Crystal Violet. 
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2.2.1.10 Virus Blocking Assays Using Chemicals 
2.2.1.10.1 Metal Ions-dependence (Ca2+, Mg2+)  
Virus binding to cells in the presence or absence of calcium chloride (CaCl2, [20 
mM]) or calcium plus magnesium chloride [20 mM of CaCl2 and MgCl2]), both in 
TBS, was performed in A549 cells in 6-well plates. Confluent monolayers were 
washed twice with TBS, TBS-CaCl2 or TBS-CaCl2/MgCl2, then 100 µl of diluted 
viruses (CVA9-wt, S2871R and P2023S) were added to the cells for 1 hour on a 
rocking platform at room temperature. Then the buffers and unbound virus were 
discarded and cells were washed twice with same buffers and plaque assay was 
performed in the presence of growth medium.  
 
2.2.1.11 Virus Blocking Assays Using Monoclonal Antibodies 
(Immunofluorescence) 
For the virus blocking assays using anti-human-integrin mAbs, sub-confluent 
A549 cells were grown on sterile coverslips in 6-well plates for 1 day.  DMEM 
was discarded and 500 µl of fresh DMEM were placed in each well. Cells were 
pretreated with 1.0 µg of mAb against integrin αvβ6, αvβ3 or isotype controls for 30 
minutes at 37 °C prior to the infection. Then 100 µl of 103 PFU/ml stock of virus 
were added to each well and incubated at 4 °C for 30 min before 2 ml of fresh 
DMEM was added into wells. Then cells were incubated for 6 hours at 37°C in a 
CO2 incubator. After that, all media were removed and cells were gently washed 
twice with 1x PBS and dried at room temperature before being fixed. 1 ml of cold 
4 % formaldehyde (FA) was added onto the cells and they were incubated at 
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room temperature on rocking platform for 20 minutes, then the cells were washed 
twice with 100 mM glycine prepared in 1x PBS for 5 minutes (to eliminate any FA 
residues, thus stopping the fixation reaction), then permeabilized for 20 minutes 
with 0.25 % Triton X-100. This was followed by a single wash with 1x PBS for 10 
minutes and then the cells were treated with blocking solution for 30 minutes on a 
rocking platform. Primary antibody (anti-CVA9) was at titre of 1:112 (diluted with 
antibody diluent) and coverslips were inverted onto 50 µl pools of antibody 
solution that were placed on parafilm in a humid chamber and incubated at least 
2 hours to overnight (16 hrs) at 4°C. The next day, cells were gently washed with 
1x PBS for 10 minutes. The secondary antibody (Alexa fluor 555-labelled anti-
mouse IgG) was diluted at (1:200), added to the cells and incubated in the dark 
for 2 hours at 4 °C. Cells then were washed with 1x PBS and mounted using 
mounting media containing DAPI on glass slides. The slides were examined and 
observed by fluorescence microscopy using a BX41 microscope. The numbers of 
red-fluorescent cells in 20 random fields were counted. 
 
2.2.2 Molecular Techniques 
2.2.2.1 Viral RNA Purification from Tissue Cultures 
Total viral RNA was extracted from cell-culture supernatant containing viral 
particles using a QIAamp Viral RNA Mini Kit (QIAGEN). A volume of 560 µl of 
Buffer AVL was mixed with 5.6 µl carrier tRNA in a 1.5 ml microcentrifuge tube. 
140 µl of cell-culture supernatant virus was added to the Buffer AVL–carrier RNA 
and mixed by pulse-vortexing for 15 s, then incubated at room temperature for 10 
min and briefly centrifuged to remove drops from the inside of the lid. After that, 
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560 µl of ethanol (100%) was added to the sample and mixed by pulse-vortexing 
for 15 s. After mixing, the tube was briefly centrifuged to remove drops from 
inside the lid. Then 630 µl of the solution was added to the QIAamp Mini column 
in a 2 ml collection tube and centrifuged at 8000 rpm for 1 min. Then the tube 
containing the filtrate was discarded and the QIAamp Mini column was placed 
into a clean 2 ml collection tube. Then the rest of the sample was loaded onto the 
spin column and centrifuged. 500 µl of Buffer AW1 was added and centrifuged. 
Then the spin column was placed in a clean 2 ml collection tube and the tube 
containing the filtrate was discarded. 500 µl of Buffer AW2 was added and 
centrifuged at full speed at 14,000 rpm for 3 min and then centrifuged at full 
speed for 1 min (to eliminate any residue of AW2 buffer). Finally, the QIAamp 
Mini column was placed into a clean 1.5 ml microcentrifuge tube and 60 µl of 
Buffer AVE was added to the centre of the filter to elute the sample and the 
column and tube was centrifuged (1 min). Viral RNA is stable for up to one year 
when stored at –20°C or –70°C. 
 
2.2.2.2 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Technique (cDNA synthesis) 
RT-PCR was performed to generate overlapping fragments spanning the P1 
region of enteroviruses, using the Superscript III One-Step RT-PCR System with 
Platinum Taq (Lifetechnologies). cDNA was generated and amplified from 5 µl of 
the purified RNA, 1 µl of a 100 mM solution of each desired forward and reverse 
primers (Table 2.1/2.2), 1 µ RT-Taq mix, 25 µl 2x reaction mix and the volume 
made up to 50 µl with nuclease-free water. The RT-PCR reactions were gently 
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mixed and run in an Applied Biosystems GeneAmp 9700 thermal cycler as 
described in (Table 2.3). The amplicons were purified using a QIAquick Gel 
Extraction kit (QIAGEN) and sequenced commercially by Source Bioscience 
Lifesciences (Nottingham, U.K.). 
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Table 2.3 RT-PCR steps used to amplify DNA fragments spanning the 
enterovirus P1 region 
Steps of the reaction Temperature (°C) Time Cycles 
cDNA synthesis and pre-
denaturation 
50 30 mins x1 
94 2 mins x1 
Denaturation 94 30 sec  
Annealing 45-50 1 min  x35-40 
Extension and 
Final Extension 
68 1 min/kb  
68 5 min x1 
 4           ∞ 
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2.2.2.3 Agarose Gel Electrophoresis 
For small analytical gels, 0.5 g of agarose was mixed with 50 ml of 1x ELFO 
buffer, then heated in a microwave until completely dissolved. This was left to 
cool at room temperature. 5µl of safeView was added to the cooled gel which 
was then poured slowly into the casting tray, and then the comb was inserted. 
Then the gel was allowed to solidify at room temperature. 
5 µl of DNA sample was mixed with 1 µl 5x clear loading buffer and loaded to the 
gel. 5 µl of 1 kb ladder was added to the first lane. Electrophoresis was carried 
out at a voltage of 100-150 V for 20-30 minutes. Then the gel was visualized 
under UV light and an image was taken using a gel documentation and analysis 
system (SYNGENE InGenius3/ GeneSys software) 
 
2.2.2.4 DNA Purification from Agarose Gel (Gel Extraction) 
TopVision Low Melting Point agarose gel was used for nucleic acid recovery after 
electrophoresis and to purify specific PCR/ DNA fragments. The agarose gel was 
prepared, run and visualized as usual, and then the desired DNA fragment was 
excise of the gel with a clean scalpel blade under UV light and placed in 1.5 ml 
microcentrifuge tube. DNA was purified from the gel using a QIAquick Gel 
Extraction kit. The procedure was done according to the protocol that was 
provided by the supplier (Qiagen, 2006). 300 µl of QG buffer was added per 100 
mg of gel. Then the tube was incubated in a water bath at 50 °C for 15-20 
minutes or until the gel slice had completely dissolved. 100 µl of isopropanol was 
added to the sample and mixed, then the mixture was transferred to the QIAquick 
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spin column, which was placed in a 1.5 ml tube and centrifuged at 14,000 rpm for 
1 minute. The flow-through was discarded. 500 µl of QG buffer was added again 
to the spin column which was centrifuged for another minute. Then, the spin 
column was washed by adding 750 µl of PE buffer and centrifuging for a minute. 
Once again the flow-through was discarded and the spin column was re-
centrifuged for an additional minute. Then the QIAquick spin column was 
transferred into a new sterile 1.5ml tube. 50 µl of EB buffer was added to the 
column to elute the DNA followed by centrifugation at 14,000 rpm for 1 minute. 
The purified DNA was analyzed by gel electrophoresis or stored at -20°C. 
 
2.2.2.5 DNA Purification using PCR Purification Kit 
In order to purify specific PCR products where a single band was obtained and 
gel separation by gel electrophoresis was not required, a QIAquick PCR 
purification kit were used. 5 volumes of Buffer PBI were added to 1 volume of the 
PCR sample and mixed gently. To bind DNA, the sample was applied to the 
QIAquick column and then centrifuged for 30–60 s. Then the flow-through was 
discarded and the QIAquick column was placed again into the same collection 
tube. To wash, 0.75 ml Buffer PE was added to the QIAquick column and 
centrifuged for 30–60 s. Then the flow-through was discarded and the QIAquick 
column was placed again into the same collection tube and centrifuged for an 
additional 1 min. The QIAquick column was placed then in a clean 1.5 ml 
microcentrifuge tube. To elute DNA, 50 µl Buffer EB or water was added to the 
centre of the QIAquick membrane and centrifuged for 1 min. Then DNA samples 
were stored at –20°C or analyzed on an agarose gel.  
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2.2.3 Bioinformatics Techniques 
2.2.3.1 DNA Sequencing and Sequence Analysis  
DNA fragments were sequenced commercially by Source BioScience 
LifeSciences. The fragments were sequenced in both orientations, using the 
primers used for amplification.  
• Chromas Lite:  (http://technelysium.com.au/?page_id=13) was used to open 
the .ab1 files to check any disagreements between the sequences. The 
sequences were assembled manually into a complete sequence, which was 
then translated into protein sequences using the ExPASy online tool 
(http://web.expasy.org/translate/). Sequence alignments were performed 
using the online (http://www.genome.jp/tools/clustalw/) tool ClustalW (Larkin 
et al., 2007). Database searches were performed using NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
• Weblogo (http://weblogo.berkeley.edu/logo.cgi) was used to produce 
sequence logos.  
• MEGA6 (http://www.megasoftware.net/) was used to produce phylogenetic 
trees. 
 
2.2.3.2 Three-Dimensional Structure (3D) 
Amino acid positions of interest were plotted onto the structure of the CVA9 
(coordinates provided by Professor David Stuart; Hendry et al., 1999) or E11 
pentamer (1H8T, Stuart et al., 2002) using the program RASMOL version 2.7.4.2. 
(http://rasmol.org/FAQ.html). 
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3.1 Introduction  
Most of the enteroviruses can be responsible for similar mild diseases but can 
also cause diverse symptoms (Brooks et al., 2007). The pathogenicity of 
enteroviruses is highly complex due to variation in the genetic background of 
populations and immunological aspects, and this is difficult to study due to 
restrictions to investigations in higher primates. This inspired scientists to develop 
animal models for studies of the important pathogen human enterovirus 71 
(HEV71)  (Wang et al., 2011; Zaini et al., 2012). Transgenic mice expressing the 
human form of CD155, the poliovirus receptor, have also been important in 
research and vaccine testing (Ren and Racaniello, 1992). Previous studies have 
identified that the 5’UTR and 3’UTR of enteroviruses are key factors in tissue 
tropism, and viral pathogenesis (Lin and Shih, 2014).   
The interaction between a virus and its cellular receptor is also potentially a key 
determinant of cell tropism and disease. Recombinants between 
coxsackieviruses A9 and B3 (CVA9, CVB3), which show different pathogenicity 
in new-born mice, showed that this usually correlated with the P1 region and so 
probably involved receptor interactions (Lin and Shih, 2014; Harvala et al., 2002). 
In addition, enteroviruses are currently being explored as possible oncolytic 
agents (Berry et al., 2008; Patel et al., 2013; Au et al., 2007). An understanding 
of virus-receptor interactions might help to design specific viruses for cancer 
therapy. Cancer cells show over-expression of some cell-surface molecules and 
as these include molecules used by some enteroviruses as receptors, these 
viruses could be potentially be potent oncolytic agents (Allen et al., 2013; Liu et 
al., 2014; Koretz et al., 1992). 
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This chapter describes an extensive series of experiments to investigate the cell 
tropism determinants of enteroviruses. A panel of enteroviruses was used to 
infect different cell lines to identify which cell types can be selectively infected. 
This was followed by FACS examination using a specific monoclonal antibody to 
detect the expression of DAF (CD55), as this receptor previously believed to be 
utilized by several of the echoviruses present in the panel (Clarkson et al., 1995; 
Bergelson et al., 1994; He et al., 2002; Powell et al., 1998). Finally, one virus, 
echovirus 11 (E11 V5-7A), was propagated on two cell lines; A549 and HeLa, to 
investigate if adapting mutations were observed.  
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3.2 Analysis of a Panel of Enteroviruses on Different Cell Lines 
3.2.1 Infectivity Assay of Enteroviruses on GMK, A549, MCF7, PC3, MDA-
MB-231, HeLa, MDA-MB-435, HT-29 and RD cells 
To analyse the cell tropism of enteroviruses towards a range of cancer cells, we 
performed a screen of enteroviruses. A panel of enteroviruses was used on 
GMK, A549, MCF-7, PC-3, MDA-MB-231, HeLa, MDA-MB-435, HT-29 and RD 
cells. Cell monolayers were infected with 10 enteroviruses: CVA9wt, CVA9D, 
CVA9B, CVA9-1884, Echo 6, Echo 11 (E11 V5-7A), Echo 15, Echo 20, Echo 30 
and EV-06. These are described more fully in Table 3.1.  
Infected cell monolayers were incubated for 4-5 days then plates were washed 
gently with PBS before being stained with Crystal Violet. The results are shown in 
(Figure 3.1). It can be seen that the mock (uninfected) wells have a monolayer of 
cells in each case. All the viruses in the panel caused complete or partial 
destruction of the monolayers in at least one of the cell lines, apart from EV-06. 
None of the viruses had a clear effect on MDA-MB-231 or MDA-MB-435 cells but 
there were signs of possible CPE in MDA-MB-231 caused by Echo 20 and 
CVA9B, and similar signs on MDA-MB-435 caused by Echo 20 and CVA9wt.  
On the other hand, most of the panel had a large effect on RD cells, except EV-
06. As this sample did not have a clear effect on any of the cell lines, it may be 
that the virus concentration was low or the virus had become inactivated. None of 
the tested echoviruses infect GMK cells, although a few plaques were seen in the 
Echo 15 sample. Most echoviruses killed the A549 cells. This shows that 
enteroviruses can have different tropism for cells. Both CVA9wt and the A549-
adapted strain CVA9D caused extensive cell death in GMK, A549, RD and HT-29 
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cells. However, as expected the A549 adapted mutant infects these cells more 
efficiently than CVA9wt, but caused less death of GMK cells. CVA9D also had a 
much larger effect than CVA9wt on PC3 cells. Surprisingly, the other CVA9 
isolate, CVA9-1884 did not infect any of the cell lines except PC-3 and RD cells, 
while CVA9B, did not infect HeLa, MBA-MD-435 or HT-29 cells. This shows that 
there can be differences in cell tropism within an enterovirus type.  
Echo 6, 11 (E11 V5-7A) and 20 had a clear effect on A549, MCF-7, HT-29 and 
RD cells, while less effect could be seen on PC-3 and HeLa cells, except that 
Echo 11 (E11 V5-7A) was more effective than Echo 6 and Echo 20 on PC-3 
cells.  
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Table 3.1 : Enteroviruses present in the panel used to infect cell lines.  
Name Description Source 
CVA9wt 
CVA9 Griggs strain recovered from cDNA 
clone but later found to have S287R 
mutation in VP1. 
Hughes et al., 
1995 
CVA9D 
CVA9 Griggs adapted on A549 cells and 
containing a mutation at position D233N in 
VP2 
Williams, 2002 
CVA9B 
CVA9 Griggs adapted on A549 cells and 
containing mutations at position T73A in 
VP3 and S287R in VP1 
Williams, 2002 
CVA9-1884 Clinical isolate of CVA9-1884  Finland *  
Echo 11 Clinical isolate of E 11 (strain V5-7A) Finland *  
Echo 15 Clinical isolate of E 15  Finland *  
Echo 20 Clinical isolate of E 20  Finland *  
Echo 30 Clinical isolate of E 30 Finland *  
Echo 6 Clinical isolate of E 6 Finland *  
EV-06 Clinical enterovirus isolate, type unknown  Finland *  
* Clinical isolates were provided by Dr. Merja Roivainen, THL, Finland. 
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Mock      Echo30     CVA9-1884    Echo6       EV-06     CVA9B 
 Mock       CVA9wt     CVA9D       Echo11     Echo15      Echo20 
GMK 
 
 
 
 
 
 
 
 
 
 
A549 
 
 
 
 
 
 
 
 
 
 
MCF-7 
 
 
 
 
 
 
 
 
 
 
MDA-MB-231 
 
 
 
 
 
 
 
 
 
 
MDA-MB-435 
 
Mock       CVA9wt     CVA9D     Echo11    Echo15     Echo20 
Mock       Echo30   CVA9-188    Echo6     EV-06       CVA9B 
Mock        CVA9wt     CVA9D     Echo11    Echo15    Echo20 
Mock       Echo30   CVA9-1884   Echo6      EV-06      CVA9B 
Mock         CVA9wt     CVA9D      Echo11    Echo15      Echo20 
Mock        Echo30   CVA9-1884   Echo6      EV-06      CVA9B 
Mock      CVA9wt     CVA9D      Echo11      Echo15    Echo20 
Mock      Echo30   CVA9-1884   Echo6      EV-06      CVA9B 
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Figure 3.1 Differences in enterovirus tropism; shown by the growth of a panel of 10 
enterovirus isolates or mutants. Monolayers of cells in 24-well plates were mock-infected 
or incubated with 5 µl of undiluted samples in 500 µl of medium of CVA9 strains or 
several echoviruses for 45 min at room temperature (section 2.2.1.6). 1 ml of growth 
medium was added to each well and the plates were transferred to a 37°C (5% CO2) 
incubator and incubated for 4-5 days before being stained with Crystal Violet. Each cell 
line was tested 3 times and the results obtained were consistent in each case.  
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HT-29 
 
 
 
 
 
 
 
 
 
 
RD 
 
Mock      CVA9wt     CVA9D      Echo11     Echo15     Echo20 
Mock       Echo30    CVA9-1884  Echo6       EV-06     CVA9B 
Mock      CVA9wt     CVA9D      Echo11      Echo15     Echo20 
Mock      Echo30    CVA9-1884  Echo6       EV-06       CVA9B 
Mock      CVA9wt     CVA9D     Echo11     Echo15      Echo20 
Mock      Echo30    CVA9-1884  Echo6       EV-06      CVA9B 
Mock       CVA9wt     CVA9D     Echo11     Echo15     Echo20 
Mock       Echo30    CVA9-1884   Echo6      EV-06     CVA9B 
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3.3 Analysis of DAF (CD55) Surface Expression on Different Cell 
Lines by Flow Cytometry   
Viral capsid interactions with the host cell surface by binding to its receptor 
decay-accelerating factor (DAF; CD55) are a major determinant of the cellular 
infectivity of echovirus 11 (Stuart et al., 2002a,b; Rezaikin et al., 2009). A number 
of other echoviruses are also known to utilize DAF as a receptor such as 
echovirus 3, 6, 7, 11, 12, 13, 19, 21, 24, 25, 29, 30 and 33 (Clarkson et al., 1995; 
Bergelson et al., 1994; Ward et al., 1994; Bhella, et al., 2004; He et al., 2002; 
Powell et al., 1998).  
A flow cytometric (FACS analysis) study was done to investigate whether DAF 
(CD55) is expressed on the cell surface of the different cell lines in our panel and 
so could be used as a receptor to initiate echoviruses infections. 5 µg/ml of PE 
anti-human CD55 antibody and 5 µg/ml of PE mouse Isotype control (IgG1, k) 
were used. Then samples were analysed with a FACS (BD Accuri C6). The 
results was analysed and gated by FlowJo software. As shown in Figure 3.2, flow 
cytometry analysis indicates that GMK cells show a little-to-no DAF expression. 
Expression on RD cells is very low. A549 and HeLa expressed abundant levels 
of cell surface DAF, whilst PC-3, MDA-MB-231, MCF-7, HT-29 and MDA-MB-435 
expressed low levels of surface DAF (Table 3.2). It has previously been reported 
that RD, HeLa, HT-29 and PC-3 cells express DAF, in agreement with the results 
shown in Figure 3.2 (Pasch et al., 1999; Gullberg et al., 2010; Nasu et al., 1998; 
Berry, et al., 2008). There is no published information on GMK, MCF-7, MDA-
MB-231 and MDA-MB-435 cells.  
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Figure 3.2 Flow cytometric analysis of DAF (CD55) expression on the surface of 
different cell lines. Cells were at a density of 5 x 105 cells per ml. (A) Histograms show 
detection of 5 µg/ml PE mouse IgG1 Isotype controls (grey plots) and detection of DAF 
by 5 µg/ml PE anti-human CD55 antibody (red plots). Results were generated and gated 
with a FACS (BD Accuri C6) then analyzed and gated by FlowJo software. (B) A chart 
shows a comparison of the Isotype and anti-CD55 antibody on different cell lines 
(logarithmic scale, base 10).  
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Table 3.2 Fluorescence intensity ratio of DAF antibody compared to 
the Isotype control. Ratios are used to define categories of expression for 
use in Figure 3.3.  
< 1= no expression, then 1 - 5, 5 -15, > 15 increasing levels of expression.   
Cells  Isotype (IgG1) DAF (CD55) Ratio 
MDA-MB-231 3554 5086 1.43 
MDA-MB435 4122 42347 10.27 
MCF7 3864 28631 7.41 
GMK 8341 8012 0.96 
RD 6304 7371 1.17 
A549 7046 247000 35.05 
PC3 7511 63969 8.51 
HeLa 5436 266000 48.93 
HT-29 4301 54098 12.57 
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It can be seen that there is only a slight correlation between expression of the 
receptor and the observed virus CPE, except for echoviruses and GMK cells 
where there is no DAF expression and no CPE caused by any echoviruses. 
MDA-MB-231 and MDA-MB-435 cells express low but significant levels of DAF 
but are not killed by most of the echoviruses. On the other hand, RD cells 
express little DAF but are killed efficiently by all the echoviruses except EV-06. 
MDA-MB-231 cells are reported to express both αvβ3 and αvβ6 (Goodman et al., 
2012) but are not killed by most of the CVA9 strains. MCF-7, A549 and PC-3 
cells are reported to express no αvβ3 and αvβ6 and are infected by several of the 
CVA9 strains.       
 
3.3.1 Conclusion of Cell Tropism and Receptor Expression Studies 
The reported receptors used by echoviruses (DAF) and CVA9 (integrin αvβ6/αvβ3) 
seem to show very different expression patterns. DAF is expressed on all the cell 
lines tested, except GMK. While αvβ6/αvβ3 are not widely expressed according to 
the work of Goodman et al., 2012. In both cases we find that receptor expression 
does not correlate well with the ability of echoviruses or CVA9 to infect the cells. 
This suggests that other receptors or other factors may be involved in defining 
cell tropism. In the case of CVA9, it is already known that mutants lacking the 
RGD motif can be infectious, which implies that the virus can use non-integrin 
receptors for entry (Hughes et al., 1995). Similarly, adaptation of echoviruses to 
different cell lines can involve loss DAF binding (Stuart et al., 2002b; Rezaikin et 
al., 2009; Novoselov et al., 2012).        
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3.4 Adaptation of an Echovirus 11 Isolate (E11 V5-7A) to A549 
and HeLa Cells   
Previous studies have identified echovirus 11 mutants associated with adaptation 
into HT-29, Vero and RD cells (Stuart et al., 2002b; Rezaikin et al., 2009; 
Novoselov et al., 2012). To extend our understanding of adaptation to other cell 
lines, we propagated Echovirus 11 (E11 V5-7A strain) on HeLa and A549 cells. 
 
3.4.1 Capsid Sequences of Echovirus 11 Strain E11 V5-7A 
The E11 V5-7A strain had not been sequenced previously, so initially sequence 
analysis of the P1 region was performed. Pan-enterovirus (5’UTR and VP2 
primers) and primers based on conserved regions in an echovirus 11 alignments 
(Table 2.2a) were used for RT-PCR and sequencing (Figure 3.4). Four 
overlapping fragments were generated and sequenced using the same primers in 
both orientations. The whole sequence was then assembled and translated to 
give the amino acid sequence using the ExPASy online tool (Artimo et al., 2012).  
 
3.4.2 Relationship of E11 V5-7A to other E11 Isolates  
The predicted P1 amino acid sequence of E11 V5-7A was aligned with the 
sequence of all echovirus 11 isolates in the GenBank sequence database with a 
complete P1 sequence available. A maximum likelihood method tree was 
generated using MEGA6 (Figure 3.5). It can be seen that E11 V5-7A clusters 
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relatively closely with a few other isolates. These originate from several 
European countries including Finland, Hungary and Romania (Chevaliez et al., 
2004; Lukashev et al., 2004) and the isolations were made from 1986- 2011. It is 
more distant from a cluster of strains which are mainly cell-line adapted variants 
of the Russian strain 7611 isolated in 1993 (Rezaikin et al., 2009; Novoselov et 
al., 2012). E11 V5-7A is also distant from the 1953 E11 prototype Gregory and 
adapted variants. 
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Figure 3.4 Schematic diagram of the echovirus 11 capsid proteins (VPs) in the P1 
region. Overlapping fragments were generated using pan-enterovirus primers (red 
arrows) and primers based on E11 alignments (black arrows).     
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Figure 3.5 Molecular phylogenetic analyses of Echovirus 11 isolates by Maximum 
Likelihood method.  The evolutionary history was inferred by using the Maximum 
Likelihood method based on the JTT matrix-based model (Jones et al., 1992). The 
dendrogram shows phylogenetic relationships between sequenced E11 V5-7A isolate 
(red square) and the E11 isolates (green square indicated the isolates obtained by 
Rezaikin et al., 2009; Novoselov et al., 2012) of the GenBank sequence database for 
which complete P1 sequences are available. The analysis involved 34 amino acid 
sequences. Numbers at nodes shown next to the branches correspond to the 
percentage of replicates tree in which the associated taxa clustered together in the 
bootstrap test (1000 replicates). The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site. Evolutionary analyses were conducted 
in MEGA6 (Tamura et al., 2013). 
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3.4.3 Generation of Adapted Variants of E11 V5-7A by Passaging on A549 
and HeLa Cells 
We propagated 5 µl of the original E11 V5-7A stock on 25 cm2 flasks containing 
monolayers of A549 and HeLa cells supplemented with 5 ml of DMEM culture 
medium. These showed a complete cytopathic effect (CPE) at the first passage 
on these cells, which developed after 3 days post-infection. Infected cells were 
freeze-thawed three times to release the virus and then 5 µl of the culture was 
added to fresh cell monolayers. The process was then repeated until nine 
passages. Passage 3, 6 and 9 (P3, P6 and P9) were analysed using a plaque 
assay (Figure 3.6). It can be seen that surprisingly the amount of virus presented 
at each passage level decreased. For the virus passaged on A549 cells there 
was a slight increase in plaque size from the original to P9. A much clearer 
increase was seen for the virus passaged on HeLa cells. The original pinprick 
plaques become much larger by P6 and P9.  
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Figure 3.6 A plaque assay of the original E11 (E11 V5-7A) and P3, 6 and 9 
propagated on A549 and HeLa cells.  (A) Schematic diagram describing the panel 
organization. A plaque assay comparing E11 V5-7A with P3, P6 and P9: (B) A549-
adapted virus tested on A549 cells (C) HeLa-adapted virus tested on A549 cells (D) 
HeLa-adapted virus tested on HeLa cells. 
Mock   Mock Mock Mock 
P3 P6 P9 Original E11 
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3.4.4 Sequencing of Passaged E11 V5-7A  
Viral RNAs were isolated from E11 V5-7A adapted A549 and HeLa cells (P3, P6 
and P9) then amplification was carried out by RT-PCR using specific primers 
(Table 2.2b) to give overlapping fragments. These primers were designed from 
the sequence generated from E11 V5-7A to improve the quality of the RT-PCR 
and sequencing. RT-PCR samples were separated by agarose gel 
electrophoresis and the amplicons were purified using a QIAquick Gel Extraction 
kit. The purified fragments were at position ~900 bp, ~880 bp, ~800 bp and ~780 
bp respectively as expected (Figure 3.7). Then total DNA fragments were 
collected and sent for sequencing commercially by Source BioScience 
LifeSciences. 
 
3.4.5 Sequence Analysis of Passaged E11 V5-7A  
Sequences from passages 3, 6 and 9 were assembled and the capsid encoding-
region sequence was translated into protein sequences using the ExPASy online 
tool. Then alignment comparisons were performed using the online tool ClustalW 
(Larkin et al., 2007). There was no difference between the original E11 V5-7A 
sequence and the sequence recovered for P3 and P6. However, for E11 V5-7A 
adapted to A549 cells, two mutations appeared in P9. For E11 V5-7A adapted to 
HeLa cells, one mutation appeared in P9. 
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Figure 3.7 Typical agarose gel electrophoresis of E11 V5-7A adapted to A549 and 
HeLa cells. cDNAs were amplified by RT-PCR then DNA was isolated with a QIAquick 
Gel Extraction kit. This example shows the result for P9 on A549 cells.  
Lane 1: 1 Kb ladder, Lane 2: fragment 1 (a band of ~900), Lane 3: fragment 2 (a band of 
~880), Lane 4: fragment 3 (a band of ~800), Lane 5: fragment 4 (a band of ~780). 
 
 
 
 
 
 
 
 
 
1          2          3          4          5 
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3.4.6 A549-adapted E11 V5-7A  
The alignment of the A549-adapted viruses is shown in Figure 3.8. The two 
amino acids differences are G1452S (G at position 145 in VP2 changed to S) and 
E593V (E at position 59 in VP3 changed to V). The first mutation was due to a 
GGT to AGT change and the second mutation was due to GAG to GTG.       
Furthermore, a visual inspection of the original E11 V5-7A; and passages 3, 6 
and 9 in these regions was performed by using Chromas software to open the 
AB1 files for each sequence (Figure 3.9 and 3.10). The histograms for the 
G1452S region showed only GGT for the original E11 V5-7A and P3, but there 
was apparent heterogeneity of the viral populations at P6 and P9. At P6 there 
was a small amount of AGT and the first nucleotide was read by the sequencer 
as G. At P9, AGT mostly replaced GGT and the first nucleotide was read by the 
sequencer as A. Some GGT was still present (Figure 3.9).    
The situation for the E593V region was slightly different as a small amount of the 
mutant sequence GTG was already seen at P3. This increased slightly at P6 and 
the central T of the codon becomes the larger peak at P9 (Figure 3.10).   
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                 >VP4 
E11 V5-7A       MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 A549-P3     MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 A549-p6     MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 A549-P9     MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
                ************************************************************ 
                         >VP2 
E11 V5-7A       MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 A549-P3     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 A549-p6     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 A549-P9     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
                ************************************************************ 
 
E11 V5-7A       QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 A549-P3     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 A549-p6     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 A549-P9     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
                ************************************************************ 
                                                 145 
E11 V5-7A       CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 A549-P3     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 A549-P6     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 A549-P9     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHSISEGETAKKFSATASNGTHTVQSIVT 240 
                *********************************.************************** 
 
E11 V5-7A       NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 A549-P3     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 A549-P6     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 A549-P9     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
                ************************************************************ 
																																																																																																																													>VP3 
E11 V5-7A       SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 A549-P3     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 A549-P6     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 A549-P9     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
                ************************************************************ 
                                             59 
E11 V5-7A       VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 A549-P3     VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 A549-P6     VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 A549-P9     VTPELDIPGEVKNLMEIAEVDSVVPVNNVVGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
                ***************************** ****************************** 
 
E11 V5-7A       GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 A549-P3     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 A549-P6     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 A549-P9     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
                ************************************************************ 
 
E11 V5-7A       LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 A549-P3     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 A549-P6     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 A549-P9     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
                ************************************************************ 
																																																																																																																								>VP1 
E11 V5-7A       IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 A549-P3     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 A549-P6     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 A549-P9     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
                ************************************************************ 
 
E11 V5-7A       TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 A549-P3     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 A549-P6     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 A549-P9     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
                ************************************************************ 
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E11 V5-7A       NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 A549-P3     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 A549-P6     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 A549-P9     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
                ************************************************************ 
 
E11 V5-7A       PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 A549-P3     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 A549-P6     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 A549-P9     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
                *********************************************************** 
 
E11 V5-7A       TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 A549-P3     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 A549-P6     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 A549-P9     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
                ************************************************************ 
 
E11 V5-7A       TDKRNSITYIPDTVKPDVSNH 861 
E11 A549-P3     TDKRNSITYIPDTVKPDVSNH 861 
E11 A549-P6     TDKRNSITYIPDTVKPDVSNH 861 
E11 A549-P9     TDKRNSITYIPDTVKPDVSNH 861 
                ********************* 
 
 
 
 
Figure 3.8 ClustalW alignments of the E11 V5-7A amino acid sequence and the 
consensus sequence derived from the 4 RT-PCR fragments from the A549-
passaged viruses (E11 A549-P3, E11 A549-P6 and E11 A549-P9). The amino acid 
differences are seen in P9, G145S in VP2 and E59V in VP3 (marked with blue and pink 
respectively). 
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Figure 3.9 Histograms of the sequence analysis of the A549-adapted E11 V5-7A, 
P3, P6 and P9 using Chromas software. The arrows indicate the nucleotide change to 
give G1452S (G to A). Result shows that there is a single peak in the E11 V5-7A 
sequence and P3, whereas, two peaks appeared at the same position in P6 and P9, 
indicating heterogeneity of the viral population. 
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Figure 3.10 Histograms of the sequence analysis of the A549-adapted E11 V5-7A, 
P3, P6 and P9 using Chromas software. The arrows indicate the nucleotide change to 
give E593V (A to T). Results shows that there is a single peak in the E11 V5-7A 
sequence, whereas, two peaks appeared at the same position in P3, P6 and P9, 
indicating heterogeneity of the viral population. 
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3.4.7 Sequence alignment of E11 V5-7A with other E11 Isolates  
The same E11 isolate sequences used for the phylogenetic tree (Figure 3.5) 
were aligned with the E11 V5-7A sequence (Appendix 1). Predicted secondary 
structural domains based on the E7 X-ray crystallography structure are marked 
on the alignment (Plevka et al., 2010). The most variable regions are: part of the 
VP2 puff, between βE and αβ1, and between αβ1 and αβ2; the VP3 Knob 
domain in the αZ2/αZ2 region; the C-terminus of VP3 and N-terminus of VP1; the 
αZ2 of VP1 and the VP1 βB- βC loop; the VP1 βD- βE loop; the VP1 C-terminus. 
The puff and knob are very exposed on the cell surface as is the VP1 βB- βC 
loop, and βD- βE and are therefore probably more flexible and can tolerate 
changes, as well as possibly being under immune system selection, even though 
these are all E11 isolates. The termini of the protein are mainly internal but 
unstructured and therefore changes can be tolerated (Plevka et al., 2010). Also 
marked on the alignment are amino acids likely to be involved in the DAF 
footprint, based on an alignment with E7 (Appendix 2), where the footprint has 
been defined (Plevka et al., 2010; Yoder et al., 2012). The footprint shows that 3 
DAF SCR domains (SCR2-4) bind to E7, SCR2 to part of VP1, SCR3 mainly to 
the VP2 puff and SCR4 mainly to the VP3 knob domain. E7 and E11 V5-7A are 
closely related and the overall surface structure is likely to be similar, although 
there are several amino acid differences in the puff and knob domains.    
The VP2 G145S mutation is in the puff domain and VP3 E59V is in the knob 
domain (Appendix 1). The G1452S is in the predicted binding site for DAF SCR3. 
The E593V is in the DAF SCR4 binding site. This VP2 145 site, as shown in 
Appendix 1, shows some variations between different E11 isolates and S145 is 
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seen in 14 isolates, while 17 have G and three have A. The VP3 59 site also 
shows some variations between E11 isolates, although only one (kust-86) has a 
V.  
The mutations were mapped onto the E11 coordinates (PDB ID: 1H8T) (Stuart et 
al., 2002b), together with other mutations seen in E11 adaptation experiments on 
the other cell lines (Figure 3.11 and 3.12). These mutations fall into two groups, 
one closer to the 5-fold axis and at the north side of the canyon, the other one 
further from the 5-fold axis and at the south rim of the canyon. The A549-adapted 
E11 V5-7A mutations fall into the second group, which are associated with the 
DAF binding domains. G1452S clusters with several other previously seen 
mutations (Stuart et al., 2002b; Rezaikin et al., 2009; Novoselov et al., 2012). 
E593V is further away from other mutations. As expected from the sequence 
alignment when both mutations are plotted onto the DAF binding footprint (Figure 
3.13) of a surface projection of E7 (Yoder et al., 2012), G1452S maps to the 
binding site for DAF SCR3 and E593V to the SCR4 binding site.       
    
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 The three-dimensional structure of the E11 protomer (coordinates PDB 
ID: 1H8T), using Rasmol software to map the mutations seen in A549-adapted E11 
V5-7A. VP2 position 145 is shown in spacefill, green. VP3 position 59 shown in spacefill, 
yellow. Other mutations associated with adaptation to other cell lines are shown in 
spacefill, white (Stuart et al., 2002b; Rezaikin et al., 2009; Novoselov et al., 2012). The 
position of the 5-fold axis is shown by a red pentagon.     
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Figure 3.12 Part of the three-dimensional half-capsid structure of E11 (coordinates 
PDB ID: 1H8T) shown using Rasmol software. The results show five copies of VP2 
position 145 (shown in spacefill, green) and VP3 position 59 (shown in spacefill, yellow). 
Other mutations associated with adaptation to other cell lines are shown in spacefill 
white. A red pentagon is centered on the 5-fold axis (Stuart et al., 2002b; Rezaikin et al., 
2009; Novoselov et al., 2012).      
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Figure 3.13 Surface projection of E7 (Yoder et al., 2012), showing the location of the 
amino acids which bind to DAF domains SCR2 (yellow), SCR3 (orange) and SCR4 (red). 
The predicted positions of the amino acid mutations seen in the P9 passage of A549-
adapted E11 V5-7A are shown as a yellow circle (E593V) and a red circle (G1452S).  
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3.4.8 HeLa-adapted E11 V5-7A  
E11 V5-7A was also propagated on HeLa cells for 9 passages as for A549 cells 
(Section 3.4.3). The HeLa-adapted virus P3, P6 and P9 were then sequenced 
and the alignments were compared to E11 V5-7A sequence (Figure 3.14). One 
amino acid change was seen in P9, at VP4 position 16 (G164R, G at position 16 
in VP4 changed to R). The mutation was due to a GGA to AGA change.       
A visual inspection of the original E11 V5-7A and passages (3, 6 and 9) in this 
region was performed by using Chromas software to open the AB1 files for each 
sequence (Figure 3.15). The histograms showed only GGA for E11 V5-7A and 
E11 V5-7A-P3, but there was apparent heterogeneity of the viral populations at 
P6 and P9. At P6 there was a small amount of AGA and the first nucleotide was 
read by the sequencer as G. At P9, there seems to be approximately equal 
amounts of AGA and GGA and the first nucleotide was read by the sequencer as 
A in the negative sense but G in the positive sense (Figure 3.15).    
The G164R mutation is probably located on the inner surface of the capsid, but 
this position is not visible by X-ray crystallography. The nearest amino acid 
whose position is known is position 15 and this was used and mapped onto the 
E11 (coordinates PDB ID: 1H8T) (Stuart et al., 2002b), as shown in Figure 3.16. 
All E11 isolates shown in the alignment in Figure 3.11 have G16, and no 
variations appeared between different E11 isolates. R at this position is not seen 
frequently in other enteroviruses. An alignment of the sequences of all 
enteroviruses in the database with R at position 16 is shown in Figure 3.17. It is 
seen in the Nancy CBV3 strain, some isolates of E14, E2 and E9 and in a few 
untyped viruses isolated from cases of acute flaccid paralyses (Enterovirus B). It 
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is also seen in some CVA6 (Enterovirus A) isolates. Interestingly, a mutation of 
G164R was associated with increased virulence in a CBV3 strain (Ramsingh and 
Collins, 1995).      
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                 >VP4          16 
E11 V5-7A       MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 Hela-P3     MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 Hela-P6     MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 Hela-P9     MGTQVSTQKTGAHETRLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
                *************** ******************************************** 
                         >VP2 
E11 V5-7A       MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 Hela-P3     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 Hela-P6     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
E11 Hela-P9     MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
                ************************************************************ 
 
E11 V5-7A       QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 Hela-P3     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 Hela-P6     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11 Hela-P9     QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
                ************************************************************ 
 
E11 V5-7A       CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 Hela-P3     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 Hela-P6     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
E11 Hela-P9     CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
                ************************************************************ 
 
E11 V5-7A       NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 Hela-P3     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 Hela-P6     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
E11 Hela-P9     NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
                ************************************************************ 
                                               >VP3 
E11 V5-7A       SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 Hela-P3     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 Hela-P6     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11 Hela-P9     SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
                ************************************************************ 
 
E11 V5-7A       VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 Hela-P3     VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 Hela-P6     VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
E11 Hela-P9     VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
                ************************************************************ 
 
E11 V5-7A       GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 Hela-P3     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 Hela-P6     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11 Hela-P9     GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
                ************************************************************ 
 
E11 V5-7A       LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 Hela-P3     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 Hela-P6     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11 Hela-P9     LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
                ************************************************************ 
                                             >VP1 
E11 V5-7A       IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 Hela-P3     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 Hela-P6     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11 Hela-P9     IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
                ************************************************************ 
 
E11 V5-7A       TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 Hela-P3     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 Hela-P6     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
E11 Hela-P9     TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
                ************************************************************ 
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E11 V5-7A       NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 Hela-P3     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 Hela-P6     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
E11 Hela-P9     NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
                ************************************************************ 
 
E11 V5-7A       PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 Hela-P3     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 Hela-P6     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11 Hela-P9     PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
                ************************************************************ 
 
E11 V5-7A       TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 Hela-P3     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 Hela-P6     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11 Hela-P9     TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
                ************************************************************ 
 
E11 V5-7A       TDKRNSITYIPDTVKPDVSNH 861 
E11 Hela-P3     TDKRNSITYIPDTVKPDVSNH 861 
E11 Hela-P6     TDKRNSITYIPDTVKPDVSNH 861 
E11 Hela-P9     TDKRNSITYIPDTVKPDVSNH 861 
                ********************* 
 
 
 
 
 
 
Figure 3.14 ClustalW alignments of the E11 V5-7A amino acid sequence and the 
consensus sequence derived from the 4 RT-PCR fragments from the HeLa-
passaged viruses (E11 HeLa-P3, E11 HeLa-P6 and E11 HeLa-P9). The amino acid 
difference is seen in P9, G164R in VP4 (marked with red). 
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Figure 3.15 Histograms of the sequence analysis of the HeLa-adapted E11 V5-7A, 
P3, P6 and P9 using Chromas software.  The arrows indicate the nucleotide change to 
give G164R (G to A). Result shows that there is a single peak in E11 V5-7A sequence 
and P3, whereas, two peaks appeared at the same position in P6 and P9, indicating 
heterogeneity of the viral population. 
P3 E11 V5-7A 
P9 (-ve sense) 
P6 P9 (+ve sense) 
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Figure 3.16 Part of the three-dimensional half-capsid structure of E11 (coordinates 
PDB ID: 1H8T) shown using Rasmol software to map the mutation seen in the 
HeLa-adapted E11 V5-7A. A) Inside view of VP4. B) Zoom in showing five copies of the 
VP4 position 15, which is the nearest visible amino acid to our mutation at position 16 
shown, in spacefill, red. 
A 
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E11 V5-7A (G164R)    MGTQVSTQKTGAHETRLNASGNSVIHYTNI 
CVA6                 MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 3018            MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 BJXC09-239      MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 Eps             MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 GD406           MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 ICO00045        MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 M-027           MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 P-2220          MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA6 V-15558         MGAQVSTQKSGSHETRNVATEGSTINFTNI 
CVA9 Fin/1/83        MGAQVSTQKTGAHETRLSATGNSIIHYTNI 
CVB3 Nancy           MGAQVSTQKTGAHETRLNASGNSIIHYTNI  
CVB3 Cd01/Kw/2004    MGAQVSTQKTGAHETRLNASGNSIIHYANI  
E14 08-07-0579       MGAQVSTQKTGAHETRLNAQGSSVIHYTNI 
E14 08-07-0909       MGAQVSTQKTGAHETRLNAQGNSVIHYTNI 
E14 08-08-0907       MGAQVSTQKTGAHETRLNAQGNSVIHYTNI 
E14 08-08-0912       MGAQVSTQKTGAHETRLNAQGNSVIHYTNI 
E2 Cornelis          MGAQVSSQKVGAHETKLNTGNNSTINYTNI 
E9 KWamE001          MGAQVSTQKTGAHETRLNASGSSIIHYTNI 
E9 KwNs/03/3158      MGAQVSTQKTGAHETRLNASGSSIIHYTNI 
EV 09szk135          MGAQVSTQKSGSHETRNVATEGSTINFTNI 
EV 09szk142          MGAQVSTQKSGSHETRNVATEGSTINFTNI 
EV B-CAM1924         MGAQVSTQKTGAHETRLNAQGNSIIHYTNI  
EV INDIS-U406        MGAQVSTQKSGSHETRNVATEGSTINFTNI 
                      
 
 
 
Figure 3.17 Sequence alignment of the start of VP4 in all enterovirus isolates in 
the GenBank sequence database with R at position 16. E2 Cornelis has K (like R a 
basic amino acid) at this position. CVA6 belongs to the species Enterovirus A, while the 
other viruses belong to Enterovirus B.  
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3.5 Discussion  
The interaction of a virus with specific receptors on the cell surface may be one 
of the determinants of virus host range, tissue tropism and pathogenicity. Decay 
accelerating factor (DAF, CD55) is known to serve as a receptor for several 
echoviruses and mutations in DAF binding sites have been associated with 
adaptation to several cell lines (Stuart et al., 2002a,b; Rezaikin et al., 2009; 
Novoselov et al., 2012). CVA9 binds to integrin αvβ6 in cell entry, although other 
molecules also appear to be involved (Heikkila et al., 2009; Huttunen et al., 
2014). Both DAF and αvβ6 are up-regulated in some cancer cells and so 
echoviruses and CVA9 are potentially useful for oncolytic therapy (Berry et al., 
2008; Allen et al., 2013; Bandyopadhyay and Raghavan, 2009; Koretz et al., 
1992). A deep understanding of how viruses infect cells, for instance, how 
viruses may interact with cell surface receptors and enter the cells, is vital to 
establish an efficient cancer treatment based on these interactions. 
A panel of enteroviruses was used originally to investigate possible viruses that 
could target cancer cells and how receptor expression may influence infection. 
Three echoviruses E6, E11 (E11 5V-7A) and E20 caused a partial or complete 
CPE on A549, MCF-7, PC-3, HeLa, HT-29 and RD cancer cells, but not GMK, 
MDA-MB-231 or MDA-MB-435 cells that did not show significant effects. Of 
these, E11 5V-7A had the greatest effect on all the susceptible cell lines, 
particularly PC-3 cells where complete killing was seen, while E6 and E20 had a 
more limited effect. Two other echoviruses, E15 and E30 were less effective in 
cell killing. It is not clear whether these differences are due to specific molecules 
features, such as receptor tropism, or due to differences in the amount of 
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infectious virus in the sample. 
The CVA9 mutants showed a similar tropism to the echoviruses, as again there 
was no effect on MDA-MB-231 and MDA-MB-435 (except that CVA9wt had a 
slight effect) cells, while A549, HT-29 and RD cells were permissive. There are 
some differences, however. The main one is that GMK cells can be killed by 
CVA9, but is resistant to the echoviruses. In addition, MCF-7 cells are killed by 
E6, E11 and E20, but it was observed previously that CVA9 does not kill these 
cells (Ivanova et al., unpublished). The results in Figure 3.1 show some killing by 
CVA9wt but sequence analysis indicated that the sample used had acquired an 
S2871R mutation and infection can be blocked by heparin. This suggests that the 
ability to infect MCF-7 cells depends on this mutation, which allows binding to 
heparan sulphate. The few plaques obtained from the CVA9D mutant could also 
be blocked by heparin (data not shown). Infection of MCF-7 cells by E6, E11 
(E11 5V-7A) and E20 is not blocked by heparin (data not shown) suggesting that 
infection does not depend on heparan sulphate (data not shown). Another 
difference between the echoviruses and CVA9 is that HeLa cells seem to be 
more susceptible to the echoviruses. The data suggest that relatively similar 
viruses, such as echoviruses and CVA9, both members of Enterovirus B, can 
show different cell tropism. This is emphasized by differences in the CVA9 
mutants on some of the cell lines such as A549 and PC-3 cells.     
To find if receptor distribution may be responsible for differences in cell tropism, a 
flow cytometric analysis (FACS) was performed (Figure 3.2). This showed that 
DAF is expressed on the cell surface of most of the cancer cell lines but not the 
green monkey kidney cell line (GMK). This suggests that the failure to infect GMK 
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cells could be due to the absence of DAF. However, it may also be that the DAF 
antibody used does not recognise the form of DAF found on monkey cells. It 
would be interesting to propagate the echoviruses on GMK cells to find if adapted 
mutants appear and therefore to possibly identify host tropism determinants. A 
similar experiment was performed on the green monkey kidney cell line (BGM) 
(Rezaikin et al., 2009). Adapting mutations were observed in VP1 at the 5’ axis 
and at the north rim of the canyon, which are not close to the region that binds to 
DAF. This suggests that adaptation involves a different receptor rather than DAF. 
The fact that MDA-MB-231 and MDA-MB-435 cells express DAF but are not 
infected by the echoviruses suggests that there are other blocks to infection. 
These could be receptors interactions or intracellular events. CVA9 tropism also 
does not correlated with expression of integrin αvβ3 or αvβ6 as published by 
Goodman et al., 2012. 
The enterovirus entry pathways and tissue tropism may notably depend on the 
expression of specific cellular receptor on the plasma membrane and the 
receptor-binding site on the virion surface. However, the situation is more 
complex in some echoviruses and seems not to be depending on single cell 
surface molecule. Several types of cell surface molecules are known to 
contribute with E11 infection into susceptible cells. In addition to DAF, another 
molecule, HLA class I associated β2-microglobulin is known to be involved in the 
E11 internalization process in rhabdomyosarcoma (RD) cells (Chevaliez et al., 
2008; Ward et al., 1998; Novoselov et al., 2012). Moreover, another unknown 44 
kDa glycoprotein molecule was previously identified in human and simian origin 
cell lines by monoclonal antibody and immunoaffinity purification (Novoselov et 
al., 2012). It has also been reported that an antibody to integrin αvβ3 can block 
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the infection of E11 on GMK cells (Ylipaasto et al., 2010; Novoselov et al., 2012). 
β2-microglobulin also seems to be involved in the entry of CVA9 and another 
molecule GRP78 could also be needed (Heikkila et al., 2009; Triantafilou et al., 
2002). Any of these molecules could be absent in the cells which could not be 
infected.  
The 5’UTR has also been shown to influence cell tropism of poliovirus and CVBs 
(La Monica and Racaniello, 1989; Lin and Shih, 2014). Non-structural proteins 2B 
and 3A influence host tropism of rhinoviruses (Harris and Racaniello, 2005). In 
addition, the assay used to assess tropism of echoviruses and CVA9 was based 
on visible cell death. It has been reported that CVB2 can infect cells in a non-
cytolytic way but a mutation in VP1 gives a mutant that gives a lytic infection 
(Gullberg et al., 2010). It could be that cells which were not killed were infected. 
This could be investigated by detecting virus infection by immunofluorescence, 
but as the aim of the work is to develop viruses capable of killing specific cancer 
cells, it was decided to concentrate on the cells which were killed.   
Since the most promising virus was E11, (strain 7V-5A), which killed the A549, 
MCF-7, PC-3 and HeLa cancer cells, but not GMK cells (Figure 3.1), this was 
chosen for further study. The capsid encoding-region of E11 7V-5A was 
sequenced to identify the basis of the phenotype. Furthermore, E11 was 
propagated on A549 and HeLa cell lines and mutations were observed after the 9 
passage.  
For adapted E11 5V-7A on HeLa cells, this resulted in a single nucleotide 
substitution at position 16 in VP4 causing a replacement of Glycine with Arginine. 
Previous studies indicated that the same VP4-16 (G164R) substitution occurred 
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in CVB4. Here it caused an increase in virulence and it was suggested that as 
the N-terminus of VP4 is known to occur on the inner surface of the virion of 
picornaviruses and interacts with the flexible N-terminus of the other capsid 
proteins causing an interwined network within the virion, this might affect its 
stability and/or tropism (Ramsingh and Collins, 1995). Moreover, a mutation that 
was introduced into the VP4 coding sequence of poliovirus can affect cell entry, 
host range and pathogenicity. This mutation at position 28 did not affect the 
stability of the particle or its interaction with receptor but blocked a late stage in 
entry showing that VP4 is involved in entry (Moscufo et al., 1993). The precise 
function of VP4 is not fully understood, but is related to entry through the 
myristate at the N-terminus that presumably interacts with cell membranes. VP4 
has recently been shown to form pores in cell membranes (Davis et al., 2008; 
Panjwari et al., 2014). Changes in VP4 could therefore be important in entry by 
allowing more efficient interactions with the different membrane environment in 
different cell lines.  
As only approximately 50% of the virus RNA in HeLa P9 has the mutation, it will 
be important in the future to isolate viruses containing the mutant and original 
VP4 position 16 sequences to confirm that G164R gives the large plaque 
phenotype. This mutation was not observed in the other E11 (E11 V5-7A) 
adaptation experiments previously reported (summarised in Table 3.3) and is 
therefore a novel adapting mutation. It will be interested to adapt CVA9 to HeLa 
cells, where it grows poorly, to see if a similar mutation would be selected. 
Subsequently, after passaging E11 V5-7A on A549 cells two mutations were 
identified at P9. These are both in regions likely to be involved in DAF binding 
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based on the structure of the E7-DAF complex (Plevka et al., 2010), G145S in 
the SCR3 binding domains and E59V in the SCR4 binding domain. Previous 
work (Table 3.3) reported that adaptation to cell lines is due to changes in the 
VP2 puff and VP3 knob domains. In some cases, this causes a loss of DAF 
binding, such as position 165 in VP2 seems to be an important amino acid in 
DAF binding. Propagating E11 on L41 cells gave a T1652A mutant that cannot 
bind to DAF, and propagating this mutant on RD cells selected an A1652T which 
could bind to DAF (Novoselov et al., 2012). Propagating E11 on HEp-2, HEF and 
HT-29 cells also led to changes in VP2 (A1562T, T1652M and S1352G, N1642D 
respectively), which are probably responsible for the DAF- phenotype (Rezaikin 
et al., 2009; Stuart et al., 2002b). It would be interesting to analyse the DAF 
phenotype of the A549 mutants, especially as these mutations have not been 
observed in previous experiments.  
Some adapted viruses also showed mutations in VP1 and it was proposed that 
this allowed binding to a different receptor which interacted with the canyon, 
possibly an immunoglobulin superfamily member. Two of these mutations may 
also allow binding to heparan sulphate, Q1321K and Q1291R (Stuart et al., 
2002b; Rezaikin et al., 2009). It was reported that CVA9 and some echoviruses 
with a basic amino acid at CVA9 VP1 position 132 and the equivalent position in 
echoviruses gave a cluster of positive charges due to the symmetry of the virus 
as position 132 is at the 5-fold axis (McLeish et al., 2012). Both Q129R and 
Q132K are mutations to a basic amino acid close to the 5-fold axis.   
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Table 3.3 A comparison of all mutations seen when E11 is adapted to 
different cell lines. Our mutations are shaded by blue; the mutations seen by 
other research groups are shaded by yellow. DAF+ and DAF- mutants with these 
mutations are shown as + or - (Stuart et al., 2002b; Novoselov et al., 2012; 
Rezaikin et al., 2009).  
Cell lines 
Mutations 
VP4 VP2 VP3 VP1 
A549  G145S? E59V?  
HeLa G16R?    
HT-29  N164D−  E83D− 
RD  A165T+   
Vero  G139R+  
E78Q+ 
K88E+ 
Q132K+ 
F240L+ 
K259E+ 
HEF  
S135G− 
T165M− 
  
BGM    
K88E+ 
Q129R+ 
Hep-2  A156T−  
K88E− 
N265S− 
L41  
T165A− 
S233L− 
Q86R− K286R− 
 
 
 
 
 
 
 
 
 
  Chapter 4
 
Heparan Sulphate Interaction with 
Coxsackievirus A9 (CVA9) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
4.1 Introduction  
Receptor binding is a crucial event during viral infection and tissue tropism. 
Heparan sulphate proteoglycans (HSPGs) are found at the cell surface and in the 
extracellular matrix (ECM) (Sarrazin, et al., 2011; Zhu et al., 2011). HSPG has 
been reported to be a receptor for several viruses including herpes simplex 
viruses (HSV), swine vesicular disease virus (SVDV), human papillomavirus 16 
(HPV16), Theiler’s murine encephalomyelitis virus (TMEV), Enterovirus 71 (EV-
71), foot-and-mouth disease viruses (FMDV) and human rhinoviruses (HRV -89 
and -54) (Shieh et al., 1992; Escribano-Romero et al., 2004; Knappe et al., 2007; 
Reddi and Lipton, 2002; Tan et al., 2013; Jackson et al., 2003; Vlasak et al., 
2005; Khan et al., 2007). Several enteroviruses have been reported to bind to 
HSPG, but the basis of this binding has not usually been explored (Israelsson et 
al., 2010; Goodfellow et al., 2001). Adaptations of viruses to cell cultures have 
been frequently associated with gaining the ability to bind to HSPG by at least a 
single amino acid substitution (Fry et al., 1999, Maree et al., 2011; Bai et al., 
2014).  
In CVA9, it has been found that an amino acid difference at position 132 in VP1 
is associated with HSPG binding through symmetry-related clusters of positive 
charges (McLeish et al., 2012). Non-binding isolates tested (CO62, CO87 and 
Griggs) have a threonine (T) at this position, while HSPG-binding isolates (CO79 
and CO85) have the positively charged amino acid arginine (R) (McLeish et al., 
2012). Variants of some other Enterovirus B species viruses were found to have 
a similar polymorphism that correlated with HSPG binding.    
 
 
 
 
127 
The aim of this chapter is to find whether there are any other mechanisms which 
CVA9 can use to bind to HSPG. We performed an extensive analysis of the 
adaptation of the non-binding CVA9 isolates CO62, CO87 and Griggs to the 
A549 cell line. 
 
4.2 Comprehensive Analysis of the CVA9 Mechanism of 
Adaptation to Heparan Sulphate Using CVA9 Griggs, CVA9 
CO62 and CVA9 CO87 
4.2.1 Adaptation of CVA9 Isolates to A549 Cells  
Previous studies identified 4 isolates (CO62, CO79, CO85 and CO87) of CVA9 
that differ in their ability to use HSPG as a receptor. CO62 and CO87 do not bind 
to HSPG and the infections were not blocked in the presence of heparin, which is 
an analogue of heparan sulphate, while CO79 and CO85 bind to HSPG and the 
infections were inhibited in the presence of heparin (Figure 4.1). Most of the 
previous experiments were performed on GMK cells (McLeish et al., 2012). To 
extend these results, non-binding CVA9 isolates CO87, CO62 and Griggs were 
propagated twice on the A549 cell line. Virus was analysed for heparin blocking 
after the second passage. As no significant reduction in plaque numbers was 
seen in any case, individual plaques were picked, propagated once in A549 cells, 
and then tested for heparin blocking (see sections 4.2.3, 4.2.4 and 4.2.5). This 
allowed heparin-blocked viruses to be identified.  
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Figure 4.1 Heparin blocking plaque assays for some CAV9 isolates on GMK cells. 
The top line shows the result of treatment with heparin (90 µl of 102 diluted virus and 10 
µl of 50 mg/ml heparin). The bottom line shows mock-treated virus (90 µl of 102 diluted 
virus and 10 µl of water). Virus-heparin mixture or the mock-treated control were 
incubated for 30 min then added to monolayers of GMK cells and then incubated for 1 
hr. Cells were overlaid with CMC/agarose/medium then incubated for 3 days then 
stained with Crystal Violet. Two isolates (CO79 and CO85) are blocked by heparin, but 
the other isolates CO62 and CO87 are not blocked.  
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4.2.2 Sequencing of CVA9 CO87, CO62 and Griggs Plaques  
Viral RNAs were isolated from picked/passaged plaques from CVA9 isolates 
CO87, CO62 and Griggs (P1 and P2) then amplification was carried out by RT-
PCR using specific primers (Table 2.1) to give 4 overlapping fragments (Figure 
4.2). The amplicons were purified using a QIAquick Gel Extraction kit after 
agarose gel electrophoresis. The purified fragments of CO87, CO62 and Griggs 
were at position ~950 bp, ~900 bp, ~950 bp and ~800 bp respectively as 
expected (data not shown). Then total DNA fragments were collected and sent 
for sequencing commercially by Source BioScience LifeSciences. 
 
4.2.3 Isolate CO87 Analysis  
4.2.3.1 Inhibition of Infection of CVA9 CO87 by Soluble Heparin 
The second passage of the propagated CO87 (CO87P2) was tested in a plaque 
assay in the presence and absence of heparin. The results are shown in Figure 
4.3. There was some reduction in the number of plaques obtained suggesting 
that some of the virus population has acquired the ability to bind the HSPG. This 
was confirmed by the results of testing one of the passaged plaques (CO87N) 
picked from the CO87P2. Infection is blocked and inhibited by heparin. In 
contrast, a second plaque (CO87PL1) showed no blocking. Similar results were 
obtained from another plaque (CO87I) picked during an independent A549 
adaptation experiment (data not shown). 
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Figure 4.2 Schematic diagram of the sequencing of the CVA9 isolates CO87, CO62 
and Griggs capsid proteins (VPs) in the P1 region. Overlapping fragments were 
generated using primers based on the available CO87, CO62 and Griggs sequences 
(Chang et al., 1989; McLeish et al., 2012).   
 
 
 
 
 
 
 
 
 
 P1 P2         P3  
 VP4 VP2 VP3 VP1    
  
Fragment 1 
Fragment 2 
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Figure 4.3 Heparin blocking assay on A549-passaged CVA9 isolate CO87. CO87P2 
(passaged twice), CO87N (plaque-purified from CO87P2) and CO87PL1 (also plaque-
purified from CO87P2). The top line shows mock-treated virus (90 µl of 102 diluted virus 
and 10 µl of water). The bottom line shows the treatment with heparin (90 µl of 102 
diluted virus and 10 µl of 50 mg/ml heparin). Virus-heparin mixture or the mock-treated 
control were incubated for 30 min then added to monolayers of A549 cells and then 
incubated for 1 hr. Cells were overlaid with CMC/agarose/medium then incubated for 3 
days then stained with Crystal Violet. It can be seen that infections of CO87N can be 
completely blocked by heparin compared with CO87P2 and CO87PL1.  
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132 
4.2.3.2 Sequence Analysis of CO87 Isolate 
The plaque purified viruses CO87N and CO87I were analysed by sequencing the 
P1 capsid encoding-region. Then alignment comparisons were performed using 
the online tool ClustalW (Larkin et al., 2007). As shown in Figure 4.4, the 
sequence alignment of the A549-CO87 adapted variant CO87N shows only one 
mutation which appeared at position 59 in VP3 (Q593R). CO87I shows the same 
mutation plus two more mutations, one at position 163 in VP2 (Q1632R) and one 
at position 222 in VP1 (R2221K). It is interesting that all three mutations in CO87I 
involve positively-charged amino acid residues as gaining a positive charge after 
gives a virus capable of binding to HSPG (McLeish et al., 2012; Maree et al., 
2010). One of the mutations R2221K is not a gain of a positive charge, but both 
Q593R and Q1632R give an extra positive charge. None of the mutations are 
surrounded by other positively-charged amino acids in the amino acid sequence 
and none gives a linear HSPG binding site of the type ‘BBXB’ or ‘BBBXXB’, 
where ‘B’ is any one of the basic amino acids and ‘X’ is a neutral or hydrophobic 
amino acid (Cardin and Weintraub, 1989).  
The Q593R mutation was seen in both heparin-blocked variants and as this is the 
only mutation seen in CO87N, it is likely that this is enough to give the heparin-
blocked phenotype. This was supported by an analysis of the Q593R region from 
several different plaques (CO87N1, CO87N2, CO87N3 and CO87N4) isolated 
during the first A549 adaptation experiment. All these had the same Q593R 
mutation. An independent adaptation experiment was performed by M. Ivanova 
on A549 cells and two plaque-purified variants (CO87M1 and CO87M2) blocked 
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by heparin were sequenced in the complete P1 region. Both had only one 
mutation, Q593R (Figure 4.5).  
An analysis of the location of the mutations seen in the three-dimensional 
structure, based on the CVA9 Griggs crystal structure was performed (Hendry et 
al., 1999) (Figure 4.6). The T1321R mutation shown to give heparin blocking in 
the CO79 and CO85 isolates is also plotted  (McLeish et al., 2012). None of the 
mutations is close to the T1321R mutation at the 5-fold axis and none is close to 
either the 3-fold axis or 2-fold axis. So the symmetry-clustering mechanism 
(McLeish et al., 2012) does not seem to be involved. The surrounding amino 
acids in the structure were therefore analysed. The amino acid at position 
Q1632R has no adjacent positive charges close enough to form a cluster (data 
not shown). However, the amino acid at position Q593R has two adjacent 
positively-charged amino acids which are located at position 275 (arginine, R) 
and 276 (lysine, K) to form a positively-charged cluster (Figure 4.7). Moreover, 
the amino acid analysis at position R2221K indicates that there are two adjacent 
positively-charged amino acids located at position 223 (histidine, H) and 84 
(lysine, K) in VP1 (Figure 4.8). 
An alignment of the sequence of CO87 with other CVA9 isolates based on the 
GenBank sequence database was done for the VP3 position 59 region and is 
presented using weblogo online software (Crooks et al., 2004; Schneider and 
Stephens, 1990) as in Figure 4.9. It can be seen that VP3 position is polymorphic 
and just under half of the isolates have R at this position, while half have Q and a 
small number have H. The VP1 position 275 and 276, which are close to VP3 59, 
are R and K in virtually all CVA9 isolates and so any isolate with R at VP3 59 
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should have a positively-charged cluster as in the CO87 variants. This may mean 
that several CVA9 isolates potentially can bind to HSPG. In addition, VP3 
position 80 is also polymorphic, but this is not close to position 59 and there is no 
correlation between VP3 59R and either K or Q at position 80 (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
                 >VP4 
CO87            MGAQVSTQKTGAHETSLSATGGSVIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
CO87N           MGAQVSTQKTGAHETSLSATGGSVIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
CO87I           MGAQVSTQKTGAHETSLSATGGSVIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
                ************************************************************ 
                         >VP2 
CO87            MIKSLPALNSPTVEECGYSDRVRSITLGNSTVTTQECANVVVGYGRWPTYLRDDEATAED 120 
CO87N           MIKSLPALNSPTVEECGYSDRVRSITLGNSTVTTQECANVVVGYGRWPTYLRDDEATAED 120 
CO87I           MIKSLPALNSPTVEECGYSDRVRSITLGNSTVTTQECANVVVGYGRWPTYLRDDEATAED 120 
                ************************************************************ 
 
CO87            QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
CO87N           QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
CO87I           QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
                ************************************************************ 
                                                                   163  
CO87            CNASKFHQGCLLVVCVPEAEMGGAVVGQAFPSAALANGDKAYEFTSTTQGDQTKIQTVVH 240 
CO87N           CNASKFHQGCLLVVCVPEAEMGGAVVGQAFPSAALANGDKAYEFTSTTQGDQTKIQTVVH 240 
CO87I           CNASKFHQGCLLVVCVPEAEMGGAVVGQAFPSAALANGDKAYEFTSTTQGDRTKIQTVVH 240 
                ***************************************************:******** 
 
CO87            NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYVNSVPMDNMFRHYNFTLMVIPFVKLDY 300 
CO87N           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYVNSVPMDNMFRHYNFTLMVIPFVKLDY 300 
CO87I           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYVNSVPMDNMFRHYNFTLMVIPFVKLDY 300 
                ************************************************************ 
                                              >VP3 
CO87            ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
CO87N           ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
CO87I           ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
                ************************************************************ 
                                            59 
CO87            TPSMDIPGEVKNLMEIAEVDSVVPVNNVQDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
CO87N           TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
CO87I           TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
                ****************************:******************************* 
 
CO87            LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
CO87N           LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
CO87I           LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
                ************************************************************ 
 
CO87            GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGFVTCWYQTGMIVPPGTPNSSSI 540 
CO87N           GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGFVTCWYQTGMIVPPGTPNSSSI 540 
CO87I           GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGFVTCWYQTGMIVPPGTPNSSSI 540 
                ************************************************************ 
                                            >VP1 
CO87            MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAIERAVVHVADTVRSGPSNSESIPALT 600 
CO87N           MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAIERAVVHVADTVRSGPSNSESIPALT 600 
CO87I           MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAIERAVVHVADTVRSGPSNSESIPALT 600 
                ************************************************************ 
 
CO87            AVETGHTSQVTPSDTMQTRHVKNYHSRSESTIENFLGRSACVYMEEYKTTDEDTNKKFVA 660 
CO87N           AVETGHTSQVTPSDTMQTRHVKNYHSRSESTIENFLGRSACVYMEEYKTTDEDTNKKFVA 660 
CO87I           AVETGHTSQVTPSDTMQTRHVKNYHSRSESTIENFLGRSACVYMEEYKTTDEDTNKKFVA 660 
                ************************************************************ 
 
CO87            WPINTRQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
CO87N           WPINTRQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
CO87I           WPINTRQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
                ************************************************************ 
 
CO87            IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQKGSYGYNT 780 
CO87N           IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQKGSYGYNT 780 
CO87I           IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQKGSYGYNT 780 
                ************************************************************ 
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                         222 
CO87            LNNLGHIYVRHVSGSSPYPITSTIRIYFKPKHTRAWVPRPPRLCQYEKAFSVDFVPTPVT 840 
CO87N           LNNLGHIYVRHVSGSSPYPITSTIRIYFKPKHTRAWVPRPPRLCQYEKAFSVDFVPTPVT 840 
CO87I           LNNLGHIYVKHVSGSSPYPITSTIRIYFKPKHTRAWVPRPPRLCQYEKAFSVDFVPTPVT 840 
                *********:************************************************** 
 
CO87            DTRKDINTVVSVQRKRRGDLSALNTH 867 
CO87N           DTRKDINTVVSVQRKRRGDLSALNTH 867 
CO87I           DTRKDINTVVSVQRKRRGDLSALNTH 867 
 
                ************************** 
       
Figure 4.4 ClustalW Sequence alignments of the capsid region of the original 
CO87 and mutants (CO87N and CO87I) from plaque-purified variants isolated from 
CO87 adapted on A549 cells in two independent experiments. The amino acid 
differences are seen at positions Q59R in VP3 (both variants), R222K in VP1 and 
Q163R in VP2 (CO87I only). 
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                                       59  
CO87N      TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87N1     TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87N2     TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87N3     TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87N4     TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87I      TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
CO87M1w    TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG          
CO87M2w    TPSMDIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 
           ************************************************************ 
 
 
 
Figure 4.5 Alignment of the sequence of different plaques variants isolated from 
CO87 adapted on A549 cells. Results from part of VP3 indicate that the amino acid R 
appears at the same position in all the different isolates.  
w Experiment was performed by M. Ivanova. The complete P1 sequences were 
obtained and only this mutation was seen.    
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Figure 4.6 The three-dimensional pentameric structure of CVA9 using Rasmol 
software, showing the predicted positions of the CO87 mutations seen in the 
heparin-blocked variants. VP3 position 59 is shown in spacefill, blue. VP2 position 163 
is shown in spacefill, salmon. VP1 position 222 is shown in spacefill, green.  VP1 
position 132, which clusters at the 5-fold axis is shown in spacefill, brown. Numbers 
indicate the 2- 3- and 5- fold axis. 
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Figure 4.7 The three-dimensional pentameric structure of CVA9 using Rasmol 
software, showing the predicted mutation positions of the VP3 at position 59 
(blue) and the surrounding positively-charged amino acids giving a cluster. These are 
lysine (K) at position 276 (white) and arginine (R) at position 275 (yellow) in VP1.  
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Figure 4.8  The three-dimensional pentameric structure of CVA9 using Rasmol 
software, showing the predicted mutation positions of the VP1 position 222 
(green) and the surrounding basic amino acids, these are histidine (H) at position 223 
(purple) and lysine (K) at position 84 (white) in VP1. 
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Figure 4.9 A Sequence alignment of part of the VP3 protein of CO87 with other 
CVA9 isolates in the GenBank sequence database shown using weblogo online 
software (Crooks et al., 2004; Schneider and Stephens, 1990). 60 amino acids are 
analysed, centered on position 59. The data for this logo involved 25 amino acid 
sequences and the height of each single-letter amino acid code is related to the number 
of times the amino acid occurs at that position.  
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4.2.4 Isolate CO62 Analysis  
4.2.4.1 Inhibition of Infection of CVA9 CO62 by Soluble Heparin 
CO62, another isolate, which is not blocked by heparin, was also passaged twice 
on A549 cells. CO62 and CO87 are strains isolated in 1962 and 1987 
respectively and are relatively diverse from one another (Figure 4.10). The 
sequence differences present may mean that adaptation to HSPG use can occur 
by a different mechanism. 
The propagated CO62 (CO62P2) was tested in a plaque assay in the presence 
and absence of heparin. The results are shown in (Figure 4.11). The population 
is not blocked extensively by heparin, but plaque purification gave plaques that 
could be blocked. One of these (CO62H) was chosen for sequence analysis.   
Interestingly, the plaque passaged CO62 isolate (CO62H) is able to infect and kill 
cells and its infection is blocked by heparin. In contrast, a second plaque 
(CO62PL3) showed no blocking. 
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Figure 4.10 Molecular phylogenetic analysis of CVA9 isolates by Maximum 
Likelihood method. The evolutionary history was inferred by using the Maximum 
Likelihood method based on the JTT matrix-based model (Jones et al., 1992). The 
dendrogram shows phylogenetic relationships between the complete P1-region 
sequences of CVA9 isolates and two E11 isolates (used as an out-group). The analysis 
involved 12 amino acid sequences. Numbers at nodes shown next to the branches 
correspond to the percentage of replicates tree in which the associated taxa clustered 
together in the bootstrap test (1000 replicates). The tree is drawn to scale, with branch 
lengths measured in the number of substitutions per site. Evolutionary analyses were 
conducted in MEGA6 (Tamura et al., 2013). 
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Figure 4.11 Heparin blocking assay on A549-passaged CVA9 isolate CO62. 
CO62P2 (passaged twice), CO62H (plaque-purified from CO62P2) and CO62PL3 (also 
plaque-purified from CO62P2). The top line shows mock-treated virus (90 µl of 102 
diluted virus and 10 µl of water). The bottom line shows the treatment with heparin (90 µl 
of 102 diluted virus and 10 µl of 50 mg/ml heparin). Virus-heparin mixture or mock-
treated control were incubated for 30 min then added to monolayers of A549 cells and 
then incubated for 1 hr. Cells were overlaid with CMC/agarose/medium then incubated 
for 3 days then stained with Crystal Violet. It can be seen that infections of CO62H can 
be completely blocked by heparin compared with CO62P2 and CO62PL3.   
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4.2.4.2 Sequence Analysis of CO62 Isolate 
The plaque purified virus CO62H was analysed by sequencing the P1 capsid 
encoding-region. As shown in Figure 4.12, the sequence alignment of the A549-
CO62 adapted variant CO62H shows four mutations compared to the original 
CO62 sequence at position: 121 in VP2 (W1212C), 59 in VP3 (Q593R), 72 in 
VP3 (A723V) and 286 in VP1 (Q2861R).  
An analysis of the location of the mutations seen in the three-dimensional 
structure, based on the CVA9 Griggs crystal structure was performed (Hendry et 
al., 1999) (Figure 4.13). The T132R mutation shown to give heparin blocking in 
the CO79 and CO85 isolates is also plotted  (McLeish et al., 2012). The amino 
acid at position W121C in VP2 is most likely not significant to HSPG binding as it 
is not on the surface of the pentamer. The same mutation, Q59R in VP3, which 
was seen in the CO87 variants was also found in CO62H. Another VP3 mutation, 
A723V is located in the same area, but is not adjacent to Q593R. The amino acid 
at position Q286R in VP1 cannot be visualised due to the flexible nature of this 
region (Hendry et al., 1999), the closest visible amino acid VP1 position 284 is 
therefore shown. This maps quite closely to Q593R and it is possible that 
Q2861R is also close. This may mean that the predicted basic cluster of Q593R, 
K2751 and R2761 is bigger in CO62H. Q2861R is also very close to the RGD 
motif, which in CO62 has two basic amino acids before it. The CO62H sequence 
RSRRRGD is not a linear HSPG binding domain but is highly basic and so this 
may be able to bind to HSPG.  
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                 >VP4       
CO62            MGAQVSTQKTGAHETSLNATGNSVIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
CO62H           MGAQVSTQKTGAHETSLNATGNSVIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
                ************************************************************ 
                         >VP2 
CO62            MIKSLPALNSPTVEECGYSDRVRSITLGNSTITTQECANVVVGYGRWPTYLRDDEATAED 120 
CO62H           MIKSLPALNSPTVEECGYSDRVRSITLGNSTITTQECANVVVGYGRWPTYLRDDEATAED 120 
                ************************************************************ 
 
CO62            QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
CO62H           QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
                ************************************************************ 
                         121 
CO62            CNASKFHQGWLLVVCVPEAEMGGAVVGQAFPSTAMANGDKAYEFTSETQSDQTKVQTAVH 240 
CO62H           CNASKFHQGCLLVVCVPEAEMGGAVVGQAFPSTAMANGDKAYEFTSETQSDQTKVQTAVH 240 
                ********* ************************************************** 
 
CO62            NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHYNFTLMVIPFVKLDY 300 
CO62H           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHYNFTLMVIPFVKLDY 300 
                ************************************************************ 
                                              >VP3 
CO62            ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
CO62H           ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
                ************************************************************ 
                                            59           72  
CO62            TPSMNIPGEVKNLMEIAEVDSVVPVNNVQDTTDQMEMFRIPATINAPLQQQVFGLRLQPG 420 
CO62H           TPSMNIPGEVKNLMEIAEVDSVVPVNNVRDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
                ****************************:************.****************** 
 
CO62            LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
CO62H           LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
                ************************************************************ 
 
CO62            GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGYVTCWYQTGMIVPPGTPNSSSI 540 
CO62H           GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGYVTCWYQTGMIVPPGTPNSSSI 540 
                ************************************************************ 
                                            >VP1 
CO62            MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAINRAIVHVADTMRSGPSNSESVPALT 600 
CO62H           MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAINRAIVHVADTMRSGPSNSESVPALT 600 
                ************************************************************ 
 
CO62            AVETGHTSQVTPSDTMQTRHVKNYHSRSESTVENFLGRSACVYMEEYKTTDNDTNKKFVA 660 
CO62H           AVETGHTSQVTPSDTMQTRHVKNYHSRSESTVENFLGRSACVYMEEYKTTDNDTNKKFVA 660 
                ************************************************************ 
 
CO62            WPINTKQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
CO62H           WPINTKQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
                ************************************************************ 
 
CO62            IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQKGSYGYNT 780 
CO62H           IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQKGSYGYNT 780 
                ************************************************************ 
 
CO62            LNNLGHIYVRHVSGSSPHPITSTIRVYFKPKHTRAWVPRPPRLCQYKKAFSVDFTPTPIT 840 
CO62H           LNNLGHIYVRHVSGSSPHPITSTIRVYFKPKHTRAWVPRPPRLCQYKKAFSVDFTPTPIT 840 
                ************************************************************ 
                             286 
CO62            DTRKDINTVTTMMQSRRRGDMSTLNTH 867 
CO62H           DTRKDINTVTTMMRSRRRGDMSTLNTH 867 
                *************:*************  
 
Figure 4.12 ClustalW Sequence alignments of the capsid region of the original 
CO62 and the mutant CO62H adapted on A549. The amino acid differences seen are: 
W121C in VP2 (grey), Q59R in VP3 (purple) and A72V in VP3 (blue) and Q286R in VP1 
(red). 
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Figure 4.13 The three-dimensional pentameric structure of CVA9 using Rasmol 
software, showing the predicted positions of the CO62 mutations seen in the 
heparin-blocked variants. VP3 position 59 is shown in spacefill, blue. VP2 position 121 
is shown in spacefill, yellow. VP3 position 72 is shown in spacefill, pink. VP1 position 
284 is shown in spacefill, green (the closest position to 286). VP1 position 132, which 
clusters at the 5-fold axis, is shown in spacefill, brown.  
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4.2.5 Isolate CVA9 Griggs Analysis  
4.2.5.1 Inhibition of Infection of CVA9 Griggs by Soluble Heparin 
The second passage of the propagated Griggs (GriggsP2) was tested in a plaque 
assay in the presence and absence of heparin. The results are shown in (Figure 
4.14). Again the population was not greatly affected by heparin, but a variant 
(GriggsN) plaque-purified from the population was blocked. A separate 
adaptation experiment was performed and another heparin-blocked variant 
(GriggsS) was isolated (data not shown). In contrast, a second plaque 
(GriggsPL5) showed no blocking. 
 
4.2.5.2 Sequence Analysis of CVA9 Griggs Variants 
The plaque purified viruses GriggsN and GriggsS were analysed by sequencing 
the P1 capsid encoding-region. As shown in Figure 4.15, the sequence alignment 
of the A549-Griggs adapted variant GriggsN shows a single mutation, located 
just before the RGD motif, of S2871R. GriggsS has four mutations at position: 76 
in VP3 (A763V), 234 in VP3 (D2343N), 11 in VP1 (V111I) and the same mutation 
seen in GriggsN, 287 in VP1 (S2871R). As S2871R is the only mutation in 
GriggsN, this is probably also the key mutation giving the heparin-blocked 
phenotype in GriggsS. In addition, the S2871R mutation was observed previously 
in some mutants adapted to A549 cells and an engineered mutant containing 
only this mutation was blocked by heparin (Williams, 2002). None of the other 
mutations seen in GriggsS involve a basic amino acid and are unlikely to be 
contributing to the heparin-blocking. In addition, V111I is on the inside of the 
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particle (4.17). An analysis of the location of the mutations seen in the three-
dimensional structure, based on the CVA9 Griggs crystal structure was 
performed (Hendry et al., 1999) (Figure 4.16 and 4.17). The T132R mutation 
shown to give heparin blocking is also plotted  (McLeish et al., 2012). The effect 
of S2871R could be due to the linear RRRR sequence, which is highly basic. 
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Figure 4.14 Heparin blocking assay on A549-passaged CVA9 Griggs isolate. 
GriggsP2 (passaged twice), GriggsN (plaque-purified from GriggsP2) and Griggs PL5 
(also plaque-purified from GriggsP2). The top line shows mock-treated virus (90 µl of 102 
diluted virus and 10 µl of water). The bottom line shows the treatment with heparin (90 µl 
of 102 diluted virus and 10 µl of 50 mg/ml heparin). Virus-heparin mixture or the mock-
treated control were incubated for 30 min then added to monolayers of A549 cells and 
then incubated for 1 hr. Cells were overlaid with CMC/agarose/medium then incubated 
for 3 days then stained with Crystal Violet. It can be seen that infections of GriggsN can 
be completely blocked by heparin compared with GriggsP2 and GriggsPL5.  
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                 >VP4 
Griggs          MGAQVSTQKTGAHETSLSAAGNSIIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
GriggsN         MGAQVSTQKTGAHETSLSAAGNSIIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
GriggsS         MGAQVSTQKTGAHETSLSAAGNSIIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDV 60 
                ************************************************************ 
                         >VP2 
Griggs          MIKSLPALNSPTVEECGYSDRVRSITLGNSTITTQECANVVVGYGRWPTYLRDDEATAED 120 
GriggsN         MIKSLPALNSPTVEECGYSDRVRSITLGNSTITTQECANVVVGYGRWPTYLRDDEATAED 120 
GriggsS         MIKSLPALNSPTVEECGYSDRVRSITLGNSTITTQECANVVVGYGRWPTYLRDDEATAED 120 
                ************************************************************ 
 
Griggs          QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
GriggsN         QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
GriggsS         QPTQPDVATCRFYTLDSIKWEKGSVGWWWKFPEALSDMGLFGQNMQYHYLGRAGYTIHVQ 180 
                ************************************************************ 
 
Griggs          CNASKFHQGCLLVVCVPEAEMGGAVVGQAFSATAMANGDKAYEFTSATQSDQTKVQTAIH 240 
GriggsN         CNASKFHQGCLLVVCVPEAEMGGAVVGQAFSATAMANGDKAYEFTSATQSDQTKVQTAIH 240 
GriggsS         CNASKFHQGCLLVVCVPEAEMGGAVVGQAFSATAMANGDKAYEFTSATQSDQTKVQTAIH 240 
                ************************************************************ 
 
Griggs          NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHYNFTLMVIPFVKLDY 300 
GriggsN         NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHYNFTLMVIPFVKLDY 300 
GriggsS         NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHYNFTLMVIPFVKLDY 300 
                ************************************************************ 
                                              >VP3 
Griggs          ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
GriggsN         ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
GriggsS         ADTASTYVPITVTVAPMCAEYNGLRLAQAQGLPTMNTPGSTQFLTSDDFQSPCALPQFDV 360 
                ************************************************************ 
                                                             76 
Griggs          TPSMNIPGEVKNLMEIAEVDSVVPVNNVQDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
GriggsN         TPSMNIPGEVKNLMEIAEVDSVVPVNNVQDTTDQMEMFRIPVTINAPLQQQVFGLRLQPG 420 
GriggsS         TPSMNIPGEVKNLMEIAEVDSVVPVNNVQDTTDQMEMFRIPVTINVPLQQQVFGLRLQPG 420 
                *********************************************.************** 
 
Griggs          LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
GriggsN         LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
GriggsS         LDSVFKHTLLGEILNYYAHWSGSMKLTFVFCGSAMATGKFLIAYSPPGANPPKTRKDAML 480 
                ************************************************************ 
 
Griggs          GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGYVTCWYQTGMIVPPGTPNSSSI 540 
GriggsN         GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGYVTCWYQTGMIVPPGTPNSSSI 540 
GriggsS         GTHIIWDIGLQSSCVLCVPWISQTHYRLVQQDEYTSAGYVTCWYQTGMIVPPGTPNSSSI 540 
                ************************************************************ 
                                       234  >VP1      11 
Griggs          MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAIERAVVHVADTMRSGPSNSASVPALT 600 
GriggsN         MCFASACNDFSVRMLRDTPFISQDNKLQGDVEEAIERAVVHVADTMRSGPSNSASVPALT 600 
GriggsS         MCFASACNDFSVRMLRDTPFISQNNKLQGDVEEAIERAIVHVADTMRSGPSNSASVPALT 600 
                ***********************:**************:********************* 
 
Griggs          AVETGHTSQVTPSDTMQTRHVKNYHSRSESTVENFLGRSACVYMEEYKTTDNDVNKKFVA 660 
GriggsN         AVETGHTSQVTPSDTMQTRHVKNYHSRSESTVENFLGRSACVYMEEYKTTDNDVNKKFVA 660 
GriggsS         AVETGHTSQVTPSDTMQTRHVKNYHSRSESTVENFLGRSACVYMEEYKTTDNDVNKKFVA 660 
                ************************************************************ 
 
Griggs          WPINTKQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
GriggsN         WPINTKQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
GriggsS         WPINTKQMVQMRRKLEMFTYLRFDMEVTFVITSRQDPGTTLAQDMPVLTHQIMYVPPGGP 720 
                ************************************************************ 
 
Griggs          IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQRGSYGYNT 780 
GriggsN         IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQRGSYGYNT 780 
GriggsS         IPAKVDDYAWQTSTNPSIFWTEGNAPARMSIPFISIGNAYSNFYDGWSNFDQRGSYGYNT 780 
                ************************************************************ 
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Griggs          LNNLGHIYVRHVSGSSPHPITSTIRVYFKPKHTRAWVPRPPRLCQYKKAFSVDFTPTPIT 840 
GriggsN         LNNLGHIYVRHVSGSSPHPITSTIRVYFKPKHTRAWVPRPPRLCQYKKAFSVDFTPTPIT 840 
GriggsS         LNNLGHIYVRHVSGSSPHPITSTIRVYFKPKHTRAWVPRPPRLCQYKKAFSVDFTPTPIT 840 
                ************************************************************ 
                              287 
Griggs          DTRKDINTVTTVAQSRRRGDMSTLNTH 867 
GriggsN         DTRKDINTVTTVAQRRRRGDMSTLNTH 867 
GriggsS         DTRKDINTVTTVAQRRRRGDMSTLNTH 867 
                ************** ************ 
     
Figure 4.15  ClustalW Sequence alignments of the capsid region of the original 
CVA9 Griggs and mutants (GriggsN and GriggsS) from plaque-purified variants 
isolated from Griggs adapted on A549 cells. The amino acid differences are seen at 
positions A76V in VP3 (blue), D234N in VP3 (yellow) and V11I in VP1 (grey) (GriggsS 
only) and S287R in VP1 (purple) (both variants). 
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Figure 4.16 The three-dimensional pentameric structure of CVA9 using Rasmol 
software, showing the predicted positions of the Griggs mutations seen in the 
heparin-blocked variants. VP3 position 76 is shown in spacefill, green. VP3 position 
234 is shown in spacefill, magenta. VP1 position 11 is shown in spacefill, blue. VP1 
position 284 is shown in spacefill, white (the closest position to 287). VP1 position 132, 
which clusters at the 5-fold axis is shown in spacefill, brown.  
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Figure 4.17  Inside view of the three-dimensional pentameric structure of CVA9 
using Rasmol software, showing the predicted positions of the Griggs mutations 
seen in the heparin-blocked variants, showing VP1 position 11 (spacefill, blue).  
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4.3 Mapping All Amino Acids Differences onto the 3D Structure 
of CVA9 
A summary of all the mutations seen in adapting CVA9 isolates to A549 cells is 
shown in Figure 3.18. The previously identified T1321R, which has a heparin 
binding/blocking phenotype, is also shown. The novel Q593R mutation is located 
very far from T1321R. However, the Q2861R and S2871R mutations may be 
involved close to Q593R. Two mutations, D2343N and R2221K, are in the 
canyon region. Several of the mutations, including Q593R and Q2861R/S2871R 
(based on the 2841 position which is the closest amino acid that can be visible in 
the structure) form a line parallel to the pentamer edge. Several of the mutations 
are probably not involved in HSPG binding, but could have an effect on binding to 
other receptors as the canyon is known to be the binding site of receptors in 
several picornaviruses (Rossmann et al., 2002). 
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Figure 4.18  The three-dimensional pentameric structure of CVA9, showing the 
predicted positions of all mutations seen in adapting CVA9 isolates to A549 cells.  
VP3 position 76 (white) 
VP3 position 234 (magenta)  
VP1 position 11 (light blue) 
VP1 position 284 (green, the closest position to 286 and 287) 
VP1 position 132, which clusters at the 5-fold axis (brown) 
VP2 position 121 (yellow) 
VP3 position 59 (blue) 
VP3 position 72 (pink) 
VP1 position 222 (dark blue) 
VP2 position 163 (salmon) 
A white pentagon shows the position of the 5-fold axis. Circles show the positions of mutations 
linked to the heparin blocked phenotype. Mutations were mapped using Rasmol software. 
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4.4 Mapping All Amino Acids Differences of CVA9 Compared to 
E11 onto the 3D Structure of CVA9  
As several E11 adapting mutations (Chapter 3) were found close to the pentamer 
edge, the CVA9 A549 mutations and E11 mutations were mapped onto the CVA9 
structure (Figure 4.19). The mutations are mainly in different regions, with several 
CVA9 mutations surrounding the 3-fold axis. The 2332 mutation seen in previous 
work (Williams, 2002) at the 3-fold axis is, however, seen in CVA9 and in E11 
adapted to L41 cells. Interestingly, mutation at VP3 position 59 was observed in 
E11 V5-7A adapted to A549 cells (E593V), and in CVA9 CO87 and CO62 
adapted to A549 cells (Q593R). 
The other A549-adapting mutation in E11 V5-7A (G145S) as well as other E11 
adapting mutations are close to CVA9 Q1632R. To investigate a possible CVA9 
interaction with DAF or DAF-related molecules, the CVA9 mutations were 
mapped onto the E7 surface (Yoder et al., 2012) (Figure 4.20). Four CVA9 
mutations map in or close to the known E7 DAF binding regions.   
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Figure 4.19 The three-dimensional pentameric structure of CVA9, showing the 
predicted positions of all mutations seen in adapting CVA9 isolates to A549 cells 
and all published E11 adapting mutations (Stuart et al., 2002b; Rezaikin et al., 2009; 
Novoselov et al., 2012) (chapter 3). Mutations were mapped using Rasmol software. The 
E 11 mutations are shown in white. CVA9 mutations are: VP3 position 59 (salmon)  
VP1 position 284 (pink, the closest position to 286 and 287) 
VP3 position 76 (green) 
VP3 position 234 (burgundy) 
VP1 position 11 (grey, on inside surface) 
VP1 position 132 (brown) 
VP2 position 121 (yellow) 
VP3 position 72 (dark yellow) 
VP1 position 222 (dark blue) 
VP2 position 163 (pale blue) 
VP2 position 233 (green/pale blue) 
VP3 position 202 (blue) 
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Figure 4.20 Surface projection of E7 (Yoder et al., 2012), with the approximate 
positions of A549 adapting mutations of CVA9 shown by circles. The numbering 
used is different from that used in the rest of this chapter to make it consistent with the 
numbering in the projection. For instance, 3059 marks the position of the Q593R 
mutation. The CVA9 2233, 3073, 3202 mutations were found in previous A549 
adaptation experiments (Williams, 2002). 
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4.5 Analysis of the Effect of A549-adapting Mutations  
4.5.1  Location of A549-adapting Mutations 
As it was found that the S2871R mutation was frequently found in A549/CVA9 
Griggs adaptation experiments, it was interesting to find whether this affects 
infection. A previously engineered S2871R mutant was used. The mutations 
previously seen at the 3-fold axis (section 4.4) are also of interest. These are 
shown in Figure 4.21. Mutant D contains only a D2332N mutation. P2023S was 
previously genetically engineered from an infectious clone after being observed 
during adaptation experiments. Both these mutations cluster together in a striking 
position at the 3-fold axis. These mutations are distant from the S2871R (based 
on the nearest visible amino acid, position 2841). 
 
4.5.2 Integrin αvβ3 and αvβ6 Antibody Blocking of Infections 
In order to test whether adaptation was related to changes in receptor tropism, 
antibodies against the reported CVA9 cell receptors, integrins αvβ6 and αvβ3, 
were used to block these molecules on A549 cells. Immunofluorescence analysis 
was done for CVA9 Griggs and the S2871R and P2023S mutants (Figure 4.22). 
Treatment with the αvβ6 antibody reduced the infection of CVA9 Griggs and the 
mutants. The αvβ3 antibody had no effect. This suggests that adaptation to A549 
cells was not due to selection of an alternative receptor and αvβ6 is still used. As 
previously reported for A549 cells, αvβ3 does not seem to be a receptor for 
CVA9 Griggs and the mutants also do not seem to use this molecule (Williams et 
al., 2004; Heikkila et al., 2009). 
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Figure 4.21 Close up view of a pore-like structure at the 3-fold axis formed by the 
amino acids P2023S and D2332N. D2332N (burgundy), P2023S (green) and S2871R 
(pink, 284 the closest position to 287). Mutations were mapped using Rasmol software. 
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Figure 4.22 Effect of αvβ6 and αvβ3 antibodies on CVA9 infection of A549 cells. 1.0 
µg of PE mouse IgG2a or IgG1 Isotype controls and 1.0 µg of anti-integrin αvβ6 and αvβ3 
antibodies were used to pre-treat A549 cells (30 min, 37°C) before infecting with CVA9 
mutants. Infected cells were detected and counted using a CAV9 antibody and TRITC-
labelled secondary. The control is cells without pre-treatment. 20 random fields were 
counted in each case and 5 of the control value is given, together with standard 
deviations. Significance level: ** = 0.01    *= 0.05 
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4.5.3 Metal Ion-dependence (Ca2+, Mg2+) 
As integrin binding is dependent on divalent metal cations, virus binding to cells 
in the presence or absence of calcium chloride (CaCl2), and calcium plus 
magnesium chloride (MgCl2) was investigated.  A549 cells were grown in 6-well 
plates and then washed with medium, TBS, CaCl2 or CaCl2/MgCl2, then diluted 
viruses (CVA9wt, S2871R and P2023S) were added to the cells for 1 hour on 
rocking platform at room temperature. Then the buffers and unbound virus were 
discarded and cells were washed twice with same buffers and plaque assay was 
performed in the presence of growth medium (Figure 4.23, 4.24). It can be seen 
that in the absence of calcium (TBS), CVA9 Griggs does not infect the cells. A 
few plaques are seen for S2871R, which may be due to HS interactions allowing 
the virus to bind to the cell surface. Surprisingly, the P2023S gives a similar 
number of plaques in the presence and absence of calcium, suggesting that an 
additional molecule can be used at the cell surface. Similar results are seen for 
the calcium and magnesium experiment, except that the additional magnesium 
enhances infectivity greatly (Figure 4.24).  
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Figure 4.23 Infection of CVA9 in the presence and absence of calcium. A549 cells 
were washed with growth medium (contains calcium), TBS (no calcium) or TBS-CaCl2. 
Virus in the same solutions was added for 45 min and allowed to bind, then the solutions 
and unbound viruses were removed, the cells were washed with medium and the 
standard medium/CMC overlay was added. Cells were incubated for 3 days then stained 
with Crystal Violet.  
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Figure 4.24 Infection of CVA9 in the presence and absence of calcium plus 
magnesium. A549 cells were washed with growth medium (contains calcium), TBS or 
TBS-CaCl2/MaCl2 Virus in the same solutions was added for 45 min and allowed to bind, 
then the solutions and unbound viruses were removed, the cells were washed with 
medium and the standard medium/CMC overlay was added. Cells were incubated for 3 
days then stained with Crystal Violet.  
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4.5.4 Temperature Sensitivity Assays 
The location of the mutations in CVA9D and P2023S at the 3-fold axis and 
surrounding a pore, suggests that they could have an effect on the stability of the 
virus. Both the original CVA9wt and mutant viruses lost most of their infectivity 
when incubated for 1 hour at 37 ºC before a plaque assay was performed and 
there was no clear difference (data not shown). The effect of temperature on 
virus growth was also studied. CVA9wt, D and P2023S variants were tested by 
performing plaque assays on A549 and GMK cells at 34ºC, 37ºC and 40ºC 
(Figure 4.25 and 4.26). All the viruses showed plaques at 37 ºC and there was 
little growth at 40ºC. CVA9D seemed to be less affected by growing at 34 ºC than 
CVA9wt on both cell lines, particularly A549 cells. However, the other mutant, 
CVA9 P2023S, showed no plaques at 34 ºC, so the 3-fold axis mutations do not 
show a consistent effect. 
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Figure 4.25 Temperature sensitivity assay of CVA9wt, CVA9D and P2023S on A549 
cells. A normal plaque assay was performed, but after adding the overlay, the samples 
were incubated at 34°C, 37°C and 40°C for 3 days before being stained with Crystal 
violet. 
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Figure 4.26 Temperature sensitivity assay of CVA9wt, CVA9D and P2023S on GMK 
cells. A normal plaque assay was performed, but after adding the overlay, the samples 
were incubated at 34°C, 37°C and 40°C for 3 days before being stained with Crystal 
violet. 
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4.6 Discussion 
Virus receptors may be one of the determinants of virus host range and tissue 
tropism. Several receptors that are known to bind to CVA9 have been identified 
over the past few years. CVA9 is known to use a functional arginine-glycine-
aspartic acid (RGD) motif to interact with cell surface integrin αvβ6 during cell 
entry (Williams et al., 2004; Heikkila et al., 2009). In addition, some isolates of 
CVA9 and other enteroviruses have been identified which use heparan sulphate 
proteoglycan (HSPG) as a co-receptor for interaction of cells (McLeish et al., 
2012). It has been reported that foot-and-mouth disease virus (FMDV), in 
addition to binding to integrins, requires binding to heparan sulphate, suggesting 
that HSPG may interact with CVA9 αvβ3 on the cell surface promoting a specific 
binding of the virus (Jackson et al., 1996). 
HSPG is ubiquitously expressed by all cell types, and the expression varies on 
different cell types due to the variations in structure, differences in the sulphation 
degree, chain length and the position of the sulfate group (Tan et al., 2013). 
Despite the functions of HSPG in animal development and homeostasis, HSPG 
is a potential target for the prevention of viral infection and pathogenicity of 
number of viruses. Moreover, an efficient interaction with HSPG can increase 
virulence and enhancing viral replication within specific host tissues (Zhu et al., 
2011).  
Recently, it has been shown that CVA9 binds to HSPG by symmetry-related 
clustering of positive charges. Four CVA9 isolates (CO62, CO79, CO85, CO87) 
were studied previously. CO79 and CO85 infection were significantly inhibited in 
the presence of heparin, while CO62 and CO87 infections were not inhibited; 
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indeed, infection appeared to be enhanced (McLeish et al., 2012) (Figure 4.1). 
Analysis of the HS-binding domain showed this is due to an arginine (R) at 
position 132 in the VP1 capsid protein of the inhibited isolates (CO79 and CO85), 
rather than a threonine (T) which is seen in the non-binding isolates. This forms 
tight clusters around the 5-fold axis of symmetry, generating a patch of a 
positively-charged area allowing interactions with HSPG (McLeish et al., 2012) 
(Figures 4.6,4.13, 4.16, 4.18 and 4.19). 
To investigate HS binding further, 3 non-HS-binding isolates were passaged on 
the A549 human lung carcinoma cell line (Figure 4.3, 4.11 and 4.14). Variants 
were identified where infection found to be blocked by heparin, a HS analogue, 
suggesting HSPG involvement in infection. The results are summarised in Table 
4.1. Sequence analysis suggest that at least two more classes of mechanisms 
can be involved in adaptation of CVA9 to A549, one where a mutation close to 
the RGD motif (SRRR>RRRR) gave either a linear HS-binding motif or a cluster 
of positive charges, and one with a mutation at position 59 in VP3 (Q593R). This 
mutation, observed in CO87N, CO87I and CO62H, does not give a linear motif 
but causes a change of the neutral amino acid Q (Glutamine) to a basic amino 
acid R (Arginine). Basic amino acids, lysine (K) or arginine (R), are often 
associated with binding to HSPG. The mutated position does not form a 
symmetry-related cluster, but an analysis of the three-dimensional structure 
based on the CVA9 Griggs, as in Figure 4.7, shows two adjacent basic amino 
acids in VP1, these are arginine position 275 (R275) and lysine position 276 
(K276), so there is a conformationally-defined cluster of positive charge, which 
probably allows HSPG interactions. Thus, CVA9 binding to HSPG might occur by 
an additional mechanism to symmetry-related clustering.  
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Another possible mechanism that is utilized by CVA9 for HS-binding is a linear 
RRRR motif. This may correspond to the known motif BBXB, where B is a basic 
amino acid and X any neutral or hydrophobic amino acid (Cardin and Weintraub, 
1989). This was observed by adaptation of CVA9 Griggs to A549 cells followed 
by a complete capsid sequence analysis of plaque-purified variants 
(CVA9GriggsN and CVA9GriggsS), which showed a mutation of S2871R (Figure 
4.15). However, as RRRR is not neutral or hydrophobic, it may not be the linear 
motif but the additional positive charge close to the three already present in the 
Griggs RGD region, which is important. Unfortunately, VP1 position 287 cannot 
be seen in the three-dimensional structure based on the CVA9 Griggs, as it lies 
close to the C-terminus of VP1 where the structure was not determined (Hendry 
et al., 1999). Position 284 on VP1, which is the closest amino acid that is visible 
in the structure, was mapped in Figures (4.16, 4.18 and 4.19). This is located 
relatively close to VP3 position 59 and VP1 positions 287-290 (SRRR). It could 
even more form a larger cluster with that centered on VP3 position 59. In addition 
to Q593R, CO62H has a Q to R mutation at position 286 (Figure 4.12). It is not 
clear if this also allows HSPG binding or if both mutations in CO62H are required. 
However, the location close to the RRRGD sequence (positions 288-292) and the 
fact that the mutation gives a basic amino acid suggests it could play a role. 
An alignment of the C-terminus of VP1 of the isolates used in this work is shown 
in Figure 4.27. It can be seen that Griggs and CO62 are highly basic in this 
region due to the RRRGD sequence and this may explain why additional 
mutations that are close by (S2871R) or may be close by (Q2861R) are 
associated with HSPG binding. It is interesting that CO87 already has a run of 4 
basic amino acids RKRRGD and yet is not blocked by heparin and does not 
 
 
 
 
172 
acquire further mutations in this region in mutating to blocked variants. It may be 
that K is less useful in giving HSPG-binding or due to conformational differences 
in the region.  
The fact that S2871R lies close to the RGD motif that is used in CVA9 
interaction with integrin αvβ6 could be significant and the same could be true of 
the VP3 position 59, if this is close to the RGD motif. HSPG binding may be 
useful to the virus by making the interaction between the RGD and the integrin 
more efficient, possibly by the HSPG binding site on CVA9 binding to a cell 
surface molecule that is close to integrin αvβ6. 
The blocking experiment using anti-integrin antibodies shows that the S2871R 
mutant is still blocked by the integrin αvβ6. This suggests that integrins are still 
needed for entry and that HSPG is not an alternative receptor. The other A549-
adapting mutations, located at the 3-fold axis also do not seem to allow binding 
to an alternative receptor. The fact that binding is no longer dependent on 
calcium does though suggest that CVA9D and CVA9 P2023S can recognize 
another cell surface molecule. This interaction, like the one with HSPG, probably 
makes infection more efficient, and doesn’t replace the need to interact with an 
integrin. 
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Table 4.1 Summary of heparin blocked/non-blocked isolates. Heparin 
blocked (grey) and non-blocked (green), CVA9 isolates and the amino acid 
differences (pink) probably giving the blocked phenotype. 
Isolates 
Mutations 
VP3 59 VP1 132 VP1 287 VP1 286 
CO75 Q R S Q 
CO79 Q R S Q 
CO87 Q T R Q 
CO87N R T R Q 
CO87N1 R T R Q 
CO87N2 R T R Q 
CO87N3 R T R Q 
CO87N4 R T R Q 
CO87I R T R Q 
CO87M1 R T R Q 
CO87M2 R T R Q 
CO62 Q T S Q 
CO62H R T S   R 
Griggs Q T S Q 
GriggsN Q T R Q 
GriggsS Q T R Q 
GriggsS2871R* Q T R Q 
* Heparin-blocked viruses containing only the mutation highlighted. The 
GriggsS2871R mutant was engineered to contain only S2871R mutation. 
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Griggs          TDTRKDINTVTTVAQSRRRGDMSTLNTH 867 
GriggsN         TDTRKDINTVTTVAQRRRRGDMSTLNTH 867 
GriggsS         TDTRKDINTVTTVAQRRRRGDMSTLNTH 867 
CO87            TDTRKDINTVTTVAQRKRRGDLSALNTH 867 
CO87N           TDTRKDINTVTTVAQRKRRGDLSALNTH 867 
CO87I           TDTRKDINTVTTVAQRKRRGDLSALNTH 867 
CO62            TDTRKDINTVTTIAQSRRRGDMSTLNTH 867 
CO62H           TDTRKDINTVTTIARSRRRGDMSTLNTH 867 
CO79            TDTRKDINTVTTIAQSGRRGDLSDLNTH 867 
CO85            TDTRKDINTVTTVAQSEHRGDLAVLNTH 867 
                ************:*:  :***:: ****  
 
 
Figure 4.27 The VP1 C-terminal sequences of the CVA9 isolates used in this thesis 
and the previous analysis of HSPG binding (McLeish et al., 2012), together with 
heparin-blocked variants were aligned using ClustalW. Positions where all amino acid 
differences seen are highlighted in purple. The integrin binding RGD motif (highlighted in 
yellow) is observed in all CVA9 strains. Mutations in the variants are highlighted in red. 
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5.1 General Discussion 
The purpose of this thesis was to understand coxsackievirus A9 (CVA9) and 
echovirus 11 (E11) cell tropism. This has been done by analyzing the infection of 
a panel of cell lines and flow cytometry analysis of one possible receptor, DAF. 
These viruses were then propagated on A549 cells, and in the case of E11, also 
on HeLa cells, and sequenced to reveal amino acid changes. These methods 
helped us to understand virus binding onto the cell surface and to determine if 
other possible mechanisms can be used on different cancer cell lines. A detailed 
understanding of virus infection and cell surface receptors will help to establish 
an efficient oncolytic virus cancer treatment based on these interactions. 
Chapter 3 contains an analysis of how echovirus 11 (E11) can bind onto the cell 
surface and to determine if adapting this virus onto different cancer cell line can 
allow other possible mechanisms for binding. Several coxsackievirus A9 and 
echoviruses variants were tested in a panel of 8 cancer cell lines. Distinct 
patterns of infection were observed, but did not fully correlated with receptor 
expression, suggesting that other determinants also help to define tropism. To 
investigate this further, E11, (strain 7V-5A), was adapted by passaging on two 
cancer cell lines, A549 and HeLa, and mutations were observed after the 9 
passage. Two mutations were seen in A549-adapted virus and these are both in 
regions most likely to be involved in DAF binding based on the structure of the 
DAF-binding footprint. These mutations are: VP2 position G145S in the SCR3 
binding domains and VP3 position E59V in the SCR4 binding domain. It is not 
clear if these enhance or prevent DAF binding, but previous work suggests that 
adapting mutations selected by passaging in different cell lines can lead to a loss 
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of DAF binding (Stuart et al., 2002b; Rezaikin et al., 2009; Novoselov et al., 
2012).  In HeLa-adapted virus, a single mutation was seen in VP4 position G16R. 
Mutations in VP4 have not previously been reported in adaptation experiments 
and so this observation is particularly interesting. The mutation may affect a later 
stage in cell entry, as it is known that VP4 is exposed after enteroviruses bind to 
receptors and that a VP4 mutant can bind to receptors but cannot enter the cell 
(Moscufo et al., 1993). 
Chapter 4 contains an analysis of the molecular basis of how heparin-blocked 
(and so assumed to be able to bind to HSPG) variants of coxsackievirus A9 
(CVA9) bind onto the cell surface and to determine if there are other possible 
mechanisms can be used by adapting these viruses onto different cancer cell 
lines. To investigate CVA9 binding to HSPG, 3 isolates were propagated on A549 
cells and heparin-blocked mutants were isolated. Although the isolates are 
diverse, the same mutation (VP3 Q59R) was seen in two isolates and probably 
gives a positively-charged cluster with adjacent amino acids. Other mutations 
were seen close to the RGD motif, where there is already a highly basic 
sequence. Together with a previous identification of a different mutation related 
to HSPG use, the results suggest multiple potential mechanisms for HSPG-
binding (McLeish et al., 2012). No clear differences in entry pathways were 
observed for CVA9 variants.  
It is interesting that a mutation of the same amino acid (position 59 in VP3) is 
seen in E11 5V-7A adapted to A549 cells and CVA9 adapted on A549 cells 
followed by purification of a HSPG-binding variant. This may be coincidence, as 
VP3 position 59 is in a highly exposed part of the virus and likely to be able to 
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change without changing the structure of the particle significantly. The amino acid 
change in each case is different and in CVA9 HSPG binding results from the 
mutation, but this is not seen in E11 V5-7A. On the other hand this amino acid 
could be key to adapting different viruses to A549 cells. It would be interesting to 
adapt other viruses to A549 cells and compare the adapting mutations with those 
already seen.  
 
5.2 Future Work  
To extend the work already performed, several new experiments could be done.  
Ø Haemagglutination assays of human red blood cells by E11 variants could be 
performed. Haemagglutination has been shown to be due to interaction of the 
virus with DAF and so this is a useful method of studying DAF binding. 
Blocking experiments with DAF antibodies could also be performed. These 
experiments should show whether the A549 variants still have the ability to 
bind to DAF or if it is made more efficient.  
Ø The mutations observed could be built into an infectious E11 clone so that it 
is known that only these mutations are present and so are responsible for 
any changes in receptor interactions that are seen. 
Ø Adapting E11 and CVA9 in different cancer cell lines to identify other possible 
mechanisms that can be used for cell tropism. Of particular interest is the 
adaptation of CVA9 to HeLa cells to find whether a VP4 change is also seen. 
The E11 VP4 change could be analysed further by seeing if this has an effect 
on the pore forming ability reported for VP4. 
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Ø Studying the entry pathways of these viruses and variants, to find if the 
alteration in receptor binding can allow the virus to enter cells by different 
mechanisms. 
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Appendix 1. Alignments of the E 11 V5-7A P1 sequence with other E11 
isolates in the GenBank sequence database where a complete P1 sequence 
is available. A549-adapted E 11 V5-7A mutations are highlighted in turquoise, 
HeLa-adapted E 11 V5-7A mutation is highlighted in red, the other colours 
indicated all mutations found in Stuart et al., 2002b (pink); Rezaikin et al., 2009 
(dark yellow); Novoselov et al., 2012 (blue).  
                         >VP4          16 
E11 V5-7A_2005          MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
ROU-91_1991             MGAQVSTQKTGAHETGINASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
D207_2008               MGAQVSTQKTGAHETGINASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
Hun/90_1990             MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
HUN-1108_1989           MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
Kust-86_1986            MGAQVSTQKTGAHETGINASGNSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
FIN-06666_1989          MGAQVSTQKTGAHETGINASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
Jena799_2002            MGAQVSTQKTGAHETGLNASGNSIIHYTYINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
Kar-87_1987             MGAQVSTQKTGAHETGINASGSSIIHYTNINYYKDAASNSTNRQDFTQDPGKFTEPVKDI 60 
wv207_1983              MGAQVSTQKTGAHETGLRASGNSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
20750473_2007           MGAQVSTQKTGAHETGLNASGNSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11_18744_02_2002       MGAQVSTQKTGAHETGLTASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
61A3_2011               MGAQVSTQKTGAHETGLNASGNSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
HUN_1300_1989           MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
HUN_1337_1989           MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
HUN_1335_1989           MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
111/RD_2009             MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
MorM-82_1982            MGAQVSTQKTGAHETGLNASGNSIIHYTNINYYKDAASNSANRQDFTQDPSKFTEPVKDI 60 
Gregory_1993            MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQEFSQDPGKFTEPVKDI 60 
E11/7611_1993           MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/L41-431-1_2011      MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/L41-431-6_2011      MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/L41_2011            MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/BGM_2009            MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/Hep_2009            MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/L41-431_2011        MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
111/L41-311_2011        MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
Gregory_1953            MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQEFSQDPGKFTEPVKDI 60 
111/L41-211_2011        MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
3123_2009               MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQEFSQDPGKFTEPVKDI 60 
3123/70_2009            MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQEFSQDPGKFTEPVKDI 60 
111/L41-121_2011        MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNSANRQDFSQDPGKFTEPVKDI 60 
3123/28_2009            MGAQVSTQKTGAHETGLNASGSSIIHYTNINYYKDAASNSANRQEFSQDPGKFTEPVKDI 60 
M07067754_2007          MGAQVSTQKTGAHETGLSASGNSIIHYTNINYYKDAASNPANRQDFSQDPGKFTEPVKDI 60 
                        **:*************: ***.*:**** **********.:***:*:***.********* 
 
                                              =βA1=  =βA2=      
                                 >VP2 
E11 V5-7A_2005          MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
ROU-91_1991             MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
D207_2008               MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
Hun/90_1990             MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
HUN-1108_1989           MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
Kust-86_1986            MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQVCANVVVAYGRWPEYLSDKEATAED 120 
FIN-0666_1989           MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPKYLSDEEATAED 120 
Jena799_2002            MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
Kar-87_1987             MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
wv207_1983              MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLRDDEATAED 120 
20750473_2007           MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
E11_18744_02_2002       MVKSLPALNSPSAEECGFSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
61A3_2011               MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
HUN_1300_1989           MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
HUN_1337_1989           MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
HUN_1335_1989           MIKSMPALNSPSAEECGFSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDKEATAED 120 
111/RD_2009             MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
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MorM-82_1982            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLRDDEATAED 120 
Gregory_1993            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLKDNEATAED 120 
E11/7611_1993           MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/L41-431-1_2011      MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/L41-431-6_2011      MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/L41_2011            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/BGM_2009            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/Hep_2009            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/L41-431_2011        MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
111/L41-311_2011        MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
Gregory_1953            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLKDNEATAED 120 
111/L41-211_2011        MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
3123_2009               MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLKDNEATAED 120 
3123/70_2009            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLKDNEATAED 120 
111/L41-121_2011        MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPEYLKDDEATAED 120 
3123/28_2009            MVKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVGYGRWPEYLKDNEATAED 120 
M07067754_2007          MAKSLPALNSPSAEECGYSDRVRSITLGNSTITTQESANVVVAYGRWPNYLKDDEATAED 120 
                        * **:************:***************** .*****.*****:** *.****** 
             
                            
  
                           --αZ-        =βB      ==βC=-αA1- ----αA2---=βD1=   =βD2=         
E11 V5-7A_2005          QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
ROU-91_1991             QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
D207_2008               QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
Hun/90_1990             QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTMHVQ 180 
HUN-1108_1989           QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTMHVQ 180 
Kust-86_1986            QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
FIN-0666_1989           QPTQPDVATCRFYTLESVTWEKDSSGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
Jena799_2002            QPTQPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
Kar-87_1987             QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
wv207_1983              QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
20750473_2007           QPTQPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
E11_18744_02_2002       QPTQPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
61A3_2011               QPTQPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
HUN_1300_1989           QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
HUN_1337_1989           QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
HUN_1335_1989           QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/RD_2009             QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
MorM-82_1982            QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
Gregory_1993            QPTQPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTLHVQ 180 
E11/7611_1993           QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/L41-431-1_2011      QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/L41-431-6_2011      QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/L41_2011            QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/BGM_2009            QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/Hep_2009            QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/L41-431_2011        QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
111/L41-311_2011        QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
Gregory_1953            QPTHPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTLHVQ 180 
111/L41-211_2011        QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
3123_2009               QPTHPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTLHVQ 180 
3123/70_2009            QPTHPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTLHVQ 180 
111/L41-121_2011        QPTQPDVATCRFYTLESVTWEKDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
3123/28_2009            QPTHPDVATCRFYTLESVTWERDSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTLHVQ 180 
M07067754_2007          QPTQPDVATCRFFTLESVTWEKGSPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
                        ***:********:********: *.*******************************:*** 
 
                                          >------------------------------PUFF------- 
                               ====βE====             --αB1-                      -α  
                                                         145 
E11 V5-7A_2005          CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
ROU-91_1991             CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
D207_2008               CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
Hun/90_1990             CNASKFHQGCLLVVCVPEAEMGCSDITGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
HUN-1108_1989           CNASKFHQGCLLVVCVPEAEMGCSDITGVVNEHSISEGETAKVFSKTATNGAHTVQSIVT 240 
Kust-86_1986            CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKMFSKTATNGAHTVQSIVT 240 
FIN-0666_1989           CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGLSEGETAKVFSKTATNGAHTVQSIVT 240 
Jena799_2002            CNASKFHQGCLLVVCVPEAEMGCSDVTRGCYEHAISEGETAKRFSVTATNGAHTVQSIVT 240 
Kar-87_1987             CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGISEGETAKVFSKTATNGAHSVQSIVT 240 
wv207_1983              CNASKFHQGCLLVVCVPEAEMGCSTVDGTVNEHGLSEGETAKKFSATGTNGTNTVQSIVT 240 
20750473_2007           CNASKFHQGCLLVVCVPEAEMGCSDVTGVVSEHAISEGETAKKFSATATNGAHTVQSLVT 240 
E11_18744_02_2002       CNASKFHQGCLMVVCVPEAEMGCSQVDGTVNEHSLSEGETAKKFASTTTNGTNTVQSIVT 240 
61A3_2011               CNASKFHQGCLLVVCVPEAEMGCSDVTGVVSEHAISEGETAKKFSATATNGAHTVQSLVT 240 
HUN_1300_1989           CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
HUN_1337_1989           CNASKFHQGCLLVVCVPEAEMGCSDVTGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
HUN_1335_1989           CNASKFHQGCLLVVCVPEAEMGCSDITGVVNEHGISEGETAKVFSKTATNGAHTVQSIVT 240 
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111/RD_2009             CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNTVQSIVT 240 
MorM-82_1982            CNASKFHQGCLLVVCVPEAEMGCSTVDGTVNEHGLSEGETAKKFTATSSNGQNIVQSIVT 240 
Gregory_1993            CNASKFHQGCLLVVCVPEAEMGCSQVDGTVNEHGLSEGETAKKFSSTSTNGTNTVQTIVT 240 
E11/7611_1993           CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNETNTVQSIVT 240 
111/L41-431-1_2011      CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNTVQSIVT 240 
111/L41-431-6_2011      CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
111/L41_2011            CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
111/BGM_2009            CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNTVQSIVT 240 
111/Hep_2009            CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFTATSTNGTNTVQSIVT 240 
111/L41-431_2011        CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
111/L41-311_2011        CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
Gregory_1953            CNASKFHQGCLLVVCVPEAEMGCSQVDGTVNEHGLSEGETAKKFSSTSTNGTNTVQTIVT 240 
111/L41-211_2011        CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
3123_2009               CNASKFHQGCLLVVCVPEAEMGCSQVDGTVNEHGLSEGETAKKFSSTSTNGTNTVQTIVT 240 
3123/70_2009            CNASKFHQGCLLVVCVPEAEMGCGQVDGTVNEHGLSEGETAKKFSSTSTNGTNTVQTIVT 240 
111/L41-121_2011        CNASKFHQGCLMVVCVPEAEMGCSQIDGTVNEHSLSEGETAKKFAATSTNGTNAVQSIVT 240 
3123/28_2009            CNASKFHQGCLLVVCVPEAEMGCSQVDGTVNEHGLSEGETAKKFSSTSTNGTNMVQTIVT 240 
M07067754_2007          CNASKFHQGCLLVVCVPEAEMGCSQIDGTMNEHSLSEGETAKKFTNTPTNAANTVQSIVT 240 
                        ***********:***********. :     **.:******* *: * :*  : **::** 
 
 
                        -----< 
                        B2    --αB3--- =βF==     =βG==                 ====βH======   
E11 V5-7A_2005          NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
ROU-91_1991             NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
D207_2008               NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
Hun/90_1990             NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
HUN-1108_1989           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
Kust-86_1986            NAGMGVGVGNLTIFPHQWINLRTNNSATIVIPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
FIN-0666_1989           NAGMGVGVGNLTIFPHQWINLRTNNSATIVIPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
Jena799_2002            NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
Kar-87_1987             NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
wv207_1983              NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLNY 300 
20750473_2007           NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLEY 300 
E11_18744_02_2002       NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
61A3_2011               NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLEY 300 
HUN_1300_1989           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
HUN_1337_1989           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
HUN_1335_1989           NAGMGVGVGNLTIFPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
111/RD_2009             NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
MorM-82_1982            NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLNY 300 
Gregory_1993            NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
E11/7611_1993           NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-431-1_2011      NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-431-6_2011      NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41_2011            NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/BGM_2009            NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/Hep_2009            NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-431_2011        NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-311_2011        NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
Gregory_1953            NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-211_2011        NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
3123_2009               NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
3123/70_2009            NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
111/L41-121_2011        NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
3123/28_2009            NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLDY 300 
M07067754_2007          NAGMGVGVGNLTIFPHQWINLRTNNCATIVMPYINNVPMDNMFRHHNFTLMIIPFVPLNY 300 
                        *************:***********.****:****.********************.*:* 
 
                               ===βI===    =βI2=         
                                                       >VP3 
E11 V5-7A_2005          SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
ROU-91_1991             SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
D207_2008               SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
Hun/90_1990             SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
HUN-1108_1989           SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
Kust-86_1986            SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFVTSDDFQSPSAMPQFD 360 
FIN-0666_1989           SSDASTYVPITVTVAPMCAEYNGLRLATPLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
Jena799_2002            ASDASTYVPITVTVGPMCAEYNGLRLATSLQGLPVMNTPGSTQFLTSDDFQSPSAMPQFD 360 
Kar-87_1987             SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
wv207_1983              SSDSSTYVPITVTVAPMCAEYNGLRLSTALQGLPVINTPGSNQFLTSDDFQSPSAMPQFD 360 
20750473_2007           SSDASTYVPITVTVAPMCAEYNGLRLATSVQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11_18744_02_2002       SSDSSTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
61A3_2011               SSDASTYVPITVTVAPMCAEYNGLRLATSVQGLPVMNTPGSNQFLTSDDFQSPSVMPQFD 360 
HUN_1300_1989           SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
HUN_1337_1989           SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMSVPGSNQFLTSDDFQSPSAMPQFD 360 
HUN_1335_1989           SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNVPGSNQFLTSDDFQSPSAMPQFD 360 
 
 
 
 
212 
111/RD_2009             SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
MorM-82_1982            SSDSSTYVPITVTVAPMCAEYNGLRLSTALQGLPVMDTPGSNQFLTSDDFQSPSAMPQFD 360 
Gregory_1993            SSDSSTYVPITVTVAPMCAEYNGLRLSTSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
E11/7611_1993           SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPSAMPQFD 360 
111/L41-431-1_2011      SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/L41-431-6_2011      SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/L41_2011            SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/BGM_2009            SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/Hep_2009            SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/L41-431_2011        SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
111/L41-311_2011        SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
Gregory_1953            SSDSSTYVPITVTVAPMCAEYNGLRLSTSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
111/L41-211_2011        SSDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
3123_2009               SSDSSTYVPITVTVAPMCAEYNGLRLSTSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
3123/70_2009            SSDSSTYVPITVTVAPMCAEYNGLRLSTSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
111/L41-121_2011        SLDSSTYVPVTVTVAPMCAEYNGLRLATSLQGLPVMITPGSNQFLTSDDFQSPTAMPQFD 360 
3123/28_2009            SSDSSTYVPITVTVAPMCAEYNGLRLSTSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
M07067754_2007          SPDSSTYVPITVTVAPMCAEYNGLRLATSLQGLPVLSTPGSNQFLTSDDYQSPSAMPQFD 360 
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E11 V5-7A_2005          VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
ROU-91_1991             VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
D207_2008               VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
Hun/90_1990             VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
HUN-1108_1989           VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
Kust-86_1986            VTSELDIPGEVKNLMEIAEVDSVVPVNNVVGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
FIN-0666_1989           VTPELDIPGEVMNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
Jena799_2002            VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
Kar-87_1987             VTPELDIPGEVNNLMQVAEVDSAVPVNNVEGKLDTMDIFPHSCQSGNHQSTQVFGFQVQP 420 
wv207_1983              VTPELNIPGEVQNLMEIAEVDSVVPVNNVAGNLQTMDIYRIPVQSGNHQSSQVFGFQVQP 420 
20750473_2007           VTPELDIPGEVKNLMEIAEVDSVVPVNNVKGKLDTMDIFRIPVQSGNHQGTQVFGFQVQP 420 
E11_18744_02_2002       VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEIYRIPVQSGNHQSSQVFGFQVQP 420 
61A3_2011               VTPELDIPGEVKNLMEIAEVDSVVPVNNVKGKLDTMDIFRIPVQSGNHQGTQVFGFQVQP 420 
HUN_1300_1989           VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
HUN_1337_1989           VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
HUN_1335_1989           VTPELDIPGEVKNLMEVAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNHQSTQVFGFQVQP 420 
111/RD_2009             VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
MorM-82_1982            VTPELNIPGEVQNLMEIAEVDSVVPVNNVAGNLRTMDIYRIPVQSGNHQSSQVFGFQIQP 420 
Gregory_1993            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEVYRIPVQSGNHQSDQVFGFQVQP 420 
E11/7611_1993           VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
111/L41-431-1_2011      VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFRVQP 420 
111/L41-431-6_2011      VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFRVQP 420 
111/L41_2011            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
111/BGM_2009            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
111/Hep_2009            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
111/L41-431_2011        VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFRVQP 420 
111/L41-311_2011        VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
Gregory_1953            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEVYRIPVQSGNHQSDQVFGFQVQP 420 
111/L41-211_2011        VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
3123_2009               VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEVYRIPVQSGNHQSDQVFGFQVQP 420 
3123/70_2009            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEVYRIPVQSGNHQSDQVFGFQVQP 420 
111/L41-121_2011        VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMDIYRIPVQSGNHQSTQVFGFQVQP 420 
3123/28_2009            VTPELNIPGEVQNLMEIAEVDSVVPVNNVEGKLDTMEVYRIPVQSGNHQSDQVFGFQVQP 420 
M07067754_2007          VTPELDIPGEVRNLMEIAEVDSVVPVNNVKDKLDAMDIYQIPVQSGNHQSSQVFGFQVQP 420 
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                                ---αA---   βD1  ====βD2==      ===βE==        ---αβ-  
E11 V5-7A_2005          GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
ROU-91_1991             GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
D207_2008               GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
Hun/90_1990             GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
HUN-1108_1989           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
Kust-86_1986            GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKSRKDAM 480 
FIN-0666_1989           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPRTRKDAM 480 
Jena799_2002            GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
Kar-87_1987             GLDSVFKHTLLGEILNYYDHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
wv207_1983              GLDGVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
20750473_2007           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
E11_18744_02_2002       GLDNVFKHTLLGEMLNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
61A3_2011               GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
HUN_1300_1989           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
HUN_1337_1989           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
HUN_1335_1989           GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
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111/RD_2009             GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
MorM-82_1982            GLDGVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFSLAYAPPGANAPKSRKDAM 480 
Gregory_1993            GLDSVFKHTLLGEILNYFAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
E11/7611_1993           GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/L41-431-1_2011      GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/L41-431-6_2011      GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/L41_2011            GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/BGM_2009            GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/Hep_2009            GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/L41-431_2011        GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
111/L41-311_2011        GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
Gregory_1953            GLDSVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
111/L41-211_2011        GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
3123_2009               GLDSVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
3123/70_2009            GLDSVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
111/L41-121_2011        GLDNVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKSRKDAM 480 
3123/28_2009            GLDSVFKHTLLGEILNYYAHWSGSIKLTFVFCGSAMATGKFLLAYAPPGANAPKNRKDAM 480 
M07067754_2007          GLENVFKHTLLGEILNYYAHWSGSIKLTFIFCGSAMATGKFLLAYAPPGANAPRTRKEAM 480 
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                        - ==βF==     ==βG==                    ==βH==            ===     
E11 V5-7A_2005          LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
ROU-91_1991             LGTHIIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
D207_2008               LGTHIIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Hun/90_1990             LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
HUN-1108_1989           LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Kust-86_1986            LGTHIIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
FIN-0666_1989           LGTHIIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Jena799_2002            LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Kar-87_1987             LGTHIIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
wv207_1983              LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
20750473_2007           LGTHVIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGVVVPAGTPTSCS 540 
E11_18744_02_2002       LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
61A3_2011               LGTHVIWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGVVVPAGTPTSCS 540 
HUN_1300_1989           LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
HUN_1337_1989           LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
HUN_1335_1989           LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/RD_2009             LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
MorM-82_1982            LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Gregory_1993            LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
E11/7611_1993           LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-431-1_2011      LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-431-6_2011      LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41_2011            LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/BGM_2009            LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/Hep_2009            LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-431_2011        LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-311_2011        LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
Gregory_1953            LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-211_2011        LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
3123_2009               LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
3123/70_2009            LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
111/L41-121_2011        LGTHIIWDVGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
3123/28_2009            LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
M07067754_2007          LGTHIIWDVGLQSSCVLCVPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
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E11 V5-7A_2005          IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
ROU-91_1991             IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISSGPTNSQAVPAL 600 
D207_2008               IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISSGPTNSQAVPAL 600 
Hun/90_1990             IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISNGPTNSQAVPAL 600 
HUN-1108_1989           IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISNGPTNSQAVPAL 600 
Kust-86_1986            IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISSGPTNSQAVPAL 600 
FIN-0666_1989           MMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISSGPTNSQAVPAL 600 
Jena799_2002            LMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAVESAVARVADTISSGPTNSQAVPAL 600 
Kar-87_1987             IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISSGPTNSQAVPAL 600 
wv207_1983              IMCFVSACNDFSVRLLKDTPFIQQAALLQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
20750473_2007           IMCFVSACNDFSVRLLKDTPFIEQSTLLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
E11_18744_02_2002       IMCFVSACNDFSVRLLKDTPFIEQNALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
61A3_2011               IMCFVSACNDFSVRLLKDTPFIEQSTLLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
HUN_1300_1989           IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISNGPTNSQAVPAL 600 
HUN_1337_1989           IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISNGPTNSQAVPAL 600 
HUN_1335_1989           IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIEGAVARVADTISNGPTNSQAVPAL 600 
111/RD_2009             IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
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MorM-82_1982            IMCFVSACNDFSVRLLKDTPFIEQAALLQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
Gregory_1993            IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
E11/7611_1993           IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/L41-431-1_2011      IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/L41-431-6_2011      IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/L41_2011            IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/BGM_2009            IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/Hep_2009            IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/L41-431_2011        IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
111/L41-311_2011        IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
Gregory_1953            IMCFVSACNDFSVRLLKDTPFIEQTAILQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
111/L41-211_2011        IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
3123_2009               IMCFVSACNDFSVRLLKDTPFIEQTAILQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
3123/70_2009            IMCFVSACNDFSVRLLKDTPFIEQTAILQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
111/L41-121_2011        IMCFVSACNDFSVRLLKDTPFIEQTALLQGDVVEAVENAVARVADTISSGPSNSQAVPAL 600 
3123/28_2009            IMCFVSACNDFSVRLLKDTPFIEQTAILQGDVVEAVENAVARVADTIGSGPSNSQAVPAL 600 
M07067754_2007          IMCFVSACNDFSVRLLKDTPFIEQDAILQGDVPGAVENVIVRVADTISSGPSNSQAVPAL 600 
                        :*********************:* ::*****  *:*..:.******..**:******** 
 
 
 
                         -αZ1-     -αZ2-               --αZ3--  ===βB====        =βC   
E11 V5-7A_2005          TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
ROU-91_1991             TAVETGHTSQVVPGDTIQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
D207_2008               TAVETGHTSQVVPGDTIQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
Hun/90_1990             TAVETGHTSQVVPSDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
HUN-1108_1989           TAVETGHTSQVVPSDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
Kust-86_1986            TAVETGHTSQVVPGDTIQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
FIN-0666_1989           TAVETGHTSQVVPGDTIQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
Jena799_2002            TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
Kar-87_1987             TAVETGHTSQVVPGDTIQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
wv207_1983              TAVETGHTSQVTPSDTVQTRHVKNYHSRSESSIENFLSRSACVYMGEYHTTNSDQTKLFA 660 
20750473_2007           TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
E11_18744_02_2002       TAVETGHTSQVTPSDTIQTRHVHNYHSRSESSIENFLSRSACVYMGEYFTTNEDTSKLFA 660 
61A3_2011               TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
HUN_1300_1989           TAVETGHTSQVVPSDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
HUN_1337_1989           TAVETGHTSQVVPSDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
HUN_1335_1989           TAVETGHTSQVVPSDTMQTRHVKNYHSRSESTIENFLSRSACVYMGEYYTTNTDETKRFA 660 
111/RD_2009             TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
MorM-82_1982            TAVETGHTSQVTPSDIMQTRHVKNYHSRSESSIENFLSRSACVYMGEYHTTNTEQTKLFA 660 
Gregory_1993            TAVETGHTSQVTPSDTMQTRHVKNYHSRSESSIENFLSRSACVYMGGYHTTNTDQTKLFA 660 
E11/7611_1993           TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
111/L41-431-1_2011      TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
111/L41-431-6_2011      TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
111/L41_2011            TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
111/BGM_2009            TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASELFA 660 
111/Hep_2009            TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASELFA 660 
111/L41-431_2011        TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
111/L41-311_2011        TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
Gregory_1953            TAVETGHTSQVTPSDTMQTRHVKNYHSRSESSIENFLSRSACVYMGGYRTTNTDQTKLFA 660 
111/L41-211_2011        TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
3123_2009               TAVETGHTSQVTPSDTMQTRHVKNYHSRSESSIENFLSRSACVYMGGYCTTNTDQTKLFA 660 
3123/70_2009            TAVETGHTSQVTPSDTMQTRHVKNYHSRSESSIENFLSRSACVYMGGYCTTNTDQTKLFA 660 
111/L41-121_2011        TAVETGHTSQVTPSDIIQTRHVHNYHSRSESSIENFLCRSACVYMGEYHTTNTDASKLFA 660 
3123/28_2009            TAVETGHTSQVTPSDTMQTRHVKNYHSRSESSIENFLSRSACVYMGGYCTTNTDQTKLFA 660 
M07067754_2007          TAAETGHTSQVTPSDTIQTRHVHNYHSRSESSVENFLCRSACVYMESYYTINSDITKLFV 660 
                        **.********.*.* :*****:********::****.*:*****  * * * : :: *. 
 
                                ---αA---- ========βD========             ==βE===  
E11 V5-7A_2005          NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
ROU-91_1991             NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
D207_2008               NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQATRLGQDMPPLTHQIMYIPPGG 720 
Hun/90_1990             NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQNQGTRLGQDMPPLTHQIMYIPPGG 720 
HUN-1108_1989           NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGNRLGQDMPPLTHQIMYIPPGG 720 
Kust-86_1986            NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGTRLGQDMPPLTHQIMYIPPGG 720 
FIN-0666_1989           NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
Jena799_2002            NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
Kar-87_1987             NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQRTRLGQDMPPLTHQIMYIPPGG 720 
wv207_1983              SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
20750473_2007           SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTRLGQDMPPLTHQIMYIPPGG 720 
E11_18744_02_2002       SWTINARRMVQMRRKLEMFTYVRFDIEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
61A3_2011               SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTRLGQDMPPLTHQIMYIPPGG 720 
HUN_1300_1989           NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGTRLGQDMPPLTHQIMYIPPGG 720 
HUN_1337_1989           NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDQGTRLGQDMPPLTHQIMYIPPGG 720 
HUN_1335_1989           NWTINARRMVQMRRKLEMFTYIRFDVEVTFVITSKQDHGTRLGQDMPPLTHQIMYIPPGG 720 
111/RD_2009             SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
MorM-82_1982            SWTISARHMVQMRRKLKMFTYVRFDIEVTFVITSRQDKGAKLGQDMPPLIHQIMYIPPGG 720 
 
 
 
 
215 
Gregory_1993            SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGSRLGQDMPPLTHQIMYIPPGG 720 
E11/7611_1993           SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/L41-431-1_2011      SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/L41-431-6_2011      SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/L41_2011            SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/BGM_2009            SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDRGTKLGQDMPPLTHQIMYIPPGG 720 
111/Hep_2009            SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/L41-431_2011        SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
111/L41-311_2011        SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
Gregory_1953            SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGNRLGQDMPPLTHQIMYIPPGG 720 
111/L41-211_2011        SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
3123_2009               SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGNRLGQDMPPLTHQIMYIPPGG 720 
3123/70_2009            SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGNRLGQDMPPLTHQIMYIPPGG 720 
111/L41-121_2011        SWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTKLGQDMPPLTHQIMYIPPGG 720 
3123/28_2009            SWTISARRMVQMRRKLEIFTYVRFDVEVTFVITSKQDQGNRLGQDMPPLTHQIMYIPPGG 720 
M07067754_2007          SWTINARRMVQMRRKLELFTYVRFDIEMTFVITSRQEQGTKLGQDMPLLTHQIMYIPPGG 720 
                        .***.**:********::***:***:*:******:*::  :****** * ********** 
                        
   
 
 
                             ---αB-    =βF==      =βG1       βG2     βG3   =βG4 -α  
E11 V5-7A_2005          PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
ROU-91_1991             PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
D207_2008               PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
Hun/90_1990             PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
HUN-1108_1989           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
Kust-86_1986            PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
FIN-0666_1989           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
Jena799_2002            PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
Kar-87_1987             PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
wv207_1983              PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
20750473_2007           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11_18744_02_2002       PIPKSKTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
61A3_2011               PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSMPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
HUN_1300_1989           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
HUN_1337_1989           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
HUN_1335_1989           PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFMSIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/RD_2009             PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
MorM-82_1982            PIPKLVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
Gregory_1993            PIPKSVTDYAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
E11/7611_1993           PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-431-1_2011      PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-431-6_2011      PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41_2011            PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/BGM_2009            PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/Hep_2009            PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-431_2011        PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-311_2011        PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
Gregory_1953            PIPKSVTDYAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-211_2011        PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
3123_2009               PIPKSVTDYAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
3123/70_2009            PIPKSVTDYAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
111/L41-121_2011        PIPKSVTDYTWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
3123/28_2009            PIPKSVTDYAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 780 
M07067754_2007          PIPKTVTDCAWQTSTNPSIFWTEGNAPPRMSIPFISLGNAYSNFYDGWSHFSQNGVYGYN 780 
                         ***  ** :*********************:**:*:*********************** 
 
                        C-    ==βH==        =======βI========== 
E11 V5-7A_2005          TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
ROU-91_1991             TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
D207_2008               TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVRAWVPRPPRLCQYKNASTVNFSSTNI 840 
Hun/90_1990             TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
HUN-1108_1989           TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
Kust-86_1986            TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
FIN-0666_1989           TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
Jena799_2002            TLNNMGQLYMRHVNGPSPLPMTSIVRVYFKPKHVKVWVPRPPRLCQYKNASTVNFSSTNI 840 
Kar-87_1987             TLNHMGQLYMRHVNGPSPLPMTSIVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
wv207_1983              TLNHMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKAWVPRPPRLCQYKNASTVNFSPTDI 840 
20750473_2007           TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
E11_18744_02_2002       TLNHMGQIYVRHVNGPSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYKNASTVNFTPTNI 840 
61A3_2011               TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
HUN_1300_1989           TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
HUN_1337_1989           TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
HUN_1335_1989           TLNHMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
111/RD_2009             TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
MorM-82_1982            TLNCMGQIYVRHANGPSPLPMTSTVRMYFKPKHIKAWIPRPPRLCQYENASTVNFSPTDI 840 
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Gregory_1993            TLNHMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKAWVPRPPRLCQYKNASTVNFTPTNV 840 
E11/7611_1993           TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/L41-431-1_2011      TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/L41-431-6_2011      TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/L41_2011            TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/BGM_2009            TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/Hep_2009            TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVSFKPTNI 840 
111/L41-431_2011        TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
111/L41-311_2011        TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
Gregory_1953            TLNHMGQIYVRHVNGSSPLPMTSTVRMYLKPKHVKAWVPRPPRLCQYENASTVNFTPTNV 840 
111/L41-211_2011        TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
3123_2009               TLNHMGQIYVRHVNGSSPLPMTSTVRMYLKPKHVKAWVPRPPRLCQYENASTVNFTPTNV 840 
3123/70_2009            TLNHMGQIYVRHVNGSSPLPMTSTVRMYLKPKHVKAWVPRPPRLCQYENASTVNFTPTNV 840 
111/L41-121_2011        TLNRMGQIYVRHVNGSSPLPMTSTVRMYFKPKHVKVWVPRPPRLCQYVNASTVNFKPTNI 840 
3123/28_2009            TLNHMGQIYVRHVNGSSPLPMTSTVRMYLKPKHVKAWVPRPPRLCQYENASTVNFTPTNV 840 
M07067754_2007          TLNNMGQIYVRHVNGPSPLPMTSTVRIYFKPKHVKAWIPRPPRLCQYVNASTVNFKPTNI 840 
                        *** ***:*:**.**.******* **:*:****::.*:********* *****.*..*:: 
 
 
 
 
E11 V5-7A_2005          TDKRNSITYIPDTVKPDVSNH 861 
ROU-91_1991             TDKRDSITYVPDTVKPDVSNH 861 
D207_2008               TDKRDSITYIPDTVKPDVSNH 861 
Hun/90_1990             TDKRDSITYIPDTVKPDVSNH 861 
HUN-1108_1989           TDKRDSITYIPDTVKPDVSNH 861 
Kust-86_1986            TDKRNSITYIPDTVKPDVSNY 861 
FIN-0666_1989           TDKRDSITYIPDTVKPDVSNH 861 
Jena799_2002            TDKRDSITYIPDTVKPDVLNH 861 
Kar-87_1987             TDKRDSITYIPDTVKPDVSNH 861 
wv207_1983              TDKRNSITYIPDTVKPDVSNH 861 
20750473_2007           TDKRDSITYIPDTVKPDVSNY 861 
E11_18744_02_2002       TEKRQSINYIPDTVKPSVSTN 861 
61A3_2011               TDKRDSITYIPDTVKPDVSNY 861 
HUN_1300_1989           TDKRDSITYIPDTVKPDVSNH 861 
HUN_1337_1989           TDKRDSITYIPDTVKPDVSNH 861 
HUN_1335_1989           TDKRDSITYIPHTVKPDVSNH 861 
111/RD_2009             TEKRTSINYIPETVKPDVSTY 861 
MorM-82_1982            TDKRDSITYIPETVRPDVSNH 861 
Gregory_1993            TDKRTSINYIPETVKPDLSNY 861 
E11/7611_1993           TEKRTSINYIPETVKPDVSTY 861 
111/L41-431-1_2011      TEKRTSINYIPETVKPDVSTY 861 
111/L41-431-6_2011      TEKRTSINYIPETVKPDVSTY 861 
111/L41_2011            TEKRTSINYIPETVKPDVSTY 861 
111/BGM_2009            TEKRTSINYIPETVKPDVSTY 861 
111/Hep_2009            TEKRTSINYIPETVKPDVSTY 861 
111/L41-431_2011        TEKRTSINYIPETVKPDVSTY 861 
111/L41-311_2011        TEKRTSINYIPETVRPDVSTY 861 
Gregory_1953            TDKRTSINYIPETVKPDLSNY 861 
111/L41-211_2011        TEKRTSINYIPETVRPDVSTY 861 
3123_2009               TDKRTSINYIPETVKPDLSNY 861 
3123/70_2009            TDKRTSINYIPETVKPDLSNY 861 
111/L41-121_2011        TEKRTSINYIPETVRPDVSTY 861 
3123/28_2009            TDKRTSINYIPETVKPDLSNY 861 
M07067754_2007          TEKRESIIYIPSTVKSDVSTH 861 
                        *:** ** *:* **:..: .                                         
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Appendix 2. Alignment of the sequence of the E11 5V-7A isolate with the 
E7 Wallace strain. The structural domains of E7 are shown and the amino acids 
involved in binding to the DAF SCR domains are surrounded with: SCR2 in 
yellow, SCR3 in orange, SCR4 in red. Residues in contact with DAF are 
highlighted in grey (Plevka et al., 2010)  
                 >VP4 
E7 Wallace      MGAQVSTQKTGAHETGLNASGNSIIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
E11 V5-7A       MGTQVSTQKTGAHETGLNASGNSVIHYTNINYYKDAASNSANRQDFTQDPGKFTEPVKDI 60 
                **:********************:************************************ 
 
                                      =βA1=  =βA2= 
                         >VP2 
E7 Wallace      MIKTMPALNSPSAEESGYSDRVRSLTLGNSTITTQESANVVVGYGRWPEYLRDDEATAED 120 
E11 V5-7A       MIKSMPALNSPSAEECGYSDRVRSITLGNSTITTQECANVVVAYGRWPEYLSDEEATAED 120 
                ***:***********.********:***********.*****.******** *:****** 
 
                    --αZ-        =βB      ==βC=-αA1- ----αA2---=βD1=   =βD2=         
E7 Wallace      QPTQPDVATCRFYTLESVQWEKNSAGWWWKFPEALKDMGLFGQNMLYHYLGRAGYTIHVQ 180 
E11 V5-7A       QPTQPDVATCRFYTLESVTWERESPGWWWKFPDALKDMGLFGQNMYYHYLGRAGYTIHVQ 180 
                ****************** **::*.*******:************ ************** 
 
                                  >------------------------------PUFF------- 
                       ====βE====             --αB1-                      -α  
E7 Wallace      CNASKFHQGCLLVVCVPEAEMGCSQTDKEVAAMNLTKGEAAHKFEPTKTNGEHTVQSIVC 240 
E11 V5-7A       CNASKFHQGCLLVVCVPEAEMGCSDVNGVVNEHGISEGETAKKFSATASNGTHTVQSIVT 240 
                ************************:.:  *   .:::**:*:**..* :** *******  
 
                -----< 
                B2    --αB3--- =βF==     =βG==                 ====βH======   
E7 Wallace      NAGMGVGVGNLTIYPHQWINLRTNNCATIVMPYVNSVPMDNMFRHYNFTLMVIPFAPLDY 300 
E11 V5-7A       NAGMGVGVGNLTIYPHQWINLRTNNSATIVMPYINSVPMDNMFRHHNFTLMIIPFVSLDY 300 
                *************************.*******:***********:*****:***..*** 
 
                       ===βI===    =βI2=         
                                               >VP3  
E7 Wallace      AAQASEYVPVTVTIAPMCAEYNGLRLAY-QQGFPVLNTPGSNQFMTSDDFQSPSAMPQFD 359 
E11 V5-7A       SSDASTYVPITVTVAPMCAEYNGLRLATSLQGLPVMNTPGSNQFLTSDDFQSPSAMPQFD 360 
                :::** ***:***:*************   **:**:********:*************** 
 
                                            >----KNOB--<  
                             --αZ1-         αZ2-- -αZ3-  =βB         =βC=    
E7 Wallace      VTPHMDIPGEVHNLMEIAEVDSVVPVNNIKVNLQSMDAYHIEVNTGNHQGEKIFAFQMQP 419 
E11 V5-7A       VTPELDIPGEVKNLMEIAEVDSVVPVNNVEGKLDTMDIFRIPVQSGNQQNTQVFGFQVQP 420 
                ***.:******:****************:: :*::** ::* *::**:*. ::*.**:** 
 
                        ---αA---   βD1  ====βD2==      ===βE==        ---αβ-  
E7 Wallace      GLESVFKRTLMGEILNYYAHWSGSIKLTFTFCGSAMATGKLLLAYSPPGADVPATRKQAM 479 
E11 V5-7A       GLDSVFKHTLLGEILNYYAHWSGSVKLTFVFCGSAMATGKFLLAYSPPGANAPKTRKDAM 480 
                **:****:**:*************:****.**********:*********:.* ***:** 
 
                - ==βF==     ==βG==                    ==βH==            ===     
E7 Wallace      LGTHMIWDIGLQSSCVLCIPWISQTHYRLVQQDEYTSAGNVTCWYQTGIVVPPGTPNKCV 539 
E11 V5-7A       LGTHVVWDVGLQSSCVLCIPWISQTHYRLVHQDEYTSAGNVTCWYQTGIVVPAGTPTSCS 540 
                ****::**:*********************:*********************.***..*  
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                =βI====      
                                             >VP1 
E7 Wallace      VLCFASACNDFSVRMLRDTPFIGQTALLQGDTETAIDNAIARVADTVASGPSNSTSIPAL 599 
E11 V5-7A       IMCFVSACNDFSVRLLKDTPFIEQSALLQGDVVEAIESAVARVADTISSGPTNSQAVPAL 600 
                ::**.*********:*:***** *:******.  **:.*:******::***:** ::*** 
 
                 -αZ1-     -αZ2-               --αZ3--  ===βB====        =βC                 
E7 Wallace      TAVETGHTSQVEPSDTMQTRHVKNYHSRSESTVENFLSRSACVYIEEYYTKDQDNVNRYM 659 
E11 V5-7A       TAVETGHTSQVVPGDTMQTRHVKNYHSRSESTIENFLSRAACVYMGEYYTTNTDETKRFA 660 
                *********** *.******************:******:****: ****.: *:.:*:  
 
                        ---αA---- ========βD========             ==βE=== 
E7 Wallace      SWTINARRMVQLRRKFELFTYMRFDMEITFVITSRQLPGTSIAQDMPPLTHQIMYIPPGG 719 
E11 V5-7A       NWTINARRMVQMRRKLEMFTYVRFDVEVTFVITSKQDQGTQLGQDMPPLTHQIMYIPPGG 720 
                .**********:***:*:***:***:*:******:*  **.:.***************** 
 
 
                       ---αB-    =βF==      =βG1       βG2     βG3   =βG4 -α  
E7 Wallace      PVPNSVTDFAWQTSTNPSIFWTEGNAPPRMSIPFISIGNAYSNFYDGWSHFSQNGVYGYN 779 
E11 V5-7A       PIPKSTTDYAWQTSTNPSIFWTEGNAPPRMSIPFVSIGNAYSNFYDGWSHFSQNGVYGYN 780 
                *:*:*.**:*************************:************************* 
 
                C-    ==βH==        =======βI==========   
E7 Wallace      ALNNMGKLYARHVNKDTPYQMSSTIRVYFKPKHIRVWVPRPPRLSPYIKSSNVNFNPTNL 839 
E11 V5-7A       TLNNMGQLYMRHVNGPSPLPMTSTVRVYFKPKHVKAWVPRPPRLCQYKNASTVNFSSTNI 840 
                :*****:** ****  :*  *:**:********::.********. * ::*.***..**: 
 
E7 Wallace      TDERSSITYVPDTIRPDVRTN 861 
E11 V5-7A       TDKRNSITYIPDTVKPDVSNH 861 
                **:*.****:***::*** .: 
 
 
 
 
 
 
 
 
 
 
 
 
